FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Kang, S
   Kim, BR
   Kang, MH
   Kim, DY
   Lee, DH
   Oh, SC
   Min, BW
   Um, JW
AF Kang, Sanghee
   Kim, Bo Ram
   Kang, Myoung-Hee
   Kim, Dae-Young
   Lee, Dae-Hee
   Oh, Sang Cheul
   Min, Byung Wook
   Um, Jun Won
TI Anti-metastatic effect of metformin via repression of interleukin
   6-induced epithelial-mesenchymal transition in human colon cancer cells
SO PLOS ONE
LA English
DT Article
ID COLORECTAL-CANCER; BREAST-CANCER; STAT3 ACTIVATION; GROWTH; PROGRESSION;
   METASTASIS; PATHOGENESIS; APOPTOSIS; RECEPTOR; SIGNALS
AB Metformin, a first-line drug used to treat type 2 diabetes, has also been shown to have anti-cancer effects against a variety of malignancies, including colorectal cancer. Although inhibition of the mTOR pathway is known to be the most important mechanism for the antitumor effects of metformin, other mechanisms remain unclear. The purpose of this study was to identify the antitumor mechanism of metformin in colorectal cancer using high-throughput data, and then test the mechanism experimentally. We identified the gene signature of metformin-treated colon cancer cells. This signature was processed for prediction using colon adenocarcinoma patient data from the Cancer Genome Atlas to classify the patients showing a gene expression pattern similar to that in metformin-treated cells. This patient group showed better overall and disease-free survival. Furthermore, pathway analysis revealed that the metformin-predicted group was characterized by decreased interleukin (IL)-6 pathway signaling, epithelial-mesenchymal transition, and colon cancer metastatic signaling. We induced epithelial-mesenchymal transition in colon cancer cell lines via IL-6 treatment, which increased cell motility and promoted invasion. However, these effects were blocked by metformin. These findings suggest that blockade of IL-6-induced epithelial-mesenchymal transition is an antitumor mechanism of metformin.
C1 [Kang, Sanghee; Min, Byung Wook] Korea Univ, Coll Med, Dept Surg, Guro Hosp, Seoul, South Korea.
   [Kim, Bo Ram; Lee, Dae-Hee; Oh, Sang Cheul] Korea Univ, Dept Oncol, Guro Hosp, Seoul, South Korea.
   [Kang, Myoung-Hee] Univ Ulsan, Coll Med, Dept Convergence Med, ASAN Med Ctr, Seoul, South Korea.
   [Kim, Dae-Young; Lee, Dae-Hee] Korea Univ, Grad Sch Med, Coll Med, Seoul, South Korea.
   [Um, Jun Won] Korea Univ, Coll Med, Ansan Hosp, Dept Surg, Gyeonggi Do, South Korea.
RP Um, JW (reprint author), Korea Univ, Coll Med, Ansan Hosp, Dept Surg, Gyeonggi Do, South Korea.
EM junwonum@korea.ac.kr
OI Kang, Sanghee/0000-0002-6097-8831
FU Korea University [K0716521]; National Research Foundation of Korea (NRF)
   grant - Korea government (MSIP) [NRF-2018R1C1B6007721]
FX This work is supported by Korea University Grant (K0716521) to JWU and
   National Research Foundation of Korea (NRF) grant funded by the Korea
   government (MSIP) (No. NRF-2018R1C1B6007721) to SHK. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   Bae YK, 2015, J BREAST CANCER, V18, P256, DOI 10.4048/jbc.2015.18.3.256
   Ben Sahra I, 2008, ONCOGENE, V27, P3576, DOI 10.1038/sj.onc.1211024
   Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Colomiere M, 2009, BRIT J CANCER, V100, P134, DOI 10.1038/sj.bjc.6604794
   Deng XS, 2012, CELL CYCLE, V11, P367, DOI 10.4161/cc.11.2.18813
   Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310
   Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7
   Farina AR, 2014, CANCERS, V6, P240, DOI 10.3390/cancers6010240
   Franciosi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071583
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   He JJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep17423
   Huang L, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0301-7
   Hussain SP, 2007, INT J CANCER, V121, P2373, DOI 10.1002/ijc.23173
   Isakovic A, 2007, CELL MOL LIFE SCI, V64, P1290, DOI 10.1007/s00018-007-7080-4
   Jalving M, 2010, EUR J CANCER, V46, P2369, DOI 10.1016/j.ejca.2010.06.012
   Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782
   Knupfer H, 2010, INT J COLORECTAL DIS, V25, P135, DOI 10.1007/s00384-009-0818-8
   Lee JH, 2012, INT J CANCER, V131, P752, DOI 10.1002/ijc.26421
   Li LH, 2012, J AM STAT ASSOC, V107, P120, DOI 10.1198/jasa.2011.ap10446
   Li XY, 2014, TOHOKU J EXP MED, V233, P175, DOI 10.1620/tjem.233.175
   Ma FX, 2015, CELL TRANSPLANT, V24, P2585, DOI 10.3727/096368915X687462
   Nagasaki T, 2014, BRIT J CANCER, V110, P469, DOI 10.1038/bjc.2013.748
   Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2
   Qaseem A, 2017, ANN INTERN MED, V166, P58, DOI 10.7326/M16-0570
   Quante M, 2013, GASTROENTEROLOGY, V145, P63, DOI 10.1053/j.gastro.2013.03.052
   Quinn BJ, 2013, TRENDS ENDOCRIN MET, V24, P469, DOI 10.1016/j.tem.2013.05.004
   Rena G, 2013, DIABETOLOGIA, V56, P1898, DOI 10.1007/s00125-013-2991-0
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Vazquez-Martin A, 2010, CELL CYCLE, V9, P3807, DOI 10.4161/cc.9.18.13131
   Wang XH, 2013, MOL CANCER THER, V12, P1026, DOI 10.1158/1535-7163.MCT-12-0895
   Yeh HH, 2006, ONCOGENE, V25, P4300, DOI 10.1038/sj.onc.1209464
   Yuhara H, 2011, AM J GASTROENTEROL, V106, P1911, DOI 10.1038/ajg.2011.301
   Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500
   Zhao ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095884
NR 38
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 11
PY 2018
VL 13
IS 10
AR e0205449
DI 10.1371/journal.pone.0205449
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GW7TO
UT WOS:000447173500080
PM 30308035
OA DOAJ Gold
DA 2019-06-25
ER

PT J
AU Peleg, N
   Arbib, OS
   Issachar, A
   Cohen-Naftaly, M
   Braun, M
   Shlomai, A
AF Peleg, Noam
   Arbib, Orly Sneh
   Issachar, Assaf
   Cohen-Naftaly, Michel
   Braun, Marius
   Shlomai, Amir
TI Noninvasive scoring systems predict hepatic and extra-hepatic cancers in
   patients with nonalcoholic fatty liver disease
SO PLOS ONE
LA English
DT Article
ID UNITED-STATES; FIBROSIS; STEATOHEPATITIS; ASSOCIATION; NAFLD; RISK;
   TRANSPLANTATION; METAANALYSIS; MORTALITY; CIRRHOSIS
AB Background
   Liver fibrosis predicts liver-related morbidity and mortality in patients with non-alcoholic fatty liver disease (NAFLD). Non-invasive scores correlate with the degree of liver fibrosis in these patients.
   Aims and methods
   To investigate the accuracy of noninvasive scoring systems in predicting long-term outcomes and cancer incidence of patients with NAFLD, we performed a single-center retrospective study of patients with biopsy proven NAFLD. Mean follow up period was 100 months. Outcomes included liver-related complications, hospitalizations, overall mortality and the development of any malignancies.
   Results
   32 patients had advanced fibrosis (F3-F4) per biopsy at baseline and 121 patients had mild to moderate fibrosis (F0-F2). Both advanced histologic fibrosis stage as well as higher noninvasive scores predicted repeated hospitalizations and longer hospitalization stays. In a multivariate analysis, liver fibrosis (p = 0.002), FIB-4 score (p<0.001), NFS (p<0.001) but not APRI score (p = 0.07) were predictors of overall mortality, and the occurrence of malignancies was associated with higher APRI (p<0.001), FIB-4 (p<0.001) and NFS (p = 0.008) scores, but not with advanced fibrosis, as determined by liver biopsy (p = 0.105).
   Conclusions
   In NAFLD patients, noninvasive scoring systems are good predictors of morbidity and mortality and may have an additive value in predicting the development of hepatic and extrahepatic cancers.
C1 [Peleg, Noam; Issachar, Assaf; Shlomai, Amir] Beilinson Med Ctr, Dept Med D, Rabin Med Ctr, Petah Tiqwa, Israel.
   [Arbib, Orly Sneh; Issachar, Assaf; Cohen-Naftaly, Michel; Braun, Marius; Shlomai, Amir] Beilinson Med Ctr, Liver Inst, Rabin Med Ctr, Petah Tiqwa, Israel.
   [Issachar, Assaf; Braun, Marius; Shlomai, Amir] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
RP Shlomai, A (reprint author), Beilinson Med Ctr, Dept Med D, Rabin Med Ctr, Petah Tiqwa, Israel.; Shlomai, A (reprint author), Beilinson Med Ctr, Liver Inst, Rabin Med Ctr, Petah Tiqwa, Israel.; Shlomai, A (reprint author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
EM shlomaiamir@gmail.com
OI Shlomai, Amir/0000-0001-7437-9381; Braun, Marius/0000-0002-5644-1759
CR Angulo P, 2015, GASTROENTEROLOGY, V149, P389, DOI 10.1053/j.gastro.2015.04.043
   Angulo P, 2013, GASTROENTEROLOGY, V145, P782, DOI 10.1053/j.gastro.2013.06.057
   Diehl AM, 2017, NEW ENGL J MED, V377, P2063, DOI 10.1056/NEJMra1503519
   Ekstedt M, 2006, HEPATOLOGY, V44, P865, DOI 10.1002/hep.21327
   Esposito K, 2012, DIABETES CARE, V35, P2402, DOI 10.2337/dc12-0336
   Estes C, 2018, HEPATOLOGY, V67, P123, DOI 10.1002/hep.29466
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Kim D, 2013, HEPATOLOGY, V57, P1357, DOI 10.1002/hep.26156
   Kim GA, 2018, J HEPATOL, V68, P140, DOI 10.1016/j.jhep.2017.09.012
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Kunutsor SK, 2015, INT J CANCER, V136, P1162, DOI 10.1002/ijc.29084
   Loaeza-del-Castillo A, 2008, ANN HEPATOL, V7, P350
   Loomba R, 2013, NAT REV GASTRO HEPAT, V10, P686, DOI 10.1038/nrgastro.2013.171
   McPherson S, 2010, GUT, V59, P1265, DOI 10.1136/gut.2010.216077
   Noor MT, 2017, J CLIN TRANSL HEPATO, V5, P50, DOI 10.14218/JCTH.2016.00056
   Peleg N, 2017, DIGEST LIVER DIS, V49, P1133, DOI 10.1016/j.dld.2017.05.002
   Regev A, 2002, AM J GASTROENTEROL, V97, P2614
   Sargenti K, 2015, LIVER INT, V35, P391, DOI 10.1111/liv.12625
   Sebastiani G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128774
   Shah AG, 2009, CLIN GASTROENTEROL H, V7, P1104, DOI 10.1016/j.cgh.2009.05.033
   Stepanova M, 2013, DIGEST DIS SCI, V58, P3017, DOI 10.1007/s10620-013-2743-5
   Strasak AM, 2008, INT J CANCER, V123, P1902, DOI 10.1002/ijc.23714
   Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346
   White DL, 2012, CLIN GASTROENTEROL H, V10, P1342, DOI 10.1016/j.cgh.2012.10.001
   Wong RJ, 2015, GASTROENTEROLOGY, V148, P547, DOI 10.1053/j.gastro.2014.11.039
   Wong RJ, 2014, HEPATOLOGY, V59, P2188, DOI 10.1002/hep.26986
   Yasui K, 2011, CLIN GASTROENTEROL H, V9, P428, DOI 10.1016/j.cgh.2011.01.023
   Younossi ZM, 2011, HEPATOLOGY, V53, P1874, DOI 10.1002/hep.24268
NR 28
TC 1
Z9 1
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 14
PY 2018
VL 13
IS 8
AR e0202393
DI 10.1371/journal.pone.0202393
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GQ4SC
UT WOS:000441662800044
PM 30106985
OA DOAJ Gold
DA 2019-06-25
ER

PT J
AU Schrijnders, D
   Hendriks, SH
   Kleefstra, N
   Vissers, PAJ
   Johnson, JA
   de Bock, GH
   Bilo, HJG
   Landman, GWD
AF Schrijnders, Dennis
   Hendriks, Steven H.
   Kleefstra, Nanne
   Vissers, Pauline A. J.
   Johnson, Jeffrey A.
   de Bock, Geertruida H.
   Bilo, Henk J. G.
   Landman, Gijs W. D.
TI Sex differences in obesity related cancer incidence in relation to type
   2 diabetes diagnosis (ZODIAC-49)
SO PLOS ONE
LA English
DT Article
ID BODY-MASS INDEX; BREAST-CANCER; DETECTION BIAS; SOCIOECONOMIC-STATUS;
   PROSPECTIVE COHORT; INCREASED RISK; INSULIN LEVELS; WEIGHT-GAIN; WOMEN;
   MELLITUS
AB Background
   Diabetes and obesity seem to be partly overlapping risk factors for the development of obesity- related cancer (mainly breast, prostate and colorectal cancer) in patients with type 2 diabetes (T2DM). In the general population, women have a lower risk for obesity-related cancer compared to men. Previous studies involving cardiovascular disease have shown that T2DM eliminates a female advantage of lower CVD risk in the general population compared to men. It is unclear whether the same could be true for obesity-related cancer. This study aimed to this investigate obesity-related cancer incidence in women and men known with T2DM as compared to the Dutch general population.
   Methods
   This study included 69,583 patients with T2DM selected from a prospective primary care cohort, which was linked to the Dutch National Cancer Registry to obtain cancer specific data. Obesity-related cancers included liver, kidney, colorectal, gallbladder, pancreas, ovarian, endometrial, advanced prostate cancer, post-menopausal breast cancer and oesophageal adenocarcinoma. Primary outcome was sex-stratified, age and year of cancer diagnosis adjusted standardized incidence ratios (SIRs) for three time periods: 5 years before, the year after diagnosis and the next 4 years after T2DM diagnosis. The Dutch general population was used as reference group.
   Results
   Women with T2DM were at an increased risk for obesity-related cancer compared to women in the general population already 5 years before diabetes diagnosis (SIR 1.77; 95% CI: 1.63 +/- 1.91). In both men and women, there was a peak in obesity-related cancer incidence following diabetes diagnosis (SIR: 1.38; 95% CI 1.11 +/- 1.64 and SIR: 2.21; 95% CI 1.94-2.30, respectively). From the second to the fifth year after diabetes diagnosis the obesity-related cancer incidence was higher in women compared to women in the general population (SIR: 2.12; 95% CI 1.94 +/- 2.30).
   Conclusions
   Women with T2DM seem to have a substantially higher obesity-related cancer risk. As opposed to men, in women this risk was already increased years before diabetes diagnosis. These results could imply that a relative advantage of women in the general population with regard to cancer risk is lost in women with T2DM.
C1 [Schrijnders, Dennis; Kleefstra, Nanne; Landman, Gijs W. D.] Langerhans Med Res Grp, Zwolle, Netherlands.
   [Schrijnders, Dennis; Hendriks, Steven H.; Bilo, Henk J. G.] Diabet Ctr, Zwolle, Netherlands.
   [Kleefstra, Nanne; Bilo, Henk J. G.] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Groningen, Netherlands.
   [Vissers, Pauline A. J.] Netherlands Comprehens Canc Org, Utrecht, Netherlands.
   [Johnson, Jeffrey A.] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada.
   [de Bock, Geertruida H.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands.
   [Bilo, Henk J. G.] Dept Internal Med, Zwolle, Netherlands.
   [Landman, Gijs W. D.] Gelre Hosp, Dept Internal Med, Apeldoorn, Netherlands.
RP Schrijnders, D (reprint author), Langerhans Med Res Grp, Zwolle, Netherlands.; Schrijnders, D (reprint author), Diabet Ctr, Zwolle, Netherlands.
EM d.schrijnders@rug.nl
FU Netherlands Organization for Health Research and Development (ZonMw)
   [836041017]
FX This study was supported by a research grant (grant number 836041017) of
   the research programme Good Use of Medication from the Netherlands
   Organization for Health Research and Development (ZonMw). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.; The authors thank the
   registration teams of the Comprehensive Cancer Centre Netherlands for
   the collection of data for the Netherlands Cancer Registry and for the
   opportunity to link the Registry with the ZODIAC cohort. We would like
   to thank dr. Klaas Groenier (Department of General Practice, University
   Medical Centre Groningen, University of Groningen, Groningen, the
   Netherlands) for his advice with regard to the analyses. This study was
   supported by a research grant (grant number 836041017) of the research
   programme Good Use of Medication from the Netherlands Organization for
   Health Research and Development (ZonMw).
CR Aarts MJ, 2011, BREAST CANCER RES TR, V128, P517, DOI 10.1007/s10549-011-1363-z
   Baan Caroline A, 2009, Ned Tijdschr Geneeskd, V153, P1052
   Bansal D, 2013, PROSTATE CANCER P D, V16, P151, DOI 10.1038/pcan.2012.40
   Boyle P, STAT METHODS REGISTR
   Campbell PT, 2010, GASTROENTEROLOGY, V139, P1138, DOI 10.1053/j.gastro.2010.06.072
   Carstensen B, 2014, CURR DIABETES REP, V14, DOI 10.1007/s11892-014-0535-8
   Chan DSM, 2014, ANN ONCOL, V25, P1901, DOI 10.1093/annonc/mdu042
   Chan W, 2014, DIABETIC MED, V31, P806, DOI 10.1111/dme.12422
   COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001
   Colmers IN, 2013, DIABETES CARE, V36, P3070, DOI 10.2337/dc13-0045
   Dankner R, 2016, AM J EPIDEMIOL, V183, P1098, DOI 10.1093/aje/kwv290
   De Bruijn KMJ, 2014, EUR J CANCER, V50, P2449, DOI 10.1016/j.ejca.2014.06.019
   De Pergola G, 2013, J OBES, DOI 10.1155/2013/291546
   Derks IPM, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0553-7
   Drake I, 2017, INT J CANCER, V141, P1170, DOI 10.1002/ijc.30824
   Franssens BT, 2015, DIABETES CARE, V38, P1945, DOI 10.2337/dc15-0684
   Friedman AM, 2012, OBESITY, V20, P1611, DOI 10.1038/oby.2012.50
   Gallagher EJ, 2015, PHYSIOL REV, V95, P727, DOI 10.1152/physrev.00030.2014
   Garg SK, 2014, DIABETES OBES METAB, V16, P97, DOI 10.1111/dom.12124
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Haghighatdoost F, 2017, WORLD J DIABETES, V8, P365, DOI 10.4239/wjd.v8.i7.365
   Harding JL, 2015, DIABETES CARE, V38, P264, DOI 10.2337/dc14-1996
   Hendriks SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145907
   Huxley R, 2006, BMJ-BRIT MED J, V332, P73, DOI 10.1136/bmj.38678.389583.7C
   Johnson JA, 2012, DIABETOLOGIA, V55, P1607, DOI 10.1007/s00125-012-2525-1
   Johnson JA, 2011, DIABETOLOGIA, V54, P2263, DOI 10.1007/s00125-011-2242-1
   Johnson JL, 2010, ENDOCR PRACT, V16, P47, DOI 10.4158/EP09031.OR
   Kleefstra N, 2016, J DIABETES, V8, P863, DOI 10.1111/1753-0407.12370
   Lauby-Secretan B, 2016, NEW ENGL J MED, V375, P794, DOI 10.1056/NEJMsr1606602
   Lee WL, 2000, DIABETES CARE, V23, P962, DOI 10.2337/diacare.23.7.962
   Lega IC, 2016, CANCER
   Lipscombe LL, 2006, BREAST CANCER RES TR, V98, P303, DOI 10.1007/s10549-006-9166-3
   Louwman WJ, 2007, BREAST CANCER RES TR, V105, P369, DOI 10.1007/s10549-006-9464-9
   Salinas-Martinez AM, 2014, ARCH MED RES, V45, P432, DOI 10.1016/j.arcmed.2014.06.004
   Maruthur NM, 2009, J GEN INTERN MED, V24, P665, DOI 10.1007/s11606-009-0939-3
   Michels KB, 2003, DIABETES CARE, V26, P1752, DOI 10.2337/diacare.26.6.1752
   Moon JH, 2015, J CLIN ENDOCR METAB, V100, P3548, DOI 10.1210/JC.2015-1113
   Moore LL, 2014, CANCER EPIDEM BIOMAR, V23, P2057, DOI 10.1158/1055-9965.EPI-14-0240
   Naing N N, 2000, Malays J Med Sci, V7, P10
   Nijenhuis-Rosien L, 2017, J DIABETES COMPLICAT, V31, P675, DOI 10.1016/j.jdiacomp.2017.01.015
   Oberaigner W, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1058
   OLEFSKY JM, 1977, DIABETES, V26, P680, DOI 10.2337/diab.26.7.680
   Onitilo AA, 2014, EUR J CANCER PREV, V23, P76, DOI 10.1097/CEJ.0b013e32836162aa
   Onitilo AA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070426
   Orgel E, 2013, CURR DIABETES REP, V13, P213, DOI 10.1007/s11892-012-0356-6
   Peeters K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01019-z
   Protani M, 2010, BREAST CANCER RES TR, V123, P627, DOI 10.1007/s10549-010-0990-0
   Puolakka E, 2016, DIABETES CARE, V39, P2311, DOI 10.2337/dc16-1565
   Rahmanian K, 2016, GLOBAL J HLTH SCI, V8, p95 
   RIVM, LAND EV BEV BAARM LE
   Suissa S, 2012, DIABETES CARE, V35, P2665, DOI 10.2337/dc12-0788
   Tao XM, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0376-7
   Teoh SL, 2016, TUMOR BIOL, V37, P14363, DOI 10.1007/s13277-016-5357-7
   Tsilidis KK, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.g7607
   van Hateren KJJ, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001387
   Verlato G, 2003, DIABETES CARE, V26, P1047, DOI 10.2337/diacare.26.4.1047
   von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.1016/j.jclinepi.2007.11.008
   World Cancer Research Fund, 2015, CANC LINK GREAT BOD
NR 58
TC 3
Z9 3
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 25
PY 2018
VL 13
IS 1
AR e0190870
DI 10.1371/journal.pone.0190870
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FT8QE
UT WOS:000423416600025
PM 29370205
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Prieto, I
   del Puerto-Nevado, L
   Gonzalez, N
   Portal-Nunez, S
   Zazo, S
   Corton, M
   Minguez, P
   Gomez-Guerrero, C
   Arce, JM
   Sanz, AB
   Mas, S
   Aguilera, O
   Alvarez-Llamas, G
   Esbrit, P
   Ortiz, A
   Ayuso, C
   Egido, J
   Rojo, F
   Garcia-Foncilias, J
AF Prieto, Isabel
   del Puerto-Nevado, Laura
   Gonzalez, Nieves
   Portal-Nunez, Sergio
   Zazo, Sandra
   Corton, Marta
   Minguez, Pablo
   Gomez-Guerrero, Carmen
   Miguel Arce, Jose
   Belen Sanz, Ana
   Mas, Sebastian
   Aguilera, Oscar
   Alvarez-Llamas, Gloria
   Esbrit, Pedro
   Ortiz, Alberto
   Ayuso, Carmen
   Egido, Jesus
   Rojo, Federico
   Garcia-Foncilias, Jesus
CA DiabetesCancerConnect Consortium
TI Colon cancer modulation by a diabetic environment: A single
   institutional experience
SO PLOS ONE
LA English
DT Article
ID COLORECTAL-CANCER; ANTITUMOR-ACTIVITY; DETECTION BIAS; METFORMIN; RISK;
   TYPE-2; MORTALITY; POPULATION; MELLITUS; IMPACT
AB Background
   Multiple observational studies suggest an increased risk of colon cancer in patients with diabetes mellitus (DM). This can theoretically be the result of an influence of the diabetic environment on carcinogenesis or the tumor biologic behavior.
   Aim
   To gain insight into the influence of a diabetic environment on colon cancer characteristics and outcomes.
   Material and methods
   Retrospective analysis of clinical records in an academic tertiary care hospital with detailed analysis of 81 diabetic patients diagnosed of colon cancer matched with 79 non-diabetic colon cancer patients. The impact of streptozotocin-induced diabetes on the growth of colon cancer xenografts was studied in mice.
   Results
   The incidence of DM in 1,137 patients with colorectal cancer was 16%. The diabetic colon cancer cases and non-diabetic colon cancer controls were well matched for demographic and clinical variables. The ECOG Scale Performance Status was higher (worse) in diabetics (ECOG >= 1, 29.1% of controls vs 46.9% of diabetics, p = 0.02), but no significant differences were observed in tumor grade, adjuvant therapy, tumor site, lymphovascular invasion, stage, recurrence, death or cancer-related death. Moreover, no differences in tumor variables were observed between patients treated or not with metformin. In the xenograft model, tumor growth and histopathological characteristics did not differ between diabetic and nondiabetic animals.
   Conclusion
   Our findings point towards a mild or negligible effect of the diabetes environment on colon cancer behavior, once cancer has already developed.
C1 [Prieto, Isabel; Aguilera, Oscar] UAM, Oncohlth Inst, Radiat Oncol, IIS,Fdn Jimenez Diaz, Madrid, Spain.
   [del Puerto-Nevado, Laura; Garcia-Foncilias, Jesus] UAM, Oncohlth Inst, Translat Oncol Div, IIS,Fdn Jimenez Diaz, Madrid, Spain.
   [Gonzalez, Nieves; Gomez-Guerrero, Carmen; Belen Sanz, Ana; Mas, Sebastian; Ortiz, Alberto; Egido, Jesus] UAM, Renal Vasc & Diabet Res Lab, IIS, Fdn Jimenez Diaz, Madrid, Spain.
   [Gonzalez, Nieves; Gomez-Guerrero, Carmen; Mas, Sebastian; Egido, Jesus] Spanish Biomed Res Network Diabet & Associated Me, Madrid, Spain.
   [Portal-Nunez, Sergio; Esbrit, Pedro] UAM, Bone & Mineral Metab Lab, IIS, Fdn Jimenez Diaz, Madrid, Spain.
   [Zazo, Sandra; Rojo, Federico] UAM, Dept Pathol, IIS, Fdn Jimenez Diaz, Madrid, Spain.
   [Corton, Marta; Minguez, Pablo; Ayuso, Carmen] UAM, Dept Genet, IIS, Fdn Jimenez Diaz, Madrid, Spain.
   [Miguel Arce, Jose] Fdn Jimenez Diaz, Hlth Informat Management Dept, Madrid, Spain.
   [Alvarez-Llamas, Gloria] UAM, Immunoallergy & Prote Lab, IIS, Fdn Jimenez Diaz, Madrid, Spain.
RP Prieto, I (reprint author), UAM, Oncohlth Inst, Radiat Oncol, IIS,Fdn Jimenez Diaz, Madrid, Spain.
EM iprieto@fjd.es
RI Alvarez-Llamas, Gloria/C-8938-2015; ortiz, alberto/Y-7582-2018; Mas,
   S/T-1489-2018; Portal-Nunez, Sergio/L-7391-2014; Miguez,
   Pablo/D-4822-2013
OI Alvarez-Llamas, Gloria/0000-0002-3313-721X; ortiz,
   alberto/0000-0002-9805-9523; Mas, S/0000-0001-6604-3327; Portal-Nunez,
   Sergio/0000-0003-0659-1545; Miguez, Pablo/0000-0003-4099-9421; Corton,
   Marta/0000-0003-0087-1626; J, Garcia-Foncillas/0000-0002-7591-8006;
   Rojo, Federico/0000-0001-9989-0290; Ayuso, Carmen/0000-0002-9242-7065;
   Sanz, Ana Belen/0000-0002-0255-5689
FU Institute de Salud Carlos III-Fondos FEDER [PIE13/00051, P114/00386];
   Institute de Salud Carlos III and Alberto Ortiz [MS1114/00031, RETICEF
   RD12/0043/008, MS12/03256, MS12/03262, CPI115/00027, RD012/0021,
   RD016/007]; Institute de Salud Carlos III [PIE13/00051]
FX This study was supported by a grant from the Institute de Salud Carlos
   III-Fondos FEDER (PIE13/00051; P114/00386). Nieves Gonzalez
   (MS1114/00031), Sergio Portal (RETICEF RD12/0043/008), Marta Colton
   (MS12/03256), Ana Belen Sanz (MS12/03262) and Gloria Alvarez-Llamas
   (CPI115/00027) are recipients of a research contract from Institute de
   Salud Carlos III and Alberto Ortiz belongs to REDINREN RD012/0021 and
   RD016/007. Pablo Minguez, Sebastian Mas and Irene Bejarano are
   recipients of a research contract from the Institute de Salud Carlos III
   (PIE13/00051). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Algamas-Dimantov A, 2014, ONCOTARGET, V5, P9851, DOI 10.18632/oncotarget.2453
   Aljada A, 2012, PHARMACOL THERAPEUT, V133, P108, DOI 10.1016/j.pharmthera.2011.09.004
   Barbosa-Desongles A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074179
   Cogliano V, 2010, J NATL CANCER I, V102, P134, DOI 10.1093/jnci/djp446
   Faria MCD, 2015, CHEM-BIOL INTERACT, V229, P119, DOI 10.1016/j.cbi.2015.01.027
   Dankner R, 2016, AM J EPIDEMIOL, V183, P1098, DOI 10.1093/aje/kwv290
   De Bruijn KMJ, 2014, EUR J CANCER, V50, P2449, DOI 10.1016/j.ejca.2014.06.019
   de Kort S, 2016, EUR J GASTROEN HEPAT, V28, P896, DOI 10.1097/MEG.0000000000000626
   Deng LY, 2012, DIGEST DIS SCI, V57, P1576, DOI 10.1007/s10620-012-2055-1
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Graham ML, 2011, COMPARATIVE MED, V61, P356
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hajjar J, 2013, EXPERT OPIN INV DRUG, V22, P1511, DOI 10.1517/13543784.2013.833604
   Harding JL, 2015, DIABETES CARE, V38, P264, DOI 10.2337/dc14-1996
   He J, 2010, BRIT J CANCER, V103, P120, DOI 10.1038/sj.bjc.6605721
   Hosono K, 2010, CANCER PREV RES, V3, P1077, DOI 10.1158/1940-6207.CAPR-10-0186
   International Diabetes Federation, 2015, IDF DIABETES ATLAS
   Jarvandi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074616
   Jiang Y, 2011, EUR J EPIDEMIOL, V26, P863, DOI 10.1007/s10654-011-9617-y
   Johnson JA, 2012, DIABETOLOGIA, V55, P1607, DOI 10.1007/s00125-012-2525-1
   Kapiteijn E, 2001, J PATHOL, V195, P171, DOI 10.1002/path.918
   Lee J, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3233-y
   Lee KM, 2016, ONCOTARGET, V7, P38500, DOI 10.18632/oncotarget.9522
   Lega IC, 2014, CANCER EPIDEM BIOMAR, V23, P1974, DOI 10.1158/1055-9965.EPI-14-0327
   Li FY, 2009, J ZHEJIANG UNIV-SC B, V10, P219, DOI 10.1631/jzus.B0820273
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Masur K, 2011, BRIT J CANCER, V104, P345, DOI 10.1038/sj.bjc.6606050
   Minoo P, 2010, INT J ONCOL, V37, P707, DOI 10.3892/ijo_00000720
   Renehan AG, 2012, DIABETOLOGIA, V55, P1619, DOI 10.1007/s00125-012-2526-0
   Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175
   Sharma A, 2014, CLIN COLORECTAL CANC, V13, P54, DOI 10.1016/j.clcc.2013.10.002
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Suh S, 2011, DIABETES METAB J, V35, P193, DOI 10.4093/dmj.2011.35.3.193
   Sui XB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097781
   Vissers PAJ, 2016, J CANCER SURVIV, V10, P406, DOI 10.1007/s11764-015-0486-3
   Wang JY, 2013, JPN J CLIN ONCOL, V43, P258, DOI 10.1093/jjco/hys228
   Wang M, 2015, SCI REP-UK, V5, DOI 10.1038/srep11503
   Wang Y, 2014, GENET MOL RES, V13, P7173, DOI 10.4238/2014.September.5.3
   Wu L, 2015, SCI REP-UK, V5, DOI 10.1038/srep10147
NR 39
TC 1
Z9 2
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 2
PY 2017
VL 12
IS 3
AR e0172300
DI 10.1371/journal.pone.0172300
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EN4XX
UT WOS:000396011300015
PM 28253286
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Murphy, N
   Falk, RT
   Messinger, DB
   Pollak, M
   Xue, XN
   Lin, J
   Sgueglia, R
   Strickler, HD
   Gaudet, MM
   Gunter, MJ
AF Murphy, Neil
   Falk, Roni T.
   Messinger, Diana B.
   Pollak, Michael
   Xue, Xiaonan
   Lin, Juan
   Sgueglia, Robin
   Strickler, Howard D.
   Gaudet, Mia M.
   Gunter, Marc J.
TI Influence of Fasting Status and Sample Preparation on Metabolic
   Biomarker Measurements in Postmenopausal Women
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-I; SERUM C-PEPTIDE; COLORECTAL-CANCER; BREAST-CANCER;
   PLASMA ADIPONECTIN; DIABETES-MELLITUS; HEALTHY-SUBJECTS;
   BINDING-PROTEIN; RISK; INSULIN
AB Background
   Epidemiologic data linking metabolic markers-such as insulin, insulin-like growth factors (IGFs)-and adipose tissue-derived factors with cancer are inconsistent. Between-study differences in blood collection protocols, in particular participant's fasting status, may influence measurements.
   Methods
   We investigated the impact of fasting status and blood sample processing time on components of the insulin/IGF axis and in adipokines in a controlled feeding study of 45 healthy postmenopausal-women aged 50-75 years. Fasting blood samples were drawn (T0), after which subjects ate a standardized breakfast; subsequent blood draws were made at 1 hour (T1), 3 hours (T3), and 6 hours (T6) after breakfast. Serum samples were assayed for insulin, C-peptide, total-and free-IGF-I, IGF-binding protein [BP]-1 and -3, total and high molecular weight (HMW)-adiponectin, retinol binding protein-4, plasminogen activator inhibitor (PAI)-1, and resistin.
   Results
   Insulin and C-peptide levels followed similar postprandial trajectories; intra-class correlation coefficients [ICC] for insulin = 0.75, (95% CI: 0.64-0.97) and C-peptide (ICC = 0.66, 95% CI: 0.54-0.77) were similarly correlated in fasting (Spearman correlation, r = 0.78, 95% CI: 0.64-0.88) and postprandial states (T1, r = 0.77 (95% CI: 0.62-0.87); T3, r = 0.78 (95% CI: 0.63-0.87); T6, r = 0.77 (95% CI: 0.61-0.87)). Free-IGF-I and IGFBP-1 levels were also affected by fasting status, whereas total-IGF-I and IGFBP-3 levels remained unchanged. Levels of adipokines were largely insensitive to fasting status and blood sample processing delays.
   Conclusion
   Several components of the insulin/IGF axis were significantly impacted by fasting state and in particular, C-peptide levels were substantially altered postprandially and in a similar manner to insulin.
C1 [Murphy, Neil] Imperial Coll London, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England.
   [Murphy, Neil; Gunter, Marc J.] Int Agcy Res Canc, Lyon, France.
   [Falk, Roni T.] NCI, Div Canc Epidemiol & Genet, Hormonal & Reprod Epidemiol Branch, Bethesda, MD 20892 USA.
   [Messinger, Diana B.] Rockefeller Univ Hosp, 1230 York Ave, New York, NY 10021 USA.
   [Pollak, Michael] McGill Univ, Dept Oncol, Montreal, PQ, Canada.
   [Xue, Xiaonan; Lin, Juan; Sgueglia, Robin; Strickler, Howard D.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   [Gaudet, Mia M.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA USA.
RP Murphy, N (reprint author), Imperial Coll London, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England.; Murphy, N (reprint author), Int Agcy Res Canc, Lyon, France.
EM murphyn@iarc.fr
RI Murphy, Neil/E-1189-2017
OI Murphy, Neil/0000-0003-3347-8249
FU National Center for Advancing Translational Sciences (NCATS), National
   Institutes of Health [UL1RR024143]; National Cancer Institute
   [R03CA143956-01]; ICTR Einstein-Montefiore CTSA [UL1TR001073]; Diabetes
   Research Center [DK020541];  [8 UL1 TR000043]
FX The study population were recruited at the Center for Clinical and
   Translational Science (CCTS) at the Rockefeller University Hospital (New
   York, NY) using funds Grant # 8 UL1 TR000043. Supported in part by grant
   # UL1RR024143 from the National Center for Advancing Translational
   Sciences (NCATS), National Institutes of Health. The funds for the
   measurement of adipokines were obtained from the National Cancer
   Institute (R03CA143956-01). Robin Sgueglia is supported by the ICTR
   Einstein-Montefiore CTSA (UL1TR001073) and the Diabetes Research Center
   (DK020541).
CR Aleksandrova K, 2012, CARCINOGENESIS, V33, P1211, DOI [10.1093/carcin/bgs133d, 10.1093/carcin/bgs133]
   BONSER AM, 1984, CRC CR REV CL LAB SC, V19, P297, DOI 10.3109/10408368409165766
   COTTERILL AM, 1993, CLIN ENDOCRINOL, V39, P357, DOI 10.1111/j.1365-2265.1993.tb02377.x
   Esposito K, 2003, AM J CLIN NUTR, V78, P1135
   Esposito K, 2012, DIABETES CARE, V35, P2402, DOI 10.2337/dc12-0336
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Gunter MJ, 2009, J NATL CANCER I, V101, P48, DOI 10.1093/jnci/djn415
   Harris TG, 2006, GROWTH HORM IGF RES, V16, P86, DOI 10.1016/j.ghir.2006.01.002
   HOLLY JMP, 1988, CLIN ENDOCRINOL, V29, P667, DOI 10.1111/j.1365-2265.1988.tb03715.x
   Imbeault P, 2004, CLIN ENDOCRINOL, V60, P429, DOI 10.1111/j.1365-2265.2004.01997.x
   Jellema A, 2004, EUR J CLIN INVEST, V34, P766, DOI 10.1111/j.1365-2362.2004.01414.x
   Jenab M, 2007, INT J CANCER, V121, P368, DOI 10.1002/ijc.22697
   Karlsson FA, 2004, OBES RES, V12, P1031, DOI 10.1038/oby.2004.126
   Keinan-Boker L, 2003, INT J CANCER, V106, P90, DOI 10.1002/ijc.11193
   Lewandowski KC, 2005, MOL GENET METAB, V85, P61, DOI 10.1016/j.ymgme.2004.12.014
   Lukanova A, 2006, CANCER EPIDEM BIOMAR, V15, P401, DOI 10.1158/1055-9965.EPI-05-0836
   Ma J, 2004, JNCI-J NATL CANCER I, V96, P546, DOI 10.1093/jnci/djh082
   Peake PW, 2003, INT J OBESITY, V27, P657, DOI 10.1038/sj.ijo.0802289
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Sanders TAB, 2001, AM J CLIN NUTR, V73, P715
   Shea SA, 2005, J CLIN ENDOCR METAB, V90, P2537, DOI 10.1210/jc.2004-2232
   Verheus M, 2006, INT J CANCER, V119, P659, DOI 10.1002/ijc.21861
   Wei EK, 2005, JNCI-J NATL CANCER I, V97, P1688, DOI 10.1093/jnci/dji376
NR 23
TC 3
Z9 3
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 8
PY 2016
VL 11
IS 12
AR e0167832
DI 10.1371/journal.pone.0167832
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EE4OA
UT WOS:000389580900048
PM 27930694
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Tseng, CH
AF Tseng, Chin-Hsiao
TI Factors Associated with Cancer- and Non-Cancer-Related Deaths among
   Taiwanese Patients with Diabetes after 17 Years of Follow-Up
SO PLOS ONE
LA English
DT Article
ID OBESITY PARADOX; BLADDER-CANCER; MORTALITY; POPULATION; HYPERTENSION;
   PREVALENCE; INSULIN; DISEASE; IMPACT
AB Objective
   A previous 12-year follow-up of a large diabetes cohort in Taiwan suggested a survival advantage in the patients with obesity. The present study further investigated additional determinants for cancer and non-cancer death in the cohort after a follow-up of 17 years.
   Methods
   A cohort of 92546 diabetes patients recruited since 1995 was followed for vital status by matching the National Death Certificate Database until 2011. Cox regression estimated the hazard ratios for the following variables: age at baseline, sex, diabetes type, screen-detected diabetes (diabetes diagnosed accidentally through epidemiological screening programs or during visits to medical settings without a history of diabetes), diabetes duration, body mass index, insulin use, hypertension, smoking, and living region. Fasting glucose and history of dyslipidemia were available for additional adjustment in a subcohort of the patients (n = 14559).
   Results
   A total of 40229 diabetes patients (43.5% of the cohort) died during follow-up and 10.9% died under the age of 60. Insulin use and smoking significantly predicted cancer and non-cancer death. The adjusted hazard ratio (95% confidence interval) associated with insulin use was 1.161 (1.052-1.281) for cancer death and 1.469 (1.413-1.526) for non-cancer death. Screen-detected diabetes and body mass index were consistently associated with a lower risk, but diabetes duration a higher risk, for non-cancer death, with adjusted hazard ratio of 0.683 (0.666-0.702), 0.955 (0.951-0.958) and 1.018 (1.017-1.020), respectively. Diabetes type had a null association disregarding the causes of death and living in rural areas was significantly associated with a higher mortality from non-cancer death. Hypertension, fasting glucose and dyslipidemia showed differential impacts on cancer and non-cancer death, and were significantly predictive for non-cancer death.
   Conclusions
   Screen-detected diabetes and a higher body mass index provide a survival advantage, especially for non-cancer death. However, insulin use is associated with a significantly higher risk of either cancer or non-cancer death.
C1 [Tseng, Chin-Hsiao] Natl Taiwan Univ, Dept Internal Med, Coll Med, Taipei, Taiwan.
   [Tseng, Chin-Hsiao] Natl Taiwan Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Taipei, Taiwan.
   [Tseng, Chin-Hsiao] Natl Hlth Res Inst, Div Environm Hlth & Occupat Med, Taipei, Taiwan.
RP Tseng, CH (reprint author), Natl Taiwan Univ, Dept Internal Med, Coll Med, Taipei, Taiwan.; Tseng, CH (reprint author), Natl Taiwan Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Taipei, Taiwan.; Tseng, CH (reprint author), Natl Hlth Res Inst, Div Environm Hlth & Occupat Med, Taipei, Taiwan.
EM ccktsh@ms6.hinet.net
FU Department of Health [DOH89-TD-1035]; Ministry of Science and Technology
   of Taiwan [MOST 103-2314-B-002-187-MY3]
FX The study was supported by the Department of Health (DOH89-TD-1035) and
   the Ministry of Science and Technology (MOST 103-2314-B-002-187-MY3) of
   Taiwan.
CR [Anonymous], 2015, IDF DIABETES ATLAS
   Brun E, 2000, DIABETES CARE, V23, P1119, DOI 10.2337/diacare.23.8.1119
   Calori G, 2011, DIABETES CARE, V34, P210, DOI 10.2337/dc10-0665
   Canchola AJ, COX REGRESSION USING
   Carpenter CL, 2013, J OBES, DOI 10.1155/2013/790654
   Chang HY, 2010, DIABETES RES CLIN PR, V90, P358, DOI 10.1016/j.diabres.2010.09.032
   Eborall HC, 2007, BMJ-BRIT MED J, V335, P486, DOI 10.1136/bmj.39303.723449.55
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Gu K, 1998, DIABETES CARE, V21, P1138, DOI 10.2337/diacare.21.7.1138
   Hainer V, 2013, DIABETES CARE, V36, pS276, DOI 10.2337/dcS13-2023
   Hsieh MC, 2012, EXP DIABETES RES, DOI 10.1155/2012/413782
   Jones MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077941
   Lavie CJ, 2011, CLIN PHARMACOL THER, V90, P23, DOI 10.1038/clpt.2011.87
   Lavie CJ, 2009, J AM COLL CARDIOL, V53, P1925, DOI 10.1016/j.jacc.2008.12.068
   Rahman M, 2012, DIABETIC MED, V29, P886, DOI 10.1111/j.1464-5491.2012.03570.x
   Rahman M, 2012, DIABETOLOGIA, V55, P1651, DOI 10.1007/s00125-011-2441-9
   Rotella CM, 2013, INT J ENDOCRINOL MET, V11, P137, DOI 10.5812/ijem.7551
   Simmons RK, 2011, DIABETOLOGIA, V54, P312, DOI 10.1007/s00125-010-1949-8
   Tseng CH, 2006, DIABETOLOGIA, V49, P1755, DOI 10.1007/s00125-006-0314-4
   Tseng CH, 2012, ANN ONCOL, V23, P153, DOI 10.1093/annonc/mdr334
   Tseng CH, 2009, DIABETOLOGIA, V52, P240, DOI 10.1007/s00125-008-1204-8
   Tseng CH, 2004, DIABETES CARE, V27, P1605, DOI 10.2337/diacare.27.7.1605
   TSENG CH, 2009, OPEN DIABETES J, V2, P18
   Tseng CH, 2008, CIRC J, V72, P1419, DOI 10.1253/circj.CJ-08-0009
   Tseng CH, 2007, CIRC J, V71, P1749, DOI 10.1253/circj.71.1749
   Tseng Chin-Hsiao, 2006, CMAJ, V174, P319, DOI 10.1503/cmaj.050680
   Tseng CH, 2006, ARCH INTERN MED, V166, P1184, DOI 10.1001/archinte.166.11.1184
   Tseng CH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1876-7
   Tseng CH, 2015, J DIABETES RES, DOI 10.1155/2015/678756
   Tseng CH, 2015, J ENVIRON SCI HEAL C, V33, P67, DOI 10.1080/10590501.2015.1003496
   Tseng CH, 2014, J ENVIRON SCI HEAL C, V32, P1, DOI 10.1080/10590501.2014.877645
   Tseng CH, 2013, ATHEROSCLEROSIS, V226, P186, DOI 10.1016/j.atherosclerosis.2012.09.004
   Tseng CH, 2012, DIABETES CARE, V35, P278, DOI 10.2337/dc11-1449
   Tseng CH, 2011, DIABETES CARE, V34, P616, DOI 10.2337/dc10-1640
   Tseng CH, 2010, ATHEROSCLEROSIS, V210, P585, DOI 10.1016/j.atherosclerosis.2009.12.015
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   World Health Organization, 1999, DEF DIAGN CLASS DI 1
   World Health Organization (WHO), 1985, TECHNICAL REPORT SER, V727
   XU Y, 2010, JAMA-J AM MED ASSOC, V310, P948, DOI DOI 10.1001/JAMA.2013.168118
NR 39
TC 4
Z9 4
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 1
PY 2016
VL 11
IS 12
AR e0147916
DI 10.1371/journal.pone.0147916
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EE3JC
UT WOS:000389482700001
PM 27906989
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Peng, XS
   Xie, GF
   Qiu, WZ
   Tian, YH
   Zhang, WJ
   Cao, KJ
AF Peng, Xing-Si
   Xie, Guo-Feng
   Qiu, Wen-Ze
   Tian, Yun-Hong
   Zhang, Wei-Jun
   Cao, Ka-Jia
TI Type 2 Diabetic Mellitus Is a Risk Factor for Nasopharyngeal Carcinoma:
   A 1: 2 Matched Case-Control Study
SO PLOS ONE
LA English
DT Article
ID COLON-CANCER; BREAST-CANCER; PANCREATIC-CANCER; CONSENSUS REPORT;
   SURVIVAL; IMPACT; WOMEN; ACTIVATION; EXPRESSION; PROGNOSIS
AB Background
   Diabetes has been identified as an adverse prognostic variable which associated with an increased mortality in various cancers, including colorectal, lung, and breast cancers. However, previous studies provided inconsistent results on the association between diabetes and nasopharyngeal carcinoma (NPC). The main aim of this study was to investigate the associations between diabetes mellitus and the survival of NPC patients.
   Methods
   This study was designed as a 1: 2 matched case-control study. Cases were patients who met the criteria for the diagnosis of type 2 diabetic mellitus (DM) below. Controls, matched 1: 2, were patients who were normoglycemic (NDM). The survival rates were assessed by Kaplan-Meier analysis, and the survival curves were compared using a log-rank test. Multivariate analysis was conducted using the Cox proportional hazard regression model.
   Results
   Both locoregional relapse-free survival (LRRFS) and disease-free survival (DFS) in the NDM group were higher than that in the DM group (p = 0.001 and p = 0.033). Additionally, subset analyses revealed that the differences in OS, LRRFS, and DFS were all significant between the two groups in the N0-N1 subset (p = 0.007, p = .000 and p = 0.002). The LRRFS was higher in the NDM group in the III-IV, T3-T4 and N0-N1 subsets (p = 0.004, p = 0.002 and p = .000). In T3-T4 subset, the NDM group experienced higher DFS than the DM group (p = 0.039). In multivariate analysis, T stage and N stage were found to be independent predictors for OS, DMFS and DFS; chemotherapy was a significant prognostic factor for DMFS and DFS, age for OS, and diabetes for LRRFS and DFS.
   Conclusions
   Type 2 diabetic mellitus is associated with poorer prognosis among patients with NPC.
C1 [Peng, Xing-Si; Qiu, Wen-Ze; Cao, Ka-Jia] Sun Yat Sen Univ, Dept Nasopharyngeal Carcinoma, Ctr Canc, Guangzhou, Guangdong, Peoples R China.
   [Peng, Xing-Si; Xie, Guo-Feng; Qiu, Wen-Ze; Cao, Ka-Jia] Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Guangdong, Peoples R China.
   [Peng, Xing-Si; Xie, Guo-Feng; Qiu, Wen-Ze; Cao, Ka-Jia] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Guangdong, Peoples R China.
   [Xie, Guo-Feng; Tian, Yun-Hong; Zhang, Wei-Jun] Guangzhou Med Univ, Ctr Canc, Dept Radiat Oncol, Guangzhou, Guangdong, Peoples R China.
RP Cao, KJ (reprint author), Sun Yat Sen Univ, Dept Nasopharyngeal Carcinoma, Ctr Canc, Guangzhou, Guangdong, Peoples R China.; Cao, KJ (reprint author), Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Guangdong, Peoples R China.; Cao, KJ (reprint author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Guangdong, Peoples R China.
EM caokj@sysucc.org.cn
CR Amptoulach S, 2015, J SURG RES, V199, P378, DOI 10.1016/j.jss.2015.05.059
   Chen KH, 2014, ONCOLOGIST, V19, P951, DOI 10.1634/theoncologist.2013-0423
   Dehal AN, 2012, J CLIN ONCOL, V30, P53, DOI 10.1200/JCO.2011.38.0303
   Ding J, 2016, PATHOL ONCOL RES
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163-7258(98)00071-0
   Giovannucci E, 2010, CA-CANCER J CLIN, V60, P207, DOI 10.3322/caac.20078
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Jin TR, 2008, MED HYPOTHESES, V71, P241, DOI 10.1016/j.mehy.2008.03.025
   Liaw YP, 2015, J CANCER, V6, P734, DOI 10.7150/jca.12197
   Liu H, 2006, MED ONCOL, V23, P341, DOI 10.1385/MO:23:3:341
   Luo J, 2015, BRIT J CANCER, V113, P827, DOI 10.1038/bjc.2015.249
   Luo JH, 2016, BRIT J CANCER, V115, P76, DOI 10.1038/bjc.2016.141
   Mao YX, 2015, J CLIN ONCOL, V33, P2120, DOI 10.1200/JCO.2014.60.2896
   Nardon E, 2003, J CLIN PATHOL, V56, P599, DOI 10.1136/jcp.56.8.599
   Nicholas DA, 2016, CELL MOL LIFE SCI
   OuYang PY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111073
   Peng H, 2016, SCI REP-UK, V6, DOI 10.1038/srep22200
   Piatkiewicz P, 2016, DIABETOL METAB SYNDR, V8, DOI 10.1186/s13098-016-0152-6
   Pollak M, 2009, CELL METAB, V9, P401, DOI 10.1016/j.cmet.2009.04.006
   [齐蕾(综述) Qi Lei], 2014, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V41, P1544
   [屈展(综述) Qu Zhan], 2012, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V39, P1670
   Shikata K, 2013, CANCER SCI, V104, P9, DOI 10.1111/cas.12043
   Shimomoto T, 2012, CLIN EXP METASTAS, V29, P915, DOI 10.1007/s10585-012-9480-6
   Tseng CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101553
   Wang Maoxin, 2013, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V27, P1187
   Yang WS, 2013, ANN ONCOL, V24, P1679, DOI 10.1093/annonc/mdt017
   Yang XL, 2010, DIABETES, V59, P1254, DOI 10.2337/db09-1371
   Yuan C, 2015, J CLIN ONCOL, V33, P29, DOI 10.1200/JCO.2014.57.5688
NR 29
TC 0
Z9 0
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 19
PY 2016
VL 11
IS 10
AR e0165131
DI 10.1371/journal.pone.0165131
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DZ9NW
UT WOS:000386204000087
PM 27760202
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Tang, Z
   Wang, JW
   Zhang, H
   Sun, L
   Tang, FR
   Deng, QL
   Yu, JM
AF Tang, Zheng
   Wang, Jiwei
   Zhang, Hao
   Sun, Li
   Tang, Furong
   Deng, Qinglong
   Yu, Jinming
TI Associations between Diabetes and Quality of Life among Breast Cancer
   Survivors
SO PLOS ONE
LA English
DT Article
ID CONSENSUS REPORT; ELDERLY-WOMEN; MELLITUS; OUTCOMES; INSULIN; RISK;
   CHEMOTHERAPY; METAANALYSIS; PROGNOSIS; MORTALITY
AB Objective
   We aimed to investigate the associations between diabetes and quality of life (QOL) among breast cancer survivors.
   Methods
   A cross-sectional survey was conducted at 34 Cancer Recovery Clubs across China from May 2014 to January 2015. Quality of life was measured by the Quality of Life Question-naire-Core 30 (EORTC QLQ-C30) and the Quality of Life Questionnaire-Breast Cancer Module 23 (QLQ-BR23, simplified Chinese version). Information on social-demography, diagnosis and treatment of tumors, and diabetes mellitus were collected by self-reported questionnaires. Univariate analyses of covariance (ANCOVA) was performed to assess the difference in QOL between patients with or without diabetes mellitus, and multiple linear regression models were used to examine the associations after controlling for confounders.
   Results
   Diabetes, both of type 1 diabetes (T1DM) and type 2 diabetes (T2DM) significantly reduced QOL. This effect of diabetes on QOL is independent of tumor size, regional lymph node metastasis, distant metastasis and tumor stage index (TNM). After adjusting for different social-demography, diagnosis and treatment of the tumor, the tumor's stage and other chronic comorbidities, breast cancer survivors with diabetes got significantly lower scores in functional dimensions (including physical, role, emotional and social functionings measured by EORTC QLQ-C30; body image (BRBI) and future perspective (BRFU) measured by QLQ-BR23, as well as economic difficulties than those without diabetes (P-adjusted<0.05). Diabetic patients also obtained higher scores in symptom dimensions, including fatigue, nausea and vomiting, pain, dyspnoea, insomnia, constipation and diarrhoea measured by EORTC QLQ-C30; side effects, breast symptoms and upset by hair loss measured by QLQ-BR23 (P-adjusted<0.05). Compared to patients with T1DM, those with T2D Mare likely to suffer more by loss of functioning.
   Conclusions
   Diabetes was associated with the decreased QOL for breast cancer survivors.
C1 [Tang, Zheng; Wang, Jiwei; Sun, Li; Tang, Furong; Deng, Qinglong; Yu, Jinming] Fudan Univ, Sch Publ Hlth, Key Lab Publ Hlth Safety, Inst Clin Epidemiol,Minist Educ, 130 Dong An Rd, Shanghai 200032, Peoples R China.
   [Tang, Zheng; Yu, Jinming] Fudan Univ, Collaborat Innovat Ctr Social Risks Governance Hl, Shanghai 200032, Peoples R China.
   [Zhang, Hao] Fudan Univ, Shanghai Med Coll, Zhongshan Hosp, Div Nephrol, 180 Feng Lin Rd, Shanghai 200032, Peoples R China.
   [Zhang, Hao] Shanghai Key Lab Kidney & Blood Purificat, Shanghai 200032, Peoples R China.
RP Yu, JM (reprint author), Fudan Univ, Sch Publ Hlth, Key Lab Publ Hlth Safety, Inst Clin Epidemiol,Minist Educ, 130 Dong An Rd, Shanghai 200032, Peoples R China.; Yu, JM (reprint author), Fudan Univ, Collaborat Innovat Ctr Social Risks Governance Hl, Shanghai 200032, Peoples R China.
EM jmy@fudan.edu.cn
FU National Social Science Foundation of China [13CSH076]; Shanghai
   Municipal Commission of Health and Family Planning [20134068]
FX This study was supported by grants from the National Social Science
   Foundation of China (Award Number 13CSH076). Shanghai Municipal
   Commission of Health and Family Planning (Award Number 20134068).
CR Bao PP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117419
   Bowker SL, 2006, DIABETES CARE, V29, P254, DOI 10.2337/diacare.29.02.06.dc05-1558
   Chen WW, 2012, ONCOLOGIST, V17, P485, DOI 10.1634/theoncologist.2011-0412
   Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6
   Romero-Figueroa MD, 2013, CLIN BREAST CANCER, V13, P482, DOI 10.1016/j.clbc.2013.08.001
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Epplein M, 2011, J CLIN ONCOL, V29, P406, DOI 10.1200/JCO.2010.30.6951
   Erickson K, 2011, J CLIN ONCOL, V29, P54, DOI 10.1200/JCO.2010.29.3183
   Giovannucci E, 2010, CA-CANCER J CLIN, V60, P207, DOI 10.3322/caac.20078
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Hardefeldt Prue J, 2012, Endocr Relat Cancer, V19, P793, DOI 10.1530/ERC-12-0242
   Hernandez AV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099317
   Hsieh MC, 2012, EXP DIABETES RES, DOI 10.1155/2012/413782
   Jia XQ, 2015, DIABETES TECHNOL THE, V17, P248, DOI 10.1089/dia.2014.0226
   Jiralerspong S, 2013, ANN ONCOL, V24, P2506, DOI 10.1093/annonc/mdt224
   Joshi S, 2015, BIOMED RES INT, DOI 10.1155/2015/390863
   Joung KH, 2015, BIOMED RES INT, DOI 10.1155/2015/920618
   Krajcik RA, 2002, CANCER EPIDEM BIOMAR, V11, P1566
   Larsson SC, 2007, INT J CANCER, V121, P856, DOI 10.1002/ijc.22717
   Lawlor DA, 2004, CANCER CAUSE CONTROL, V15, P267, DOI 10.1023/B:CACO.0000024225.14618.a8
   Li LY, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0242-4
   Lipscombe LL, 2015, BREAST CANCER RES TR, V150, P613, DOI 10.1007/s10549-015-3323-5
   Luo J, 2015, BRIT J CANCER, V113, P827, DOI 10.1038/bjc.2015.249
   Mohammadzadeh G, 2013, INT J ENDOCRINOL MET, V11, P3, DOI 10.5812/ijem.6535
   Peairs KS, 2011, J CLIN ONCOL, V29, P40, DOI 10.1200/JCO.2009.27.3011
   Richardson LC, 2005, NAT CLIN PRACT ONCOL, V2, P48, DOI 10.1038/ncponc0062
   Schrauder MG, 2011, J CANCER RES CLIN, V137, P975, DOI 10.1007/s00432-010-0960-2
   Srokowski TP, 2009, J CLIN ONCOL, V27, P2170, DOI 10.1200/JCO.2008.17.5935
   Tseng CH, 2009, DIABETOLOGIA, V52, P240, DOI 10.1007/s00125-008-1204-8
   Vigneri P, 2009, ENDOCR-RELAT CANCER, V16, P1103, DOI 10.1677/ERC-09-0087
   Wolf I, 2005, LANCET ONCOL, V6, P103, DOI 10.1016/S1470-2045(05)01736-5
   World Health Organisation, 2009, 2008 2013 ACT PLAN G
   Xu H, 2015, ONCOLOGIST, V20, P1236, DOI 10.1634/theoncologist.2015-0096
   Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292
NR 34
TC 7
Z9 7
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 22
PY 2016
VL 11
IS 6
AR e0157791
DI 10.1371/journal.pone.0157791
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DP0WX
UT WOS:000378212800051
PM 27333326
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Mir, AR
   Uddin, M
   Khan, F
   Alam, K
   Ali, A
AF Mir, Abdul Rouf
   Uddin, Moin
   Khan, Farzana
   Alam, Khursheed
   Ali, Asif
TI Dicarbonyl Induced Structural Perturbations Make Histone H1 Highly
   Immunogenic and Generate an Auto-Immune Response in Cancer
SO PLOS ONE
LA English
DT Article
ID GLYCATION END-PRODUCTS; PROTEIN CROSS-LINKING; IN-VITRO; MAILLARD
   REACTION; NONENZYMATIC GLYCATION; CONFORMATIONAL-CHANGES; SERUM-ALBUMIN;
   RAGE LIGANDS; METHYLGLYOXAL; BIOMARKERS
AB Increased oxidative stress under hyperglycemic conditions, through the interaction of AGEs with RAGE receptors and via activation of interleukin mediated transcription signalling, has been reported in cancer. Proteins modifications are being explored for their roles in the development and progression of cancer and autoantibody response against them is gaining interest as a probe for early detection of the disease. This study has analysed the changes in histone H1 upon modification by methylglyoxal (MG) and its implications in auto-immuno-pathogenesis of cancer. Modified histone showed modifications in the aromatic residues, changed tyrosine microenvironment, intermolecular cross linking and generation of AGEs. It showed masking of hydrophobic patches and a hypsochromic shift in the in ANS specific fluorescence. MG aggressively oxidized histone H1 leading to the accumulation of reactive carbonyls. Far UV CD measurements showed di-carbonyl induced enhancement of the alpha structure and the induction of beta sheet conformation; and thermal denaturation (Tm) studies confirmed the thermal stability of the modified histone. FTIR analysis showed amide I band shift, generation of a carboxyethyl group and N-C alpha vibrations in the modified histone. LCMS analysis confirmed the formation of N epsilon-(carboxyethyl) lysine and electron microscopic studies revealed the amorphous aggregate formation. The modified histone showed altered cooperative binding with DNA. Modified H1 induced high titre antibodies in rabbits and the IgG isolated form sera of rabbits immunized with modified H1 exhibited specific binding with its immunogen in Western Blot analysis. IgG isolated from the sera of patients with lung cancer, prostate cancer, breast cancer and cancer of head and neck region showed better recognition for neo-epitopes on the modified histone, reflecting the presence of circulating autoantibodies in cancer. Since reports suggest a link between AGE-RAGE axis and carcinogenesis, glycoxidation of histone H1 and its immunogenicity paves ways for understanding role of glycoxidatively damaged nuclear proteins in cancer.
C1 [Mir, Abdul Rouf; Uddin, Moin; Khan, Farzana; Alam, Khursheed; Ali, Asif] Aligarh Muslim Univ, Fac Med, Jawaharlal Nehru Med Coll, Dept Biochem, Aligarh, Uttar Pradesh, India.
RP Uddin, M (reprint author), Aligarh Muslim Univ, Fac Med, Jawaharlal Nehru Med Coll, Dept Biochem, Aligarh, Uttar Pradesh, India.
EM moin_u@rediffmail.com
OI Alam, Khursheed/0000-0001-9729-9966
FU DST under its FIST programme
FX Authors are thankful to the Department of science and Technology(DST)
   for instrument facilities created with the financial help from DST under
   its FIST programme.
CR Abe R, 2008, CURR PHARM DESIGN, V14, P940, DOI 10.2174/138161208784139765
   Ahmad S, 2011, BIOCHEM BIOPH RES CO, V407, P568, DOI 10.1016/j.bbrc.2011.03.064
   Ali Rashid, 2002, Methods Mol Biol, V186, P171
   Anderson KS, 2005, J PROTEOME RES, V4, P1123, DOI 10.1021/pr0500814
   Ansari N.A., 2013, ISRN BIOCH
   Ansari NA, 2009, HUM IMMUNOL, V70, P417, DOI 10.1016/j.humimm.2009.03.015
   Arfat MY, 2014, INT J BIOL MACROMOL, V69, P408, DOI 10.1016/j.ijbiomac.2014.05.069
   Barth A, 2002, Q REV BIOPHYS, V35, P369, DOI 10.1017/S0033583502003815
   Bouma B, 2003, J BIOL CHEM, V278, P41810, DOI 10.1074/jbc.M303925200
   CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589
   Chellan P, 1999, ARCH BIOCHEM BIOPHYS, V368, P98, DOI 10.1006/abbi.1999.1291
   Chervona Y, 2012, AM J CANCER RES, V2, P589
   Correa DHA, 2009, J BIOCH, V3, P164
   Dalle-Donne I, 2006, J CELL MOL MED, V10, P389, DOI 10.1111/j.1582-4934.2006.tb00407.x
   DANNA JA, 1974, BIOCHEMISTRY-US, V13, P2093, DOI 10.1021/bi00707a015
   Dixit K, 2011, HUM IMMUNOL, V72, P219, DOI 10.1016/j.humimm.2010.12.004
   Ehrlich H, 2009, INT J BIOL MACROMOL, V44, P51, DOI 10.1016/j.ijbiomac.2008.10.001
   Ghosh S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074336
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Guedes S, 2011, ANAL BIOANAL CHEM, V399, P3529, DOI 10.1007/s00216-011-4679-y
   Hawkins CL, 2009, FREE RADICAL BIO MED, V46, P965, DOI 10.1016/j.freeradbiomed.2009.01.007
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021
   Iram A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072075
   Ishimaru D, 2003, BIOCHEMISTRY-US, V42, P9022, DOI 10.1021/bi034218k
   Jiao L, 2011, CANCER EPIDEM BIOMAR, V20, P1430, DOI 10.1158/1055-9965.EPI-11-0066
   Kalea AZ, 2011, FRONT BIOSCI-LANDMRK, V16, P2756, DOI 10.2741/3884
   Kang JH, 2006, J BIOCHEM MOL BIOL, V39, P335
   Kang R, 2012, P NATL ACAD SCI USA, V109, P7031, DOI 10.1073/pnas.1113865109
   Khan MA, 2012, SCAND J RHEUMATOL, V41, P426, DOI 10.3109/03009742.2012.698300
   Khan TA, 2011, INT J PEPT RES THER, V17, P271, DOI 10.1007/s10989-011-9267-7
   Kishore D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050380
   Ko SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110542
   Krechler T, 2010, CLIN BIOCHEM, V43, P882, DOI 10.1016/j.clinbiochem.2010.04.004
   Kuleva N V, 2006, Tsitologiia, V48, P515
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LO TWC, 1994, J BIOL CHEM, V269, P32299
   Logsdon CD, 2007, CURR MOL MED, V7, P777, DOI 10.2174/156652407783220697
   Lu HL, 2008, J PROTEOME RES, V7, P1388, DOI 10.1021/pr700818f
   Luo XG, 2011, BREAST CANC FOCUSING
   Mir AR, 2014, INT J BIOL MACROMOL, V69, P260, DOI 10.1016/j.ijbiomac.2014.05.057
   Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338
   Pashikanti S, 2011, FREE RADICAL BIO MED, V50, P1410, DOI 10.1016/j.freeradbiomed.2011.01.034
   Pedersen JW, 2011, LABMEDICINE, V42, P623, DOI 10.1309/LM2T3OU3RZRTHKSN
   Roberts MJ, 2003, MUTAT RES-FUND MOL M, V522, P45, DOI 10.1016/S0027-5107(02)00232-4
   Sambrook J., 1989, MOL CLONING LAB MANU
   Sattarahmady N, 2008, CARBOHYD RES, V343, P2229, DOI 10.1016/j.carres.2008.04.036
   Schmitt A, 2005, ANAL BIOCHEM, V338, P201, DOI 10.1016/j.ab.2004.12.003
   Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591
   Soussi T, 2000, CANCER RES, V60, P1777
   Sparvero LJ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-17
   Stopper H, 2003, CANCER LETT, V190, P151, DOI 10.1016/S0304-3835(02)00626-2
   Talasz H, 2002, J CELL BIOCHEM, V85, P24, DOI 10.1002/jcb.10103
   TARKKA T, 1993, BIOCHIM BIOPHYS ACTA, V1180, P294, DOI 10.1016/0925-4439(93)90053-4
   Van Heijst JWJ, 2005, ANN NY ACAD SCI, V1043, P725, DOI 10.1196/annals.1333.084
   Wandall HH, 2010, CANCER RES, V70, P1306, DOI 10.1158/0008-5472.CAN-09-2893
   WELLSKNECHT KJ, 1995, J ORG CHEM, V60, P6246, DOI 10.1021/jo00125a001
   Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311
   Wondrak GT, 2000, BIOCHEM J, V351, P769, DOI 10.1042/0264-6021:3510769
   Zhang G, 2011, J AGR FOOD CHEM, V59, P12037, DOI 10.1021/jf202515k
NR 59
TC 12
Z9 12
U1 2
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 28
PY 2015
VL 10
IS 8
AR e0136197
DI 10.1371/journal.pone.0136197
PG 27
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CQ0PO
UT WOS:000360299100063
PM 26317779
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Song, SS
   Wang, BS
   Zhang, X
   Hao, LL
   Hu, XL
   Li, ZX
   Sun, SL
AF Song, Shanshan
   Wang, Baosheng
   Zhang, Xin
   Hao, Liliang
   Hu, Xianliang
   Li, Zhongxiang
   Sun, Shaolong
TI Long-Term Diabetes Mellitus Is Associated with an Increased Risk of
   Pancreatic Cancer: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-I; MEDICAL HISTORY; PHYSICAL-ACTIVITY; LIFE-STYLE; COHORT;
   INSULIN; SURVIVAL; ALCOHOL; SMOKING; GLUCOSE
AB Purpose
   Previous studies have shown a bidirectional relationship between diabetes and pancreatic cancer (PC). In particular, new-onset diabetes might be induced by PC, and people with long-term diabetes might be at increased risk for the development of PC. The purpose of our study was to examine whether long-term diabetes represented an independent risk factor for PC development.
   Methodology
   A literature search was performed by searching electronic databases for studies published before July 1, 2014, and relative risks (RRs) and corresponding 95% confidence intervals (CIs) were calculated. Data pertaining to diabetes were recorded at both individual and study levels, with RRs calculated separately to analyze the relationship between the duration of diabetes and the development of PC.
   Results
   Forty-four studies were included in this meta-analysis, including 18 studies with a case-control design, 5 with a nested case-control design and 21 with a cohort design. The overall summary estimate for the relationship between the population with a duration of diabetes >= 2 years and PC was 1.64 (1.52-1.78). The pooled RR (95% CI) of PC for the population with a duration of diabetes >= 5 years was 1.58 (1.42-1.75). For the population with a duration of diabetes >= 10 years, the RR (95% CI) of PC was 1.50 (1.28-1.75).
   Conclusions
   Our study suggests that long-term diabetes mellitus is associated with an increased risk of PC. However, the level of risk is negatively correlated with increasing diabetes mellitus duration.
C1 [Song, Shanshan; Wang, Baosheng; Zhang, Xin; Hao, Liliang; Hu, Xianliang; Li, Zhongxiang; Sun, Shaolong] China Med Univ, Shengjing Hosp, Dept Pancreas & Breast Surg, Shenyang, Liaoning, Peoples R China.
RP Sun, SL (reprint author), China Med Univ, Shengjing Hosp, Dept Pancreas & Breast Surg, Shenyang, Liaoning, Peoples R China.
EM sj_sunsl@126.com
FU Science and Technology Department of Liaoning Province [2013225021]
FX This work was supported by a grant from the Science and Technology
   Department of Liaoning Province (2013225021). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ADAMI HO, 1991, CANCER CAUSE CONTROL, V2, P307, DOI 10.1007/BF00051670
   Alderson P, 2004, COCHRANE LIB, P102
   Anderson LN, 2009, CANCER CAUSE CONTROL, V20, P825, DOI 10.1007/s10552-009-9303-5
   Arano T, 2011, INT J CANCER, V129, P2226, DOI 10.1002/ijc.25861
   Arnold LD, 2009, CANCER EPIDEM BIOMAR, V18, P2397, DOI 10.1158/1055-9965.EPI-09-0080
   Aschner P, 2014, DIABETES RES CLIN PR, V103, P238, DOI 10.1016/j.diabres.2013.11.010
   Asiyanbola B, 2009, J GASTROINTEST SURG, V13, P752, DOI 10.1007/s11605-008-0762-x
   Atchison EA, 2011, INT J CANCER, V128, P635, DOI 10.1002/ijc.25362
   Attner B, 2012, CANCER CAUSE CONTROL, V23, P769, DOI 10.1007/s10552-012-9946-5
   Bao Y, 2013, CANCER EPIDEM BIOMAR, V22, P855, DOI 10.1158/1055-9965.EPI-12-1458
   Barb D, 2006, EXPERT OPIN INV DRUG, V15, P917, DOI 10.1517/13543784.15.8.917
   Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487
   Batabyal P, 2014, ANN SURG ONCOL, V21, P2453, DOI 10.1245/s10434-014-3625-6
   Ben QW, 2011, EUR J CANCER, V47, P1928, DOI 10.1016/j.ejca.2011.03.003
   Ben QW, 2011, EUR J CANCER, V47, P248, DOI 10.1016/j.ejca.2010.07.010
   Bonelli L, 2003, PANCREAS, V27, P143, DOI 10.1097/00006676-200308000-00007
   Bosetti C, 2012, NUTR CANCER, V64, P643, DOI 10.1080/01635581.2012.676141
   BOULWARE SD, 1994, J CLIN INVEST, V93, P1131, DOI 10.1172/JCI117065
   Ceni E, 2005, WORLD J GASTROENTERO, V11, P1122, DOI 10.3748/wjg.v11.i8.1122
   Chari ST, 2014, J PANCREAS, V15, P528
   Cheon YK, 2014, GUT LIVER, V8, P205, DOI [10.5009/gn1.2014.8.2.205, 10.5009/gnl.2014.8.2.205]
   Chodick G, 2010, CANCER CAUSE CONTROL, V21, P879, DOI 10.1007/s10552-010-9515-8
   CHOW WH, 1995, J NATL CANCER I, V87, P930, DOI 10.1093/jnci/87.12.930
   Colhoun HM, 2009, DIABETOLOGIA, V52, P1755, DOI 10.1007/s00125-009-1453-1
   Coschigano KT, 2000, ENDOCRINOLOGY, V141, P2608, DOI 10.1210/en.141.7.2608
   CUZICK J, 1989, INT J CANCER, V43, P415, DOI 10.1002/ijc.2910430312
   DEMESQUITA HBB, 1992, INT J CANCER, V52, P17, DOI 10.1002/ijc.2910520105
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eijgenraam P, 2013, BRIT J CANCER, V109, P2924, DOI 10.1038/bjc.2013.629
   Elena JW, 2013, CANCER CAUSE CONTROL, V24, P13, DOI 10.1007/s10552-012-0078-8
   FARROW DC, 1990, INT J CANCER, V45, P816, DOI 10.1002/ijc.2910450504
   Frye JNR, 2000, AUST NZ J SURG, V70, P722, DOI 10.1046/j.1440-1622.2000.01940.x
   Giovannucci E, 2000, CANCER EPIDEM BIOMAR, V9, P345
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Griffiths RI, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-613
   Gudjonsson B, 2009, EUR J GASTROEN HEPAT, V21, P1379, DOI 10.1097/MEG.0b013e328323aab7
   GULLO L, 1994, NEW ENGL J MED, V331, P81, DOI 10.1056/NEJM199407143310203
   Hemminki K, 2010, ONCOLOGIST, V15, P548, DOI 10.1634/theoncologist.2009-0300
   Henry SA, 2013, J PANCREAS, V14, P243, DOI 10.6092/1590-8577/1317
   HIATT RA, 1988, INT J CANCER, V41, P794, DOI 10.1002/ijc.2910410603
   Huxley R, 2005, BRIT J CANCER, V92, P2076, DOI 10.1038/sj.bjc.6602619
   JAIN M, 1991, INT J CANCER, V47, P384, DOI 10.1002/ijc.2910470313
   Jee SH, 2005, JAMA-J AM MED ASSOC, V293, P194, DOI 10.1001/jama.293.2.194
   Khan Mmh, 2006, Asian Pac J Cancer Prev, V7, P253
   Knol MJ, 2008, AM J EPIDEMIOL, V168, P1073, DOI 10.1093/aje/kwn217
   Kong D, 2014, PHARMACOL THERAPEUT, V14, P101
   Kuang TT, 2009, J DIGEST DIS, V10, P26, DOI 10.1111/j.1751-2980.2008.00359.x
   Lee CT, 1996, J GASTROEN HEPATOL, V11, P491, DOI 10.1111/j.1440-1746.1996.tb00296.x
   Li DH, 2011, CANCER CAUSE CONTROL, V22, P189, DOI 10.1007/s10552-010-9686-3
   Li W, 2011, ONCOL REP, V25, P1279, DOI 10.3892/or.2011.1150
   Lipworth L, 2011, DIABETES-METAB RES, V27, P255, DOI 10.1002/dmrr.1162
   Lo AC, 2007, PANCREAS, V35, P120, DOI 10.1097/mpa.0b013e318053e7d3
   Luo JH, 2007, CANCER CAUSE CONTROL, V18, P603, DOI 10.1007/s10552-007-9002-z
   Luo JH, 2013, CANCER CAUSE CONTROL, V24, P577, DOI 10.1007/s10552-012-9996-8
   Maisonneuve P, 2010, ANN EPIDEMIOL, V20, P92, DOI 10.1016/j.annepidem.2009.11.010
   Ollberding NJ, 2012, CANCER EPIDEM BIOMAR, V21, P810, DOI 10.1158/1055-9965.EPI-11-1105
   Otake S, 2010, WORLD J GASTROENTERO, V16, P1252, DOI 10.3748/wjg.v16.i10.1252
   Pollak M, 2008, BEST PRACT RES CL EN, V22, P625, DOI 10.1016/j.beem.2008.08.004
   SHIBATA A, 1994, INT J CANCER, V58, P46, DOI 10.1002/ijc.2910580109
   Stevens RJ, 2009, INT J CANCER, V124, P2400, DOI 10.1002/ijc.24196
   Stolzenberg-Solomon RZ, 2002, CANCER CAUSE CONTROL, V13, P417, DOI 10.1023/A:1015729615148
   Tamayo T, 2014, DIABETES RES CLIN PR, V103, P206, DOI 10.1016/j.diabres.2013.11.007
   Toriola AT, 2014, BRIT J CANCER, V111, P181, DOI 10.1038/bjc.2014.224
   Wang Z, 2014, DIABETES RES CLIN PR, V106, P19, DOI 10.1016/j.diabres.2014.04.007
   Wells GA, 2000, 3 S SYST REV BAS JUL
   Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930
   Wotton CJ, 2011, DIABETOLOGIA, V54, P527, DOI 10.1007/s00125-010-1987-2
   Xu Y, 2013, JAMA-J AM MED ASSOC, V310, P948, DOI 10.1001/jama.2013.168118
   Yeh HC, 2012, DIABETES CARE, V35, P113, DOI 10.2337/dc11-0255
   Yisahak SF, 2014, DIABETES RES CLIN PR, V103, P223, DOI 10.1016/j.diabres.2013.11.009
NR 70
TC 26
Z9 28
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 29
PY 2015
VL 10
IS 7
AR e0134321
DI 10.1371/journal.pone.0134321
PG 27
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CO0JM
UT WOS:000358836800130
PM 26222906
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Lin, CM
   Huang, HL
   Chu, FY
   Fan, HC
   Chen, HA
   Chu, DM
   Wu, LW
   Wang, CC
   Chen, WL
   Lin, SH
   Ho, SY
AF Lin, Chien-Ming
   Huang, Hui-Ling
   Chu, Fang-Ying
   Fan, Hueng-Chuen
   Chen, Hung-An
   Chu, Der-Ming
   Wu, Li-Wei
   Wang, Chung-Ching
   Chen, Wei-Liang
   Lin, Shih-Hua
   Ho, Shinn-Ying
TI Association between Gastroenterological Malignancy and Diabetes Mellitus
   and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER CELLS; HEPATOCELLULAR-CARCINOMA; IN-VITRO; METFORMIN;
   INSULIN; RISK; GROWTH; LIVER; INCREASES; MORTALITY
AB Background
   The relationship between diabetes mellitus (DM) and cancer incidence has been evaluated in limited kinds of cancer. The effect of anti-diabetic therapy (ADT) on carcinogenesis among diabetic patients is also unclear.
   Materials and Methods
   Using population-based representative insurance claims data in Taiwan, 36,270 DM patients and 145,080 comparison subjects without DM were identified from claims from 2005 to 2010. The association between the top ten leading causes of cancer-related death in Taiwan and DM was evaluated. Whether ADT altered the risk of developing cancer was also investigated.
   Results
   Incidence of cancer at any site was significantly higher in patients with DM than in those without (p<0.001). The risk of carcinogenesis imparted by DM was greatest in gastroenterological malignancies (liver, pancreas, and colorectal cancer) as well as lung, breast and oral cancer (p<0.001). Among the oral types of ADT, metformin decreased the risk of lung and liver cancer, but had less effect on reducing the risk of colorectal cancer. alpha-glucosidase inhibitor decreased the risk of developing liver, colorectal, and breast cancer. Apart from intermediateacting insulin, rapid-acting, long-acting, and combination insulin treatment significantly reduced the overall cancer risk among all DM patients. In subgroup analysis, long-acting insulin treatment significantly decreased the risk of lung, liver, and colorectal cancer.
   Conclusion
   Our results supported the notion that pre-existing DM increases the incidence of gastroenterological cancer. ADT, especially metformin, alpha-glucosidase inhibitor, and long-acting insulin treatment, may protect patients with DM against these malignancies. It is crucial that oncologists should closely collaborate with endocrinologists to provide an optimal cancerspecific therapy and diabetic treatment to patients simultaneously with cancer and DM.
C1 [Lin, Chien-Ming; Fan, Hueng-Chuen; Chu, Der-Ming] Triserv Gen Hosp, Natl Def Med Ctr, Dept Pediat, Taipei, Taiwan.
   [Lin, Chien-Ming; Wu, Li-Wei; Wang, Chung-Ching; Chen, Wei-Liang] Grad Inst Med Sci, Natl Def Med Ctr, Taipei, Taiwan.
   [Huang, Hui-Ling; Chu, Fang-Ying; Chen, Hung-An; Ho, Shinn-Ying] Natl Chiao Tung Univ, Inst Bioinformat & Syst Biol, Hsinchu, Taiwan.
   [Huang, Hui-Ling; Ho, Shinn-Ying] Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu, Taiwan.
   [Wu, Li-Wei; Wang, Chung-Ching; Chen, Wei-Liang] Triserv Gen Hosp, Natl Def Med Ctr, Dept Family & Community Med, Taipei, Taiwan.
   [Lin, Shih-Hua] Triserv Gen Hosp, Natl Def Med Ctr, Dept Med, Div Nephrol, Taipei, Taiwan.
RP Ho, SY (reprint author), Natl Chiao Tung Univ, Inst Bioinformat & Syst Biol, Hsinchu, Taiwan.
EM syho@mail.nctu.edu.tw
FU Tri-Service General Hospital [(TSGH)-C103-019]; National Science Council
   of Taiwan [NSC-103-2221-E009-117-]; "Center for Bioinformatics Research
   of Aiming for the Top University Program" of the National Chiao Tung
   University and Ministry of Education, Taiwan, R.O.C. [103W962]; USTUCSD
   International Center of Excellence in Advanced Bioengineering - Taiwan
   National Science Council I-RiCE Program [NSC-103-2911-I-009-101]
FX This work was supported by grant number Tri-Service General Hospital
   (TSGH)-C103-019. This work was also funded by National Science Council
   of Taiwan under the contract number NSC-103-2221-E009-117-, and "Center
   for Bioinformatics Research of Aiming for the Top University Program" of
   the National Chiao Tung University and Ministry of Education, Taiwan,
   R.O.C. for the project 103W962. This work was also supported in part by
   the USTUCSD International Center of Excellence in Advanced
   Bioengineering sponsored by the Taiwan National Science Council I-RiCE
   Program under Grant Number: NSC-103-2911-I-009-101.
CR Algire C, 2008, ENDOCR-RELAT CANCER, V15, P833, DOI 10.1677/ERC-08-0038
   Alimova IN, 2009, CELL CYCLE, V8, P909, DOI 10.4161/cc.8.6.7933
   Ben Sahra I, 2008, ONCOGENE, V27, P3576, DOI 10.1038/sj.onc.1211024
   Bodmer M, 2010, DIABETES CARE, V33, P1304, DOI 10.2337/dc09-1791
   Bowker SL, 2006, DIABETES CARE, V29, P254, DOI 10.2337/diacare.29.02.06.dc05-1558
   Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6
   DeCensi A, 2010, CANCER PREV RES, V3, P1451, DOI 10.1158/1940-6207.CAPR-10-0157
   Donadon V, 2009, WORLD J GASTROENTERO, V15, P2506, DOI 10.3748/wjg.15.2506
   Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310
   Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7
   Gerstein HC, 2012, NEW ENGL J MED, V367, P319, DOI 10.1056/NEJMoa1203858
   Giovannucci E, 2001, J NUTR, V131, p3109S, DOI 10.1093/jn/131.11.3109S
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Hassan MM, 2010, CANCER-AM CANCER SOC, V116, P1938, DOI 10.1002/cncr.24982
   Hemkens LG, 2009, DIABETOLOGIA, V52, P1732, DOI 10.1007/s00125-009-1418-4
   HEUSON JC, 1972, CANCER RES, V32, P226
   Jiang Y., 2009, Plant Biology (Rockville), V2009, P111
   Jonasson JM, 2009, DIABETOLOGIA, V52, P1745, DOI 10.1007/s00125-009-1444-2
   Lai SW, 2012, AM J GASTROENTEROL, V107, P46, DOI 10.1038/ajg.2011.384
   Landman GWD, 2010, DIABETES CARE, V33, P322, DOI 10.2337/dc09-1380
   Lee MS, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-20
   Lee MY, 2012, METABOLISM, V61, P242, DOI 10.1016/j.metabol.2011.06.020
   Liu BL, 2009, CELL CYCLE, V8, P2031, DOI 10.4161/cc.8.13.8814
   Mardilovich K, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-14
   Ministry of Health and Welfare Taiwan, 2012, CAUS DEATH STAT
   Monami M, 2009, ACTA DIABETOL, V46, P279, DOI 10.1007/s00592-008-0083-2
   Pinheiro SP, 2005, CANCER EPIDEM BIOMAR, V14, P2147, DOI 10.1158/1055-9965.EPI-04-0944
   Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536
   van Kruijsdijk RCM, 2009, CANCER EPIDEM BIOMAR, V18, P2569, DOI 10.1158/1055-9965.EPI-09-0372
   VANDER HMG, 2009, SCIENCE, V324, P1029, DOI DOI 10.1126/SCIENCE.1160809
   Welfare MoHa Taiwan, 2010, CANC REG ANN REP
   Wright JL, 2009, CANCER CAUSE CONTROL, V20, P1617, DOI 10.1007/s10552-009-9407-y
   Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500
   Zhang H, 2007, CANCER RES, V67, P391, DOI 10.1158/0008-5472.CAN-06-1712
NR 34
TC 15
Z9 15
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 15
PY 2015
VL 10
IS 5
AR e0125421
DI 10.1371/journal.pone.0125421
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI7AU
UT WOS:000354916100026
PM 25978841
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Lee, H
   Kuk, H
   Byun, SS
   Lee, SE
   Hong, SK
AF Lee, Hakmin
   Kuk, Harim
   Byun, Seok-Soo
   Lee, Sang Eun
   Hong, Sung Kyu
TI Preoperative Glycemic Control Status as a Significant Predictor of
   Biochemical Recurrence in Prostate Cancer Patients after Radical
   Prostatectomy
SO PLOS ONE
LA English
DT Article
ID DIABETES-MELLITUS; COLORECTAL-CANCER; SEARCH DATABASE; UNITED-STATES;
   MEN; MORTALITY; METFORMIN; SURVIVAL; TESTOSTERONE; METAANALYSIS
AB Background
   The effect of diabetes mellitus (DM) on prostate cancer (PCa) outcome remains controversial. Thus, we investigated the association of DM history, glycemic control, and metformin use with oncologic outcomes after radical prostatectomy (RP).
   Methods
   We reviewed the records of 746 contemporary patients who had hemoglobin A1c (HbA1c) measured within the 6 months preceding RP. The associations between clinical variables and risk of adverse pathological features and biochemical recurrence (BCR) were tested using a multivariate logistic regression and multiple Cox-proportional hazards model, respectively. BCR was defined as prostatic specific antigen (PSA) > 0.2 ng/mL in 2 consecutive tests.
   Results
   There were no significant differences in the rates of adverse pathologic features and BCR-free survival between patients with (n = 209) and without (n = 537) a history of DM diagnosis (all p > 0.05). In multivariate analyses, high HbA1c level (>= 6.5%) was significantly related with high pathologic Gleason score (>= 4+3; odds ratio [OR] 1.704, p = 0.019) and BCR-free survival (OR 1.853, p = 0.007). Metformin use was not associated with BCR-free survival (OR 0.662, p = 0.125).
   Conclusions
   Poor glycemic control was significantly associated with BCR after RP. Meanwhile, metformin use was not associated with biochemical outcome after RP. Further investigation would be needed to identify exact mechanism underlying the impact of glycemic control on PCa treatment outcome.
C1 [Lee, Hakmin; Kuk, Harim; Byun, Seok-Soo; Lee, Sang Eun; Hong, Sung Kyu] Seoul Natl Univ, Bundang Hosp, Dept Urol, Songnam, South Korea.
RP Hong, SK (reprint author), Seoul Natl Univ, Bundang Hosp, Dept Urol, Songnam, South Korea.
EM hsk823@chol.com
CR Barba M, 2012, ANN ONCOL, V23, P1838, DOI 10.1093/annonc/mdr540
   Ben Sahra I, 2008, ONCOGENE, V27, P3576, DOI 10.1038/sj.onc.1211024
   Bonovas S, 2004, DIABETOLOGIA, V47, P1071, DOI 10.1007/s00125-004-1415-6
   Centers for Disease Control and Prevention (CDC), 2010, NAT DIAB FACT SHEET
   Chan JM, 2005, CANCER CAUSE CONTROL, V16, P789, DOI 10.1007/s10552-005-3301-z
   Gapstur SM, 2001, CANCER CAUSE CONTROL, V12, P763, DOI 10.1023/A:1011279907108
   Garcia-Cruz E, 2012, BJU INT, V110, pE541, DOI 10.1111/j.1464-410X.2012.11232.x
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   He XX, 2011, ANN ONCOL, V22, P2640, DOI 10.1093/annonc/mdr020
   Hong SK, 2009, PROSTATE, V69, P820, DOI 10.1002/pros.20932
   Isom-Batz G, 2005, J UROLOGY, V173, P1935, DOI 10.1097/01.ju.0000158040.33531.e7
   Jayachandran J, 2010, CANCER EPIDEM BIOMAR, V19, P9, DOI 10.1158/1055-9965.EPI-09-0777
   Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437
   Kasper JS, 2008, CANCER CAUSE CONTROL, V19, P703, DOI 10.1007/s10552-008-9133-x
   Kasper JS, 2006, CANCER EPIDEM BIOMAR, V15, P2056, DOI 10.1158/1055-9965.EPI-06-0410
   Keneda K, 2012, J SURG ONCOL, V105, P606, DOI [10.1002/jso.22137, DOI 10.1002/JSO.22137]
   Kim HS, 2010, PROSTATE, V70, P1540, DOI 10.1002/pros.21189
   Krone KA, 2005, INTEGR CANC THER, V4, P25
   Ma J, 2008, LANCET ONCOL, V9, P1039, DOI 10.1016/S1470-2045(08)70235-3
   Merrick GS, 2007, CANCER, V110, P289, DOI 10.1002/cncr.22793
   Patel T, 2010, UROLOGY, V76, P1240, DOI 10.1016/j.urology.2010.03.059
   Rieken M, 2014, WORLD J UROL, V32, P999, DOI 10.1007/s00345-013-1171-7
   Siddiqui AA, 2008, DIGEST DIS SCI, V53, P2486, DOI 10.1007/s10620-008-0264-4
   Smith MR, 2008, J CLIN ONCOL, V26, P4333, DOI 10.1200/JCO.2008.16.5845
   Spratt DE, 2013, EUR UROL, V63, P709, DOI 10.1016/j.eururo.2012.12.004
   Wright JL, 2013, PROSTATE CANCER P D, V16, P204, DOI 10.1038/pcan.2013.5
   Wu CW, 2013, BJU INT, V111, pE310, DOI 10.1111/j.1464-410X.2012.11687.x
NR 27
TC 11
Z9 12
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 21
PY 2015
VL 10
IS 4
AR e0124761
DI 10.1371/journal.pone.0124761
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CG3XJ
UT WOS:000353212600084
PM 25897669
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Besic, V
   Shi, HJ
   Stubbs, RS
   Hayes, MT
AF Besic, Vinko
   Shi, Hongjun
   Stubbs, Richard S.
   Hayes, Mark T.
TI Aberrant Liver Insulin Receptor Isoform A Expression Normalises with
   Remission of Type 2 Diabetes after Gastric Bypass Surgery
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-II; MESSENGER-RNA; NEONATAL HEPATOCYTES; SPLICE VARIANTS;
   SKELETAL-MUSCLE; GLUCOSE-UPTAKE; HIGH-AFFINITY; HEPG2 CELLS; RESISTANCE;
   CANCER
AB Type 2 diabetes mellitus ( T2DM) results from a combination of progressive insulin resistance and loss of pancreatic beta cell function and/or mass. Insulin signalling occurs through the insulin receptor, (INSR) which is alternatively spliced into two isoforms: INSRA (-exon 11) and INSRB (+exon 11). Because the INSR isoforms have different functional characteristics, their relative expression ratio has been implicated in the pathogenesis of insulin resistance and T2DM. We studied levels of INSR isoform mRNA in liver samples taken from 46 individuals with or without T2DM at Roux-en-Y (RYGB) surgery, and on average 17 (+/- 5.6) months later in 16 of the same individuals (8 diabetic and non-diabetic patients). INSRA or INSRB was also overexpressed in HepG2 cells to ascertain their effect on AKT phosphorylation and PCK1 expression as markers of insulin-mediated metabolic signalling. We found the INSRB:A isoform ratio was reduced in individuals with T2DM in comparison to those with normal glucose tolerance and normalised with remission of diabetes. The INSRB:A ratio increased due to a reduction in the alternatively spliced INSRA isoform following remission of diabetes. Overexpressing INSRA isoform in HepG2 hepatoma cells reduced inhibition of PCK1 transcription and did not increase AKT phosphorylation in response to insulin load compared to the effect of overexpressing the B isoform. Data presented here revitalizes the role of the INSR isoforms in the pathogenesis of T2DM, and suggests that an abrogated INSRB:A ratio that favours the INSRA isoform may negatively impact insulin-mediated metabolic signalling.
C1 [Besic, Vinko; Shi, Hongjun; Stubbs, Richard S.; Hayes, Mark T.] Univ Otago, Wakefield Biomed Res Unit, Dept Pathol & Mol Med, Wellington, New Zealand.
   [Stubbs, Richard S.] Wakefield Hosp, Wakefield Clin, Wellington, New Zealand.
   [Hayes, Mark T.] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia.
RP Besic, V (reprint author), Univ Otago, Wakefield Biomed Res Unit, Dept Pathol & Mol Med, Wellington, New Zealand.
EM vinko.besic@otago.ac.nz; mark.hayes@anu.edu.au
RI Besic, Vinko/K-2955-2015
OI Besic, Vinko/0000-0002-8137-1019
FU Wellington Medical Research Foundation; Wakefield Gastroenterology
   Research Trust; Wakefield Clinic
FX This work was supported by the Wellington Medical Research Foundation,
   Wakefield Gastroenterology Research Trust and the Wakefield Clinic who
   provided contributions to salaries and consumables. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR ANDERSON CM, 1993, J CLIN ENDOCR METAB, V76, P1380, DOI 10.1210/jc.76.5.1380
   Belfiore A, 2009, ENDOCR REV, V30, P586, DOI 10.1210/er.2008-0047
   BENECKE H, 1992, J CLIN INVEST, V89, P2066, DOI 10.1172/JCI115819
   Birkenfeld AL, 2011, J BIOL CHEM, V286, P36163, DOI 10.1074/jbc.M111.228817
   Blanquart C, 2008, BIOCHEM PHARMACOL, V76, P873, DOI 10.1016/j.bcp.2008.07.027
   Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5
   Bock G, 2007, DIABETES, V56, P1703, DOI 10.2337/db06-1776
   Braatvedt G, 2006, NZ MED J, P119
   Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0
   Buse JB, 2009, DIABETES CARE, V32, P2133, DOI 10.2337/dc09-9036
   Campos GM, 2010, J GASTROINTEST SURG, V14, P15, DOI 10.1007/s11605-009-1060-y
   CONSOLI A, 1989, DIABETES, V38, P550, DOI 10.2337/diabetes.38.5.550
   De Meyts P, 2012, ENDOCRINOLOGY, V153, P2054, DOI 10.1210/en.2012-1234
   Denley A, 2003, HORM METAB RES, V35, P778
   Di Paola R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019462
   EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4
   Ehrhardt C, 2006, SIGNAL TRANSDUCT, V6, P179, DOI DOI 10.1002/SITA.200500073
   Escribano O, 2009, DIABETES, V58, P820, DOI 10.2337/db08-0551
   Foo J, 2011, OBES SURG, V21, P1914, DOI 10.1007/s11695-011-0527-6
   Frasca F, 1999, MOL CELL BIOL, V19, P3278
   Fukumoto Y, 2010, CYTOTECHNOLOGY, V62, P73, DOI 10.1007/s10616-010-9259-z
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Gonzalez-Rodriguez A, 2008, AM J PHYSIOL-GASTR L, V295, pG338, DOI 10.1152/ajpgi.00514.2007
   Harrington SC, 2012, GROWTH HORM IGF RES, V22, P108, DOI 10.1016/j.ghir.2012.04.001
   Johnson JA, 2012, DIABETOLOGIA, V55, P1607, DOI 10.1007/s00125-012-2525-1
   KELLERER M, 1993, DIABETOLOGIA, V36, P628, DOI 10.1007/BF00404072
   KELLERER M, 1992, BIOCHEMISTRY-US, V31, P4588, DOI 10.1021/bi00134a008
   Kleemann R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008817
   KOSAKI A, 1993, J BIOL CHEM, V268, P21990
   KOSAKI A, 1995, J BIOL CHEM, V270, P20816, DOI 10.1074/jbc.270.35.20816
   Lima MMO, 2010, J CLIN ENDOCR METAB, V95, P3871, DOI 10.1210/jc.2010-0085
   Malaguarnera R, 2012, ENDOCRINOLOGY, V153, P2152, DOI 10.1210/en.2011-1843
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   MCCLAIN DA, 1991, MOL ENDOCRINOL, V5, P734, DOI 10.1210/mend-5-5-734
   Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1
   MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263
   MOSTHAF L, 1993, P NATL ACAD SCI USA, V90, P2633, DOI 10.1073/pnas.90.7.2633
   MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x
   MOSTHAF L, 1991, P NATL ACAD SCI USA, V88, P4728, DOI 10.1073/pnas.88.11.4728
   Nevado C, 2006, ENDOCRINOLOGY, V147, P3709, DOI 10.1210/en.2005-1663
   NORGREN S, 1994, P NATL ACAD SCI USA, V91, P1465, DOI 10.1073/pnas.91.4.1465
   NORGREN S, 1993, DIABETES, V42, P675, DOI 10.2337/diabetes.42.5.675
   NORGREN S, 1994, BIOCHEM BIOPH RES CO, V199, P277, DOI 10.1006/bbrc.1994.1225
   Pandini G, 2003, J BIOL CHEM, V278, P42178, DOI 10.1074/jbc.M304980200
   Renehan AG, 2006, TRENDS ENDOCRIN MET, V17, P328, DOI 10.1016/j.tem.2006.08.006
   Savkur RS, 2001, NAT GENET, V29, P40, DOI 10.1038/ng704
   SEINO S, 1989, BIOCHEM BIOPH RES CO, V159, P312, DOI 10.1016/0006-291X(89)92439-X
   SELL SM, 1994, J BIOL CHEM, V269, P30769
   Sen S, 2009, MOL CELL BIOL, V29, P871, DOI 10.1128/MCB.01709-08
   SESTI G, 1995, DIABETOLOGIA, V38, P445, DOI 10.1007/BF00410282
   ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0
   White S, 2005, OBES SURG, V15, P155, DOI 10.1381/0960892053268282
   Wickremesekera K, 2005, OBES SURG, V15, P474, DOI 10.1381/0960892053723402
   YAMAGUCHI Y, 1993, ENDOCRINOLOGY, V132, P1132, DOI 10.1210/en.132.3.1132
NR 54
TC 7
Z9 8
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 5
PY 2015
VL 10
IS 3
AR e0119270
DI 10.1371/journal.pone.0119270
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC9KG
UT WOS:000350688100098
PM 25742416
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Chen, SC
   Su, YC
   Lu, YT
   Ko, PCI
   Chang, PY
   Lin, HJ
   Ho, HN
   Lai, YP
AF Chen, Shu-Ching
   Su, Yu-Chia
   Lu, Ya-Ting
   Ko, Patrick Chow-In
   Chang, Pei-Yu
   Lin, Hung-Ju
   Ho, Hong-Nerng
   Lai, Yo-Ping
TI Defects in the Acquisition of Tumor-Killing Capability of CD8(+)
   Cytotoxic T Cells in Streptozotocin-Induced Diabetic Mice
SO PLOS ONE
LA English
DT Article
ID CYTOLYTIC ACTIVITY; COLORECTAL-CANCER; IMMUNE-RESPONSE; B-CELL;
   LYMPHOCYTES; MELLITUS; ACTIVATION; CTL; DIFFERENTIATION; IMMUNOTHERAPY
AB Emerging evidences have shown that diabetes mellitus not only raises risk but also heightens mortality rate of cancer. It is not clear, however, whether antitumor CD8(+) cytotoxic T lymphocyte (CTL) response is down-modulated in diabetic hosts. We investigated the impact of hyperglycemia on CTLs' acquisition of tumor-killing capability by utilizing streptozotocin-induced diabetic (STZ-diabetic) mice. Murine diabetes was induced by intraperitoneal injection of STZ (200 mg/kg) in C57BL/6 mice, 2C-T cell receptor (TCR) transgenic and P14-TCR transgenic mice. The study found that, despite harboring intact proliferative capacity measured with CFSE labeling and MTT assay, STZ-diabetic CD8(+) CTLs displayed impaired effector functions. After stimulation, STZ-diabetic CD8(+) CTLs produced less perforin and TNF alpha assessed by intracellular staining, as well as expressed less CD103 protein. Furthermore, adoptive transfer of STZ-diabetic P14 CD8(+) effector cells showed an insufficient recruitment to the B16.gp33 melanoma and inadequate production of perforin, granzyme B and TNF alpha determined by immunohistochemistry in the tumor milieu. As a result, STZ-diabetic CD8(+) effector cells were neither able to eliminate tumor nor to improve survival of tumor-bearing mice. Taken together, our data suggest that CD8(+) CTLs are crippled to infiltrate into tumors and thus fail to acquire tumor-killing capability in STZ-diabetic hosts.
C1 [Chen, Shu-Ching; Chang, Pei-Yu] Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan.
   [Su, Yu-Chia] Natl Lab Anim Ctr, Natl Appl Res Labs, Taipei, Taiwan.
   [Lu, Ya-Ting; Lin, Hung-Ju; Lai, Yo-Ping] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
   [Ko, Patrick Chow-In] Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan.
   [Ho, Hong-Nerng] Natl Taiwan Univ, Coll Med, Dept Obstet & Gynecol, Taipei 10764, Taiwan.
RP Lai, YP (reprint author), Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
EM yopinglai@ntu.edu.tw
OI Ho, Hong-Nerng/0000-0002-7207-0089; /0000-0002-9904-8199
FU National Science Council (NSC) [99-2314-B-002-081-MY3]; National Taiwan
   University Hospital (NTUH) [98P22]; Liver Disease Prevention and
   Treatment Research Foundation
FX The study was supported by grants from National Science Council (NSC
   99-2314-B-002-081-MY3), National Taiwan University Hospital (NTUH.
   98P22) and Liver Disease Prevention and Treatment Research Foundation.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Anikeeva N, 2005, P NATL ACAD SCI USA, V102, P6437, DOI 10.1073/pnas.0502467102
   BENTAL M, 1993, MAGN RESON MED, V29, P317, DOI 10.1002/mrm.1910290307
   Castellino F, 2006, NATURE, V440, P890, DOI 10.1038/nature04651
   Chen HF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067420
   Connolly GC, 2012, CANCER INVEST, V30, P698, DOI 10.3109/07357907.2012.732162
   DELESPESSE G, 1974, CLIN EXP IMMUNOL, V18, P461
   DEMARIA R, 1994, EUR J IMMUNOL, V24, P999
   DIEPERSLOOT RJA, 1987, DIABETOLOGIA, V30, P397, DOI 10.1007/BF00292541
   Eibl N, 2002, CLIN IMMUNOL, V103, P249, DOI 10.1006/clim.2002.5220
   Fox CJ, 2005, NAT REV IMMUNOL, V5, P844, DOI 10.1038/nri1710
   Franciszkiewicz K, 2013, CANCER RES, V73, P617, DOI 10.1158/0008-5472.CAN-12-2569
   Franciszkiewicz K, 2009, CANCER RES, V69, P6249, DOI 10.1158/0008-5472.CAN-08-3571
   Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245
   Ganss R, 2002, CANCER RES, V62, P1462
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Jacobs SR, 2008, J IMMUNOL, V180, P4476, DOI 10.4049/jimmunol.180.7.4476
   JANEWAY CA, 1987, J IMMUNOL, V138, P1051
   Johansson A, 2012, ONCOIMMUNOLOGY, V1, P1395, DOI 10.4161/onci.20981
   Johansson A, 2012, P NATL ACAD SCI USA, V109, P7841, DOI 10.1073/pnas.1118296109
   JUNOD A, 1969, J CLIN INVEST, V48, P2129, DOI 10.1172/JCI106180
   Kaech SM, 2002, CELL, V111, P837, DOI 10.1016/S0092-8674(02)01139-X
   KAKIUCHI T, 1983, J IMMUNOL, V131, P109
   Klebanoff CA, 2005, P NATL ACAD SCI USA, V102, P9571, DOI 10.1073/pnas.0503726102
   Lai YP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007766
   LAVECCHIA C, 1991, EUR J CANCER, V27, P582, DOI 10.1016/0277-5379(91)90223-Z
   Le Floc'h A, 2007, J EXP MED, V204, P559, DOI 10.1084/jem.20061524
   Lyman MA, 2004, J IMMUNOL, V172, P6558, DOI 10.4049/jimmunol.172.11.6558
   MacIver NJ, 2008, J LEUKOCYTE BIOL, V84, P949, DOI 10.1189/jlb.0108024
   MacIver NJ, 2013, ANNU REV IMMUNOL, V31, P259, DOI 10.1146/annurev-immunol-032712-095956
   MAHMOUD AAF, 1976, J CLIN INVEST, V57, P362, DOI 10.1172/JCI108287
   Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037
   Milstein O, 2011, BLOOD, V117, P1042, DOI 10.1182/blood-2010-05-283770
   Naito Y, 1998, CANCER RES, V58, P3491
   Prevost-Blondel A, 1998, J IMMUNOL, V161, P2187
   RAKIETEN N, 1963, CANCER CHEMOTH REP, P91
   Springer TA, 2012, CURR OPIN CELL BIOL, V24, P107, DOI 10.1016/j.ceb.2011.10.004
   Stattin P, 2007, DIABETES CARE, V30, P561, DOI 10.2337/dc06-0922
   Stentz FB, 2003, CURR DRUG TARGETS, V4, P493, DOI 10.2174/1389450033490966
   WILLIAMS JC, 1984, CANCER, V54, P3070, DOI 10.1002/1097-0142(19841215)54:12<3070::AID-CNCR2820541243>3.0.CO;2-N
NR 39
TC 8
Z9 8
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 12
PY 2014
VL 9
IS 11
AR e109961
DI 10.1371/journal.pone.0109961
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA8CP
UT WOS:000349144400008
PM 25390652
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU OuYang, PY
   Su, Z
   Tang, J
   Lan, XW
   Mao, YP
   Deng, WG
   Xie, FY
AF OuYang, Pu-Yun
   Su, Zhen
   Tang, Jie
   Lan, Xiao-Wen
   Mao, Yan-Ping
   Deng, Wuguo
   Xie, Fang-Yun
TI Diabetes, Prediabetes and the Survival of Nasopharyngeal Carcinoma: A
   Study of 5,860 Patients
SO PLOS ONE
LA English
DT Article
ID FASTING BLOOD-GLUCOSE; INTENSITY-MODULATED RADIOTHERAPY; PROGNOSTIC
   IMPACT; ALL-CAUSE; CANCER; OUTCOMES; RISK; MELLITUS; MORTALITY;
   EPIDEMIOLOGY
AB Background: The incidence of diabetes is increasing. But the impact of diabetes and prediabetes on survival of patients with nasopharyngeal carcinoma (NPC) has received little evaluation.
   Methods: In a cohort of 5,860 patients, we compared the disease specific survival (DSS), locoregional relapse-free survival (LRFS) and distant metastasis-free survival (DMFS) of patients with diabetes, prediabetes and normoglycemia defined by pretreatment fasting plasma glucose (FPG) using Kaplan-Meier method, log-rank test and Cox proportional hazards model.
   Results: Comparing to normoglycemic patients, the diabetic and the prediabetic were generally older, fatter, had hypertension, heart diseases and hyperlipaemia and usually received radiotherapy alone. But both the diabetic and the prediabetic had similar DSS, LRFS and DMFS to normoglycemic patients, even adjusting for such important factors as age, gender, smoking, drinking, hypertension, heart diseases, body mass index, hyperlipaemia, titer of VCA-IgA and EA-IgA, pathology, T-stage, N-stage, chemotherapy and radiotherapy (P>0.05 for all). Additionally, the findings remained unchanged in sensitivity analysis by excluding patients with known diabetes history and in subgroups of the various factors.
   Conclusions: The diabetic and prediabetic NPC patients had similar survival to normoglycemic NPC patients. These data, in the largest reported cohort, are the first to evaluate the association between diabetes, prediabetes and the survival in NPC. The findings are relevant to patient management and provided evidence of the effect on this disease exerted by comorbidities.
C1 [OuYang, Pu-Yun; Su, Zhen; Tang, Jie; Lan, Xiao-Wen; Mao, Yan-Ping; Xie, Fang-Yun] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol,State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China.
   [Deng, Wuguo] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Dept Expt Res,State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China.
RP Xie, FY (reprint author), Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol,State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China.
EM xiefy@sysucc.org.cn
CR [Anonymous], 2014, DIABETES CARE S1, V37, pS81
   Atchison EA, 2011, INT J CANCER, V128, P635, DOI 10.1002/ijc.25362
   Bosetti C, 2012, NUTR CANCER, V64, P643, DOI 10.1080/01635581.2012.676141
   Cai Q, 2013, BRIT J CANCER, V108, P380, DOI 10.1038/bjc.2012.566
   Chang ET, 2006, CANCER EPIDEM BIOMAR, V15, P1765, DOI 10.1158/1055-9965.EPI-06-0353
   Chu CK, 2010, ANN SURG ONCOL, V17, P502, DOI 10.1245/s10434-009-0789-6
   COX DR, 1972, J R STAT SOC B, V34, P187
   Edge SB, 2010, AJCC CANC STAGING HD
   Erickson K, 2011, J CLIN ONCOL, V29, P54, DOI 10.1200/JCO.2010.29.3183
   Gerstein HC, 2012, NEW ENGL J MED, V367, P319, DOI 10.1056/NEJMoa1203858
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Huang PY, 2013, EUR J CANCER, V49, P1923, DOI 10.1016/j.ejca.2013.01.027
   Ioacara S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093132
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Kiderlen M, 2013, ANN ONCOL, V24, P3011, DOI 10.1093/annonc/mdt367
   Lai SZ, 2011, INT J RADIAT ONCOL, V80, P661, DOI 10.1016/j.ijrobp.2010.03.024
   Liu H, 2006, MED ONCOL, V23, P341, DOI 10.1385/MO:23:3:341
   Liu N, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70102-X
   Luo J, 2014, BRIT J CANCER, V110, P1847, DOI 10.1038/bjc.2014.68
   Luo JH, 2012, LUNG CANCER, V76, P242, DOI 10.1016/j.lungcan.2011.10.019
   Margel D, 2013, J CLIN ONCOL, V31, P3069, DOI 10.1200/JCO.2012.46.7043
   Meyerkardt JA, 2003, J CLIN ONCOL, V21, P433, DOI 10.1200/JCO.2003.07.125
   Minicozzi P, 2013, EUR J CANCER, V49, P3881, DOI 10.1016/j.ejca.2013.08.004
   OuYang PY, 2013, BRIT J CANCER, V109, P788, DOI 10.1038/bjc.2013.343
   OuYang PY, 2013, CANCER EPIDEM BIOMAR, V22, P2285, DOI 10.1158/1055-9965.EPI-13-0546
   Richardson LC, 2005, NAT CLIN PRACT ONCOL, V2, P48, DOI 10.1038/ncponc0062
   Schmid D, 2013, EUR J EPIDEMIOL, V28, P945, DOI 10.1007/s10654-013-9865-0
   Sonabend RY, 2009, J PEDIATR-US, V155, P73, DOI 10.1016/j.jpeds.2009.01.072
   Stott-Miller M, 2012, CANCER EPIDEM BIOMAR, V21, P294, DOI 10.1158/1055-9965.EPI-11-0590
   Sun XM, 2014, RADIOTHER ONCOL, V110, P398, DOI 10.1016/j.radonc.2013.10.020
   Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6
   Wither T, 2013, WORLD J UROL
   Zhou XH, 2010, DIABETOLOGIA, V53, P1867, DOI 10.1007/s00125-010-1796-7
NR 33
TC 3
Z9 4
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 28
PY 2014
VL 9
IS 10
AR e111073
DI 10.1371/journal.pone.0111073
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AS0BH
UT WOS:000343943100055
PM 25350747
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Jonasson, JM
   Cederholm, J
   Gudbjornsdottir, S
AF Jonasson, Junmei Miao
   Cederholm, Jan
   Gudbjornsdottir, Soffia
TI Excess Body Weight and Cancer Risk in Patients with Type 2 Diabetes Who
   Were Registered in Swedish National Diabetes Register - Register-Based
   Cohort Study in Sweden
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER; COLORECTAL-CANCER; MASS INDEX; OBESITY; SIZE;
   MALIGNANCIES; ADIPONECTIN; MORTALITY; INSULIN; WOMEN
AB Aim: To assess the association between excess body weight and cancer risk in patients with type 2 diabetes (T2D) who were registered in the Swedish National Diabetes Register (NDR).
   Methods: This is a cohort study based on 25,268 patients with T2D and baseline BMI >= 18.5 kg/m(2) from NDR 1997-1999. Subjects were grouped according to BMI into normal weight (18.5 to 24.9), overweight (25 to 29.9) or obesity (30 or more). All subjects were followed until the first occurrence of cancer, or death, or the end of follow-up (December 31, 2009). Adjusted hazard ratios (HRs) and 95% confidence interval (CI) for cancer risks were estimated by Cox regression.
   Results: In men with T2D, overweight was associated with increased risks of all cancer [1.13 (1.02-1.27)], gastrointestinal cancer [1.34 (1.07-1.72)] and colorectal cancer [1.59 (1.18-2.13)]; obesity was related to higher risks of all cancer [1.17 (1.04-1.33)], gastrointestinal cancer [1.40 (1.08-1.82)] and colorectal cancer [1.62 (1.17-2.24)]. In women with T2D, obesity was associated with increased risk of all cancer [1.30 (1.12-1.51)], gastrointestinal cancer [1.40 (1.03-1.91)] and postmenopausal breast cancer [1.39 (1.00-1.91)].
   Conclusions: Excess body weight was associated with increased risks of all cancer, gastrointestinal cancer and colorectal cancer in men with T2D. Obesity was related with elevated risks of all cancer, gestational cancer and postmenopausal breast cancer in women with T2D.
C1 [Jonasson, Junmei Miao] Univ Gothenburg, Sahlgrenska Acad, Dept Publ Hlth & Community Med, Gothenburg, Sweden.
   [Jonasson, Junmei Miao] Nord Sch Publ Hlth NHV, Gothenburg, Sweden.
   [Cederholm, Jan] Uppsala Univ, Dept Publ Hlth & Caring Sci Family Med & Prevent, Uppsala, Sweden.
   [Gudbjornsdottir, Soffia] VGR, Registerctr, Gothenburg, Sweden.
   [Gudbjornsdottir, Soffia] Univ Gothenburg, Sahlgrenska Acad, Dept Med, Gothenburg, Sweden.
RP Jonasson, JM (reprint author), Univ Gothenburg, Sahlgrenska Acad, Dept Publ Hlth & Community Med, Gothenburg, Sweden.
EM junmei.jonasson@gu.se
FU Swedish Association of Local Authorities and Regions; Swedish Society of
   Medicine; VIMMER; VINNOVA; AGFOND; Lion Cancer foundation West
FX This study was supported by The Swedish Association of Local Authorities
   and Regions, the Swedish Society of Medicine (JMJ, SG), and also VIMMER,
   VINNOVA, AGFOND and Lion Cancer foundation West (JMJ). Funding for the
   study had no influence on the study design, execution and publication of
   results. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Andersson SO, 1997, JNCI-J NATL CANCER I, V89, P385, DOI 10.1093/jnci/89.5.385
   Barb D, 2007, AM J CLIN NUTR, V86, p858S, DOI 10.1093/ajcn/86.3.858S
   Bergstrom A, 2001, INT J CANCER, V91, P421, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1053>3.0.CO;2-T
   Carmichael AR, 2006, BJOG-INT J OBSTET GY, V113, P1160, DOI 10.1111/j.1471-0528.2006.01021.x
   Cleveland RJ, 2012, CANCER CAUSE CONTROL, V23, P1193, DOI 10.1007/s10552-012-9989-7
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Hankinson Susan E, 2005, Breast Dis, V24, P3
   Hense HW, 2011, DIABETOL METAB SYNDR, V3, DOI 10.1186/1758-5996-3-15
   Jonasson JM, 2009, DIABETOLOGIA, V52, P1745, DOI 10.1007/s00125-009-1444-2
   Jonasson JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038784
   Kelesidis I, 2006, BRIT J CANCER, V94, P1221, DOI 10.1038/sj.bjc.6603051
   KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3
   MacInnis RJ, 2004, CANCER EPIDEM BIOMAR, V13, P553
   MOLLER H, 1994, EUR J CANCER, V30A, P344, DOI 10.1016/0959-8049(94)90254-2
   Reeves GK, 2007, BRIT MED J, V335, P1134, DOI 10.1136/bmj.39367.495995.AE
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Schoen RE, 1999, J NATL CANCER I, V91, P1147, DOI 10.1093/jnci/91.13.1147
   Simard J, 2001, MOL CELL ENDOCRINOL, V171, P25, DOI 10.1016/S0303-7207(00)00387-7
   Terry P, 2001, BRIT J CANCER, V85, P346, DOI 10.1054/bjoc.2001.1894
   Wolk A, 2001, CANCER CAUSE CONTROL, V12, P13, DOI 10.1023/A:1008995217664
NR 20
TC 3
Z9 4
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 8
PY 2014
VL 9
IS 9
AR e105868
DI 10.1371/journal.pone.0105868
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO4JX
UT WOS:000341304700019
PM 25198347
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Tseng, CH
AF Tseng, Chin-Hsiao
TI Diabetes but Not Insulin Increases the Risk of Lung Cancer: A Taiwanese
   Population-Based Study
SO PLOS ONE
LA English
DT Article
ID HEPATOCELLULAR-CARCINOMA; PANCREATIC-CANCER; PROSTATE-CANCER; NATIONAL
   COHORT; MORTALITY; SMOKING; EPIDEMIOLOGY; PREVALENCE
AB Background: The trend of lung cancer incidence in Taiwan is unknown, and the association between type 2 diabetes/insulin use and lung cancer is rarely studied.
   Methods: The trends of lung cancer incidence in 1979-2007 in the Taiwanese general population were calculated. A random sample of 1,000,000 subjects covered by the National Health Insurance in 2005 was recruited. A total of 494,002 men and 502,948 women and without lung cancer were followed for the annual cumulative incidence of lung cancer in 2005, with calculation of the risk ratios between diabetic and non-diabetic subjects. Logistic regression estimated the adjusted odds ratios for risk factors.
   Results: The trends increased significantly in both sexes (P<0.0001). The sex-specific annual cumulative incidence increased with age in either the diabetic or non-diabetic subjects, but the risk ratios attenuated with age. In logistic regressions, diabetes was associated with a significantly higher risk, with odds ratios (95% confidence interval) for diabetes duration <1, 1-3, 3-5 and >= 5 years versus non-diabetes of 2.189 (1.498-3.200), 1.420 (1.014-1.988), 1.545 (1.132-2.109), and 1.329 (1.063-1.660), respectively. Such an association was not related to a higher detection with chest X-ray examination. Insulin use and medications including oral anti-diabetic drugs, statin, fibrate, and anti-hypertensive agents were not significantly associated with lung cancer. Age, male sex, and chronic obstructive pulmonary disease were positively; but dyslipidemia, stroke and higher socioeconomic status were negatively associated with lung cancer.
   Conclusions: Diabetes is significantly associated with a higher risk of lung cancer, but insulin use does not increase the risk.
C1 [Tseng, Chin-Hsiao] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan.
   [Tseng, Chin-Hsiao] Natl Taiwan Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Taipei 100, Taiwan.
   [Tseng, Chin-Hsiao] Natl Hlth Res Inst, Div Environm Hlth & Occupat Med, Taipei, Taiwan.
RP Tseng, CH (reprint author), Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan.
EM ccktsh@ms6.hinet.net
OI TSENG, CHIN-HSIAO/0000-0001-9545-7123
FU National Science Council of Taiwan [NSC102-2314-B-002-067]
FX The study was supported by the National Science Council
   (NSC102-2314-B-002-067) of Taiwan. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bureau of Health Promotion, 2010, CANC REG ANN REP 200
   Carstensen B, 2012, DIABETOLOGIA, V55, P948, DOI 10.1007/s00125-011-2381-4
   Chan JCN, 2009, JAMA-J AM MED ASSOC, V301, P2129, DOI 10.1001/jama.2009.726
   Dela Cruz CS, 2011, CLIN CHEST MED, V32, P605, DOI 10.1016/j.ccm.2011.09.001
   Ehrlich SF, 2010, DIABETES CARE, V33, P55, DOI 10.2337/dc09-0880
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Hall GC, 2005, DIABETES CARE, V28, P590, DOI 10.2337/diacare.28.3.590
   Hemminki K, 2010, ONCOLOGIST, V15, P548, DOI 10.1634/theoncologist.2009-0300
   Klabunde CN, 2012, ANN FAM MED, V10, P102, DOI 10.1370/afm.1340
   Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P298
   Lai SW, 2012, CLIN LUNG CANCER, V13, P143, DOI 10.1016/j.cllc.2011.10.002
   Lee MY, 2012, METABOLISM, V61, P242, DOI 10.1016/j.metabol.2011.06.020
   Reddy Chakravarthy, 2011, Hosp Pract (1995), V39, P107, DOI 10.3810/hp.2011.10.929
   Tseng CH, 2006, DIABETOLOGIA, V49, P1755, DOI 10.1007/s00125-006-0314-4
   Tseng CH, 2012, ANN ONCOL, V23, P153, DOI 10.1093/annonc/mdr334
   TSENG CH, 2009, OPEN DIABETES J, V2, P18
   Tseng CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086517
   Tseng CH, 2014, CLIN GENITOURIN CANC, V12, pE7, DOI 10.1016/j.clgc.2013.08.004
   Tseng CH, 2013, DIABETES RES CLIN PR, V102, P193, DOI 10.1016/j.diabres.2013.10.019
   Tseng CH, 2013, ACTA DIABETOL, V50, P879, DOI 10.1007/s00592-013-0471-0
   Tseng CH, 2013, CLIN GENITOURIN CANC, V11, P508, DOI 10.1016/j.clgc.2013.04.019
   Tseng CH, 2013, DIABETES-METAB RES, V29, P515, DOI 10.1002/dmrr.2422
   Tseng CH, 2013, HEPATOL INT, V7, P693, DOI 10.1007/s12072-012-9405-0
   Tseng CH, 2013, J CLIN GASTROENTEROL, V47, pE60, DOI 10.1097/MCG.0b013e31827245eb
   Tseng CH, 2013, PANCREAS, V42, P42, DOI 10.1097/MPA.0b013e3182571ba9
   Tseng CH, 2012, METABOLISM, V61, P1003, DOI 10.1016/j.metabol.2011.11.015
   Tseng CH, 2011, ANN MED, V43, P142, DOI 10.3109/07853890.2010.530683
   Tseng CH, 2011, DIABETES CARE, V34, P616, DOI 10.2337/dc10-1640
   Tseng CH, 2011, GUT, V60, P774, DOI 10.1136/gut.2010.226522
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
NR 30
TC 11
Z9 12
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 3
PY 2014
VL 9
IS 7
AR e101553
DI 10.1371/journal.pone.0101553
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AO3RT
UT WOS:000341253400089
PM 24991802
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Linnerth-Petrik, NM
   Santry, LA
   Petrik, JJ
   Wootton, SK
AF Linnerth-Petrik, Nicolle M.
   Santry, Lisa A.
   Petrik, James J.
   Wootton, Sarah K.
TI Opposing Functions of Akt Isoforms in Lung Tumor Initiation and
   Progression
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-RECEPTOR; JAAGSIEKTE SHEEP; MOUSE MODEL;
   PROGNOSTIC-SIGNIFICANCE; CELL-PROLIFERATION; NEVER-SMOKERS; CANCER;
   RETROVIRUS; SURVIVAL; PROTEIN
AB Background: The phosphatidylinositol 3-kinase-regulated protein kinase, Akt, plays an important role in the initiation and progression of human cancer. Mammalian cells express three Akt isoforms (Akt1-3), which are encoded by distinct genes. Despite sharing a high degree of amino acid identity, phenotypes observed in knockout mice suggest that Akt isoforms are not functionally redundant. The relative contributions of the different Akt isoforms to oncogenesis, and the effect of their deficiencies on tumor development, are not well understood.
   Methods: Here we demonstrate that Akt isoforms have non-overlapping and sometimes opposing functions in tumor initiation and progression using a viral oncogene-induced mouse model of lung cancer and Akt isoform-specific knockout mice.
   Results: Akt1 ablation significantly delays initiation of lung tumor growth, whereas Akt2 deficiency dramatically accelerates tumorigenesis in this mouse model. Ablation of Akt3 had a small, not statistically significant, stimulatory effect on tumor induction and growth by the viral oncogene. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and Ki67 immunostaining of lung tissue sections revealed that the delayed tumor induction in Akt1(-/-) mice was due to the inhibitory effects of Akt1 ablation on cell growth and survival. Conversely, the accelerated growth rate of lung tumors in Akt2(-/-) and Akt3(-/-) mice was due to increased cell proliferation and reduced tumor cell apoptosis. Investigation of Akt signaling in tumors from Akt knockout mice revealed that the lack of Akt1 interrupted the propagation of signaling in tumors to the critical downstream targets, GSK-3 alpha/beta and mTOR.
   Conclusions: These results demonstrate that the degree of functional redundancy between Akt isoforms in the context of lung tumor initiation is minimal. Given that this mouse model exhibits considerable similarities to human lung cancer, these findings have important implications for the design and use of Akt inhibitors for the treatment of lung cancer.
C1 [Linnerth-Petrik, Nicolle M.; Santry, Lisa A.; Wootton, Sarah K.] Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON, Canada.
   [Petrik, James J.] Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada.
RP Wootton, SK (reprint author), Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON, Canada.
EM kwootton@uoguelph.ca
FU Cancer Research Society; Ontario Veterinary College MSc Fellowship
FX This work was supported by funding from the Cancer Research Society. LAS
   was supported by an Ontario Veterinary College MSc Fellowship. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H
   Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085
   Balsara BR, 2004, CARCINOGENESIS, V25, P2053, DOI 10.1093/carcin/bgh226
   Bilim V, 2009, BRIT J CANCER, V101, P2005, DOI 10.1038/sj.bjc.6605437
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Caporale M, 2006, J VIROL, V80, P8030, DOI 10.1128/JVI.00474-06
   Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006
   Chin YR, 2009, CELL SIGNAL, V21, P470, DOI 10.1016/j.cellsig.2008.11.015
   Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200
   Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728
   Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075
   Colmers IN, 2012, DIABETES METAB, V38, P475, DOI 10.1016/j.diabet.2012.06.003
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5
   Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005
   Ferguson RD, 2013, ENDOCR-RELAT CANCER, V20, P391, DOI 10.1530/ERC-12-0333
   Ferguson RD, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3089
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Greenaway J, 2008, GYNECOL ONCOL, V108, P385, DOI 10.1016/j.ygyno.2007.10.035
   Gregorevic P, 2004, NAT MED, V10, P828, DOI 10.1038/nm1085
   Halbert CL, 2002, NAT BIOTECHNOL, V20, P697, DOI 10.1038/nbt0702-697
   Halbert CL, 1997, J VIROL, V71, P5932
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   Hollander MC, 2011, ONCOGENE, V30, P1812, DOI 10.1038/onc.2010.556
   Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839
   Jiang HL, 2009, BIOMATERIALS, V30, P5844, DOI 10.1016/j.biomaterials.2009.07.017
   Ju XM, 2007, P NATL ACAD SCI USA, V104, P7438, DOI 10.1073/pnas.0605874104
   Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818
   Li YW, 2009, BIOORG MED CHEM LETT, V19, P834, DOI 10.1016/j.bmcl.2008.12.017
   Lindsley CW, 2010, CURR TOP MED CHEM, V10, P458, DOI 10.2174/156802610790980602
   Linnerth-Petrik NM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051400
   Liu SL, 2007, ONCOGENE, V26, P789, DOI 10.1038/sj.onc.1209850
   Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045
   Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782
   Mornex JF, 2003, CURR TOP MICROBIOL, V275, P225
   Mukohara T, 2004, ANTICANCER RES, V24, P11
   MUSCAT JE, 1995, CANCER LETT, V88, P1, DOI 10.1016/0304-3835(94)03608-L
   Novosyadlyy R, 2010, CANCER RES, V70, P741, DOI 10.1158/0008-5472.CAN-09-2141
   Ougolkov AV, 2005, CANCER RES, V65, P2076, DOI 10.1158/0008-5472.CAN-04-3642
   Palmarini M, 1997, TRENDS MICROBIOL, V5, P478, DOI 10.1016/S0966-842X(97)01162-1
   Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840
   Rosenberg N, 2001, P NATL ACAD SCI USA, V98, P4285, DOI 10.1073/pnas.091097698
   Saji M, 2011, ONCOGENE, V30, P4307, DOI 10.1038/onc.2011.136
   Sciacca L, 2013, NUTR METAB CARDIOVAS
   Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088
   Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055
   Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022
   Sun S, 2007, NAT REV CANCER, V7, P778, DOI 10.1038/nrc2190
   Tam IYS, 2006, CLIN CANCER RES, V12, P1647, DOI 10.1158/1078-0432.CCR-05-1981
   Toh CK, 2006, J CLIN ONCOL, V24, P2245, DOI 10.1200/JCO.2005.04.8033
   Toker A, 2006, CANCER RES, V66, P3963, DOI 10.1158/0008-5472.CAN-06-074
   Tsao AS, 2003, CANCER EPIDEM BIOMAR, V12, P660
   Tsurutani J, 2006, J CLIN ONCOL, V24, P306, DOI 10.1200/JCO.2005.02.4133
   Tsurutani J, 2007, LUNG CANCER, V55, P115, DOI 10.1016/j.lungcan.2006.09.026
   Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547
   Watson KL, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-375
   Wootton SK, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-94
   Wootton SK, 2005, NATURE, V434, P904, DOI 10.1038/nature03492
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Xu CX, 2008, AM J RESP CRIT CARE, V178, P60, DOI 10.1164/rccm.200707-1022OC
   Xu PZ, 2012, ONCOGENE, V31, P518, DOI 10.1038/onc.2011.243
   Yang ZZ, 2003, J BIOL CHEM, V278, P32124, DOI 10.1074/jbc.M302847200
NR 64
TC 30
Z9 31
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 10
PY 2014
VL 9
IS 4
AR e94595
DI 10.1371/journal.pone.0094595
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI5LS
UT WOS:000336909100105
PM 24722238
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Ioacara, S
   Guja, C
   Ionescu-Tirgoviste, C
   Fica, S
   Roden, M
AF Ioacara, Sorin
   Guja, Cristian
   Ionescu-Tirgoviste, Constantin
   Fica, Simona
   Roden, Michael
TI Cancer Specific Mortality in Insulin-Treated Type 2 Diabetes Patients
SO PLOS ONE
LA English
DT Article
ID RISK; GLARGINE; ANALOGS; MALIGNANCIES; COHORT
AB Aims: To test the hypothesis that cumulative exposure to insulin and long-acting insulin analogs might be associated with cancer mortality in diabetes patients.
   Methods: All consecutive diabetes patients aged over 40 years, residing in a major urban area were screened at their first diabetes outpatient visit between 01/01/2001-12/31/2008 (n = 79869). Exclusion criteria were insulin treatment at screening, no insulin treatment until 12/31/2008, less than 6 months of glucose-lowering treatment alone before insulin initiation, insulin prescription before glargine became available, age <40/>= 80 years at first insulin prescription, and <6 months of insulin exposure. A total 4990 subjects were followed-up for death based on death certificate, until 12/31/2011. Adjusted time-dependent competing risk regression analysis, with daily updates of treatment modalities was performed.
   Results are expressed for every 10,000 IU of cumulative dose or one year of cumulative time exposure to insulin. Results: Mean baseline age was 62 +/- 9 years, and follow-up 4.7 +/- 1.9 years. Glargine cumulative dose was associated with lower cancer mortality risk (subhazard ratio, SHR: 0.94 (95%CI 0.89-0.99, p = 0.033)). Cumulative exposure limited to that attained one year prior to death revealed lower SHRs for cumulative time (0.94 (95%CI 0.89-0.99, p = 0.018)) and cumulative dose of glargine (0.92 (95%CI 0.86-0.98, p = 0.014)). Glargine cumulative time and cumulative dose were significant predictors for lower pancreatic and breast cancer mortality, but not for deaths from lung, colorectal, female genital, liver, and urinary tract cancer. No increased hazards were found for any other subtypes of insulins.
   Conclusions: The cumulative dose exposure to insulin glargine was associated with a lower risk of cancer mortality in general, and of breast and pancreatic cancer in particular. This effect remained even after additional "fixed" cohort or propensity score analyses.
C1 [Ioacara, Sorin; Fica, Simona] Elias Hosp, Bucharest, Romania.
   [Ioacara, Sorin; Guja, Cristian; Ionescu-Tirgoviste, Constantin; Fica, Simona] Carol Davila Univ Med & Pharm, Bucharest, Romania.
   [Guja, Cristian; Ionescu-Tirgoviste, Constantin] N Paulescu Natl Inst Diabet Nutr & Metab Dis, Bucharest, Romania.
   [Roden, Michael] Univ Dusseldorf, Dept Endocrinol & Diabetol, Dusseldorf, Germany.
   [Roden, Michael] German Diabet Ctr, Inst Clin Diabetol, Dusseldorf, Germany.
RP Ioacara, S (reprint author), Elias Hosp, Bucharest, Romania.
EM drsorin@yahoo.com
RI Guja, Cristian/K-2334-2019
OI Ioacara, Sorin/0000-0001-5663-3593
CR Blin P, 2012, DIABETOLOGIA, V55, P644, DOI 10.1007/s00125-011-2429-5
   Carstensen B, 2012, DIABETOLOGIA, V55, P948, DOI 10.1007/s00125-011-2381-4
   Colhoun HM, 2012, DIABETOLOGIA, V55, P2929, DOI 10.1007/s00125-012-2668-0
   Colhoun HM, 2009, DIABETOLOGIA, V52, P1755, DOI 10.1007/s00125-009-1453-1
   Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Gerstein HC, 2012, NEW ENGL J MED, V367, P319, DOI 10.1056/NEJMoa1203858
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Hemkens LG, 2009, DIABETOLOGIA, V52, P1732, DOI 10.1007/s00125-009-1418-4
   Home PD, 2009, DIABETOLOGIA, V52, P2499, DOI 10.1007/s00125-009-1530-5
   Ioacara S, 2011, DIABETES RES CLIN PR, V92, P400, DOI 10.1016/j.diabres.2011.03.022
   Johnson JA, 2011, DIABETOLOGIA, V54, P2263, DOI 10.1007/s00125-011-2242-1
   Jonasson JM, 2009, DIABETOLOGIA, V52, P1745, DOI 10.1007/s00125-009-1444-2
   Mannucci E, 2010, DIABETES CARE, V33, P1997, DOI 10.2337/dc10-0476
   Morden NE, 2011, DIABETES CARE, V34, P1965, DOI 10.2337/dc11-0699
   Renehan AG, 2012, DIABETOLOGIA, V55, P7, DOI 10.1007/s00125-011-2352-9
   Rosenstock J, 2009, DIABETOLOGIA, V52, P1971, DOI 10.1007/s00125-009-1452-2
   Ruiter R, 2012, DIABETOLOGIA, V55, P51, DOI 10.1007/s00125-011-2312-4
   Stefansdottir G, 2011, DIABETOLOGIA, V54, P1608, DOI 10.1007/s00125-011-2104-x
   Suissa S, 2011, DIABETOLOGIA, V54, P2254, DOI 10.1007/s00125-011-2190-9
   van Staa TP, 2012, DIABETOLOGIA, V55, P654, DOI 10.1007/s00125-011-2390-3
   WHO Collaborating Center for Drug Statistics Methodology, 2012, ATC DDD IND
NR 22
TC 11
Z9 12
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 25
PY 2014
VL 9
IS 3
AR e93132
DI 10.1371/journal.pone.0093132
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE0SD
UT WOS:000333675600146
PM 24667573
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Tseng, CH
AF Tseng, Chin-Hsiao
TI Human Insulin Does Not Increase Bladder Cancer Risk
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-I; DIABETIC-PATIENTS; PIOGLITAZONE; ACTIVATION; BINDING;
   ANALOGS; TAIWAN; COHORT; CELLS
AB Background: Whether human insulin can induce bladder cancer is rarely studied.
   Methods: The reimbursement databases of all Taiwanese diabetic patients from 1996 to 2009 were retrieved from the National Health Insurance. An entry date was set at 1 January 2004 and a total of 785,234 patients with type 2 diabetes were followed up for bladder cancer incidence until the end of 2009. Users of pioglitazone were excluded and the period since the initiation of insulin glargine (marketed after the entry date in Taiwan) was not included in the calculation of follow-up. Incidences for ever-users, never-users and subgroups of human insulin exposure (using tertile cutoffs of time since starting insulin, duration of therapy and cumulative dose) were calculated and the hazard ratios were estimated by Cox regression.
   Results: There were 87,940 ever-users and 697,294 never-users, with respective numbers of incident bladder cancer of 454 (0.52%) and 3,330 (0.48%), and respective incidence of 120.49 and 94.74 per 100,000 person-years. The overall hazard ratios (95% confidence intervals) indicated a significant association with insulin in the age-sex-adjusted models [1.238 (1.122-1.366)], but not in the model adjusted for all covariates [1.063 (0.951-1.187)]. There was also a significant trend for the hazard ratios for the different categories of the dose-response parameters in the age-sex-adjusted models, which became insignificant when all covariates were adjusted.
   Conclusions: This study relieves the concern of a bladder cancer risk associated with human insulin. Appropriate adjustment for confounders is important in the evaluation of cancer risk associated with a medication.
C1 [Tseng, Chin-Hsiao] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan.
   [Tseng, Chin-Hsiao] Natl Taiwan Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Taipei 100, Taiwan.
   [Tseng, Chin-Hsiao] Natl Hlth Res Inst, Div Environm Hlth & Occupat Med, Taipei, Taiwan.
RP Tseng, CH (reprint author), Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan.
EM ccktsh@ms6.hinet.net
OI TSENG, CHIN-HSIAO/0000-0001-9545-7123
FU National Science Council of Taiwan [NSC102-2314-B-002-067]
FX The study was supported by the National Science Council
   (NSC102-2314-B-002-067) of Taiwan. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Cheng TM, 2003, HEALTH AFFAIR, V22, P61, DOI 10.1377/hlthaff.22.3.61
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Hursting SD, 2009, MOL CARCINOGEN, V48, P671, DOI 10.1002/mc.20548
   Jacobs BL, 2010, CA-CANCER J CLIN, V60, P244, DOI 10.3322/caac.20077
   Kurtzhals P, 2000, DIABETES, V49, P999, DOI 10.2337/diabetes.49.6.999
   Larsson SC, 2006, DIABETOLOGIA, V49, P2819, DOI 10.1007/s00125-006-0468-0
   Lewis JD, 2011, DIABETES CARE, V34, P916, DOI 10.2337/dc10-1068
   Liu S, 2011, DIABETES RES CLIN PR, V91, P177, DOI 10.1016/j.diabres.2010.11.009
   MacKenzie T, 2011, CANCER-AM CANCER SOC, V117, P1552, DOI 10.1002/cncr.25641
   Mannucci E, 2010, DIABETES CARE, V33, P1997, DOI 10.2337/dc10-0476
   Metalli D, 2010, AM J PATHOL, V176, P2997, DOI 10.2353/ajpath.2010.090904
   Ornskov D, 2006, FEBS J, V273, P5479, DOI 10.1111/j.1742-4658.2006.05539.x
   Tseng CH, 2011, DIABETOLOGIA, V54, P2009, DOI 10.1007/s00125-011-2171-z
   Tseng CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053096
   Tseng CH, 2013, PANCREAS, V42, P42, DOI 10.1097/MPA.0b013e3182571ba9
   Tseng CH, 2012, J ENVIRON SCI HEAL C, V30, P368, DOI 10.1080/10590501.2012.735519
   Tseng CH, 2012, J FORMOS MED ASSOC, V111, P123, DOI 10.1016/j.jfma.2011.10.003
   Tseng CH, 2009, ANN MED, V41, P371, DOI 10.1080/07853890902729778
   van Stralen KJ, 2010, NEPHRON CLIN PRACT, V116, pC143, DOI 10.1159/000315883
   Watson JA, 2009, BJU INT, V103, P694, DOI 10.1111/j.1464-410X.2008.08213.x
   Zhao H, 2003, J UROLOGY, V169, P714, DOI 10.1097/01.ju.0000036380.10325.2a
NR 21
TC 4
Z9 4
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 20
PY 2014
VL 9
IS 1
AR e86517
DI 10.1371/journal.pone.0086517
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 297FH
UT WOS:000330240500136
PM 24466131
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Cizmeci, D
   Arkun, Y
AF Cizmeci, Deniz
   Arkun, Yaman
TI Regulatory Networks and Complex Interactions between the Insulin and
   Angiotensin II Signalling Systems: Models and Implications for
   Hypertension and Diabetes
SO PLOS ONE
LA English
DT Article
ID NITRIC-OXIDE; RECEPTOR SUBSTRATE-1; ENDOTHELIAL-CELLS; METABOLIC
   SYNDROME; OXIDATIVE STRESS; FEEDBACK LOOPS; HUMAN-DISEASE; KINASE-B;
   AKT; RESISTANCE
AB The cross-talk between insulin and angiotensin II signalling pathways plays a significant role in the co-occurrence of diabetes and hypertension. We developed a mathematical model of the system of interactions among the biomolecules that are involved in the cross-talk between the insulin and angiotensin II signalling pathways. We have identified several feedback structures that regulate the dynamic behavior of the individual signalling pathways and their interactions. Different scenarios are simulated and dominant steady-state, dynamic and stability characteristics are revealed. The proposed mechanistic model describes how angiotensin II inhibits the actions of insulin and impairs the insulin-mediated vasodilation. The model also predicts that poor glycaemic control induced by diabetes contributes to hypertension by activating the renin angiotensin aystem.
C1 [Cizmeci, Deniz; Arkun, Yaman] Koc Univ, Dept Chem & Biol Engn, Istanbul, Turkey.
RP Arkun, Y (reprint author), Koc Univ, Dept Chem & Biol Engn, Istanbul, Turkey.
EM yarkun@ku.edu.tr
OI Cizmeci, Deniz/0000-0003-3231-7726
FU Koc University
FX Koc University supported this research. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ando K, 2006, DIABETES OBES METAB, V8, P396, DOI 10.1111/j.1463-1326.2005.00526.x
   Andreozzi F, 2004, CIRC RES, V94, P1211, DOI 10.1161/01.RES.0000126501.34994.96
   Angeli D, 2004, P NATL ACAD SCI USA, V101, P1822, DOI 10.1073/pnas.0308265100
   Blendea MC, 2005, AM J PHYSIOL-ENDOC M, V288, pE353, DOI 10.1152/ajpendo.00402.2004
   Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]
   Carvalho MA, 2005, DIABETES, V54, P959, DOI 10.2337/diabetes.54.4.959
   Ceriello A, 2004, DIABETOLOGIA, V47, P1535, DOI 10.1007/s00125-004-1487-3
   Chu EC, 2004, MED SCI MONITOR, V10, pRA235
   CIZMECI D, 2012, REGULATORY NETWORKS
   Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881
   Csibi A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010070
   de Kloet AD, 2010, PHYSIOL BEHAV, V100, P525, DOI 10.1016/j.physbeh.2010.03.018
   Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544
   Fan QL, 2004, NEPHROL DIAL TRANSPL, V19, P3012, DOI 10.1093/ndt/gfh499
   Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8
   Giovannucci E, 2007, AM J CLIN NUTR, V86, p836S, DOI 10.1093/ajcn/86.3.836S
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Giri Lopamudra, 2004, Theor Biol Med Model, V1, P2, DOI 10.1186/1742-4682-1-2
   Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007
   Guo W, 2003, AM J PHYSIOL-HEART C, V285, pH1396, DOI 10.1152/ajpheart.00096.2003
   Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484
   Henriksen EJ, 2001, HYPERTENSION, V38, P884, DOI 10.1161/hy1101.092970
   Henriksen EJ, 2007, AM J PHYSIOL-REG I, V293, pR974, DOI 10.1152/ajpregu.00147.2007
   Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kim JR, 2008, BIOPHYS J, V94, P359, DOI 10.1529/biophysj.107.105106
   Kobori H, 2007, PHARMACOL REV, V59, P251, DOI 10.1124/pr.59.3.3
   Kurtz A, 1998, AM J PHYSIOL-RENAL, V275, pF849
   Kwon YK, 2008, BIOINFORMATICS, V24, P1926, DOI 10.1093/bioinformatics/btn337
   Liao Y, 2010, AM J TRANSL RES, V2, P19
   Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161
   Nawano M, 1999, METABOLISM, V48, P1248, DOI 10.1016/S0026-0495(99)90263-9
   Nayak S, 2011, IET SYST BIOL, V5, P2, DOI 10.1049/iet-syb.2009.0065
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006
   Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816
   Perkins JM, 2008, CURR OPIN ENDOCRINOL, V15, P147, DOI 10.1097/MED.0b013e3282f7026f
   Peti-Peterdi J, 2008, NEPHROL DIAL TRANSPL, V23, P3047, DOI 10.1093/ndt/gfn377
   Pueyo ME, 1998, AM J PHYSIOL-CELL PH, V274, pC214
   Pulakat L, 2011, CARDIORENAL MED, V1, P102, DOI 10.1159/000327140
   Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898
   Ravichandran LV, 2001, MOL ENDOCRINOL, V15, P1768, DOI 10.1210/me.15.10.1768
   Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a
   Scheen AJ, 2004, DIABETES METAB, V30, P498, DOI 10.1016/S1262-3636(07)70147-7
   SOWERS JR, 1990, MOL CELL ENDOCRINOL, V74, pC87, DOI 10.1016/0303-7207(90)90110-T
   Stelling J, 2004, CELL, V118, P675, DOI 10.1016/j.cell.2004.09.008
   Tee AR, 2005, SEMIN CELL DEV BIOL, V16, P29, DOI 10.1016/j.semcdb.2004.11.005
   Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6
   Wang GY, 2010, PHYS BIOL, V7, DOI 10.1088/1478-3975/7/4/046015
   Wattanapitayakul SK, 2000, FASEB J, V14, P271
   Wei YZ, 2006, J BIOL CHEM, V281, P35137, DOI 10.1074/jbc.M601320200
   Wenzel P, 2008, FREE RADICAL BIO MED, V45, P619, DOI 10.1016/j.freeradbiomed.2008.05.009
   Winter JN, 2011, AM J PHYSIOL-CELL PH, V300, pC1172, DOI 10.1152/ajpcell.00504.2010
   Yasukawa T, 2005, J BIOL CHEM, V280, P7511, DOI 10.1074/jbc.M411871200
   Zeng GY, 2000, CIRCULATION, V101, P1539, DOI 10.1161/01.CIR.101.13.1539
NR 55
TC 7
Z9 8
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2013
VL 8
IS 12
AR e83640
DI 10.1371/journal.pone.0083640
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 284NF
UT WOS:000329325200098
PM 24400038
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Simo, R
   Plana-Ripoll, O
   Puente, D
   Morros, R
   Mundet, X
   Vilca, LM
   Hernandez, C
   Fuentes, I
   Procupet, A
   Tabernero, JM
   Violan, C
AF Simo, Rafael
   Plana-Ripoll, Oleguer
   Puente, Diana
   Morros, Rosa
   Mundet, Xavier
   Vilca, Luz M.
   Hernandez, Cristina
   Fuentes, Inmaculada
   Procupet, Adriana
   Tabernero, Josep M.
   Violan, Concepcion
TI Impact of Glucose-Lowering Agents on the Risk of Cancer in Type 2
   Diabetic Patients. The Barcelona Case-Control Study
SO PLOS ONE
LA English
DT Article
ID INSULIN GLARGINE; INCIDENT CANCER; REDUCED RISK; PRIMARY-CARE;
   METFORMIN; COHORT; METAANALYSIS; MORTALITY; THERAPY; THIAZOLIDINEDIONES
AB Background: The aim of the present study is to evaluate the impact of glucose-lowering agents in the risk of cancer in a large type 2 diabetic population.
   Methods: A nested case-control study was conducted within a defined cohort (275,164 type 2 diabetic patients attending 16 Primary Health Care Centers of Barcelona). Cases (n = 1,040) comprised those subjects with any cancer diagnosed between 2008 and 2010, registered at the Cancer Registry of Hospital Vall d'Hebron (Barcelona). Three control subjects for each case (n = 3,120) were matched by age, sex, diabetes duration, and geographical area. The treatments analyzed (within 3 years prior to cancer diagnosis) were: insulin glargine, insulin detemir, human insulin, fast-acting insulin and analogues, metformin, sulfonylureas, repaglinide, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, and alpha glucosidase inhibitors. Conditional logistic regressions were used to calculate the risk of cancer associated with the use of each drug adjusted by age, BMI, dose and duration of treatment, alcohol use, smoking habit, and diabetes duration.
   Results: No differences were observed between case and control subjects for the proportion, dose or duration of exposure to each treatment. None of the types of insulin and oral agents analyzed showed a significant increase in the risk of cancer. Moreover, no cancer risk was observed when glargine was used alone or in combination with metformin.
   Conclusions: Our results suggest that diabetes treatment does not influence the risk of cancer associated with type 2 diabetes. Therefore, an eventual increase of cancer should not be a reason for biasing the selection of any glucose-lowering treatment in type 2 diabetic population.
C1 [Simo, Rafael; Hernandez, Cristina] Inst Recerca Hosp Vall Hebron, Grp Recerca Diabet & Metab, Barcelona, Spain.
   [Simo, Rafael; Hernandez, Cristina] Inst Recerca Hosp Vall Hebron, CIBER Diabet & Malalties Metab Assoc CIBERDEM, Barcelona, Spain.
   [Simo, Rafael; Plana-Ripoll, Oleguer; Puente, Diana; Morros, Rosa; Mundet, Xavier; Vilca, Luz M.; Tabernero, Josep M.; Violan, Concepcion] Univ Autonoma Barcelona, Bellaterra, Spain.
   [Plana-Ripoll, Oleguer; Puente, Diana; Morros, Rosa; Mundet, Xavier; Violan, Concepcion] Inst Univ Invest Atencio Primaria Jordi Gol IDIAP, Barcelona, Spain.
   [Plana-Ripoll, Oleguer] Aarhus Univ, Dept Publ Hlth, Epidemiol Sect, Aarhus, Denmark.
   [Morros, Rosa; Procupet, Adriana] Inst Catala Salut, Barcelona, Spain.
   [Vilca, Luz M.] Hosp Univ Vall Hebron, Serv Farmacol Clin, Barcelona, Spain.
   [Fuentes, Inmaculada] Hosp Univ Vall Hebron, Serv Med Prevent & Epidemiol, Barcelona, Spain.
   [Tabernero, Josep M.] Hosp Univ Vall Hebron, Serv Oncol, Barcelona, Spain.
RP Simo, R (reprint author), Inst Recerca Hosp Vall Hebron, Grp Recerca Diabet & Metab, Barcelona, Spain.
EM rafael.simo@vhir.org
RI Plana-Ripoll, Oleguer/E-1448-2015; Violan, Concepcion/I-4493-2019;
   Puente, Diana/N-9108-2018
OI Plana-Ripoll, Oleguer/0000-0002-6470-7465; Violan,
   Concepcion/0000-0003-3309-5360; Puente, Diana/0000-0003-4725-537X;
   Tabernero, Josep/0000-0002-2495-8139; Vilca Yengle, Luz
   Maria/0000-0002-9217-2912; Simo Canonge, Rafael/0000-0003-0475-3096;
   Morros, Rosa/0000-0001-6752-8748
FU Ministry of Health and Social Policy [EC10-338]
FX This work has received financial support by a grant for the development
   of independent clinical research from Ministry of Health and Social
   Policy EC10-338. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bowker SL, 2006, DIABETES CARE, V29, P254, DOI 10.2337/diacare.29.02.06.dc05-1558
   CHANG C, 2011, FILM COMMENT, V47, P6, DOI DOI 10.1371/J0URNAL.P0NE.0021368]
   Ciaraldi TP, 2011, HORM METAB RES, V43, P1, DOI 10.1055/s-0030-1267203
   Col NF, 2012, BREAST CANCER RES TR, V135, P639, DOI 10.1007/s10549-012-2170-x
   Colhoun HM, 2009, DIABETOLOGIA, V52, P1755, DOI 10.1007/s00125-009-1453-1
   Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6
   DeCensi A, 2010, CANCER PREV RES, V3, P1451, DOI 10.1158/1940-6207.CAPR-10-0157
   Elashoff M, 2011, GASTROENTEROLOGY, V141, P150, DOI 10.1053/j.gastro.2011.02.018
   Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7
   Fagot JP, 2013, DIABETES CARE, V36, P294, DOI 10.2337/dc12-0506
   Garcia-Gil M Del Mar, 2011, Inform Prim Care, V19, P135
   Gerstein HC, 2012, NEW ENGL J MED, V367, P319, DOI 10.1056/NEJMoa1203858
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Govannucci E, 2007, GASTROENTEROLOGY, V132, P2208, DOI 10.1053/j.gastro.2007.03.050
   Govindarajan R, 2007, J CLIN ONCOL, V25, P1476, DOI 10.1200/JCO.2006.07.2777
   Hemkens LG, 2009, DIABETOLOGIA, V52, P1732, DOI 10.1007/s00125-009-1418-4
   Hosmer D. W., 2000, APPL LOGISTIC REGRES
   Hsu IR, 2007, AM J CLIN NUTR, V86, p867S, DOI 10.1093/ajcn/86.3.867S
   Johnson JA, 2011, DIABETOLOGIA, V54, P25, DOI 10.1007/s00125-010-1933-3
   Jonasson JM, 2009, DIABETOLOGIA, V52, P1745, DOI 10.1007/s00125-009-1444-2
   Koro C, 2007, PHARMACOEPIDEM DR S, V16, P485, DOI 10.1002/pds.1352
   Lewis JD, 2008, GASTROENTEROLOGY, V135, P1914, DOI 10.1053/j.gastro.2008.09.004
   Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175
   Lind M, 2012, PRIM CARE DIABETES, V6, P53, DOI 10.1016/j.pcd.2011.10.004
   Mamtani R, 2012, JNCI-J NATL CANCER I, V104, P1411, DOI 10.1093/jnci/djs328
   Mannucci E, 2010, DIABETES CARE, V33, P1997, DOI 10.2337/dc10-0476
   Monami M, 2008, EXP CLIN ENDOCR DIAB, V116, P184, DOI 10.1055/s-2007-992157
   Monami M, 2007, DIABETES-METAB RES, V23, P479, DOI 10.1002/dmrr.736
   Morden NE, 2011, DIABETES CARE, V34, P1965, DOI 10.2337/dc11-0699
   Noto H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033411
   Pierre-Eugene C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041992
   Ramos R, 2012, REV ESP CARDIOL, V65, P29, DOI [10.1016/j.rec.2011.07.016, 10.1016/j.recesp.2011.07.017]
   Rattan R, 2012, J ONCOL, DOI 10.1155/2012/928127
   Renehan Andrew G., 2008, Archives of Physiology and Biochemistry, V114, P71, DOI [10.1080/13813450801954303, 10.1080/13813450801954303 ]
   Ruiter R, 2012, DIABETOLOGIA, V55, P51, DOI 10.1007/s00125-011-2312-4
   Ruiter R, 2012, DIABETES CARE, V35, P119, DOI 10.2337/dc11-0857
   Seshasai SRK, 2011, NEW ENGL J MED, V364, P829, DOI 10.1056/NEJMoa1008862
   Singh S, 2013, AM J GASTROENTEROL, V108, P881, DOI 10.1038/ajg.2013.5
   Singh S, 2013, WORLD J CLIN ONCOL, V4, P43, DOI 10.5306/wjco.v4.i2.43
   Smith U, 2009, DIABETOLOGIA, V52, P1699, DOI 10.1007/s00125-009-1441-5
   Soranna D, 2012, ONCOLOGIST, V17, P813, DOI 10.1634/theoncologist.2011-0462
   Stevens RJ, 2012, DIABETOLOGIA, V55, P2593, DOI 10.1007/s00125-012-2653-7
   Suissa S, 2011, DIABETOLOGIA, V54, P2254, DOI 10.1007/s00125-011-2190-9
   van Staa TP, 2012, DIABETOLOGIA, V55, P654, DOI 10.1007/s00125-011-2390-3
   Vinagre I, 2012, DIABETES CARE, V35, P774, DOI 10.2337/dc11-1679
   Violan C, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-251
   WHO-World Health Organization, ICD 10 INT STAT CLAS
   Zhang ZJ, 2011, DIABETES CARE, V34, P2323, DOI 10.2337/dc11-0512
NR 48
TC 18
Z9 18
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 21
PY 2013
VL 8
IS 11
AR e79968
DI 10.1371/journal.pone.0079968
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 259PW
UT WOS:000327539800041
PM 24278227
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Onitilo, AA
   Berg, RL
   Engel, JM
   Glurich, I
   Stankowski, RV
   Williams, G
   Doi, SA
AF Onitilo, Adedayo A.
   Berg, Richard L.
   Engel, Jessica M.
   Glurich, Ingrid
   Stankowski, Rachel V.
   Williams, Gail
   Doi, Suhail A.
TI Increased Risk of Colon Cancer in Men in the Pre-Diabetes Phase
SO PLOS ONE
LA English
DT Article
ID TYPE-2 DIABETES-MELLITUS; COLORECTAL-CANCER; SEX-HORMONES; METAANALYSIS;
   INSULIN; ASSOCIATIONS; PEOPLE; GENDER
AB Background: Historically, studies exploring the association between type 2 diabetes mellitus (DM) and cancer lack accurate definition of date of DM onset, limiting temporal analyses. We examined the temporal relationship between colon cancer risk and DM using an electronic algorithm and clinical, administrative, and laboratory data to pinpoint date of DM onset.
   Methods: Subjects diagnosed with DM (N = 11,236) between January 1, 1995 and December 31, 2009 were identified and matched at a 5:1 ratio with 54 365 non-diabetic subjects by age, gender, smoking history, residence, and diagnosis reference date. Colon cancer incidence relative to the reference date was used to develop Cox regression models adjusted for matching variables, body mass index, insurance status, and comorbidities. Primary outcomes measures included hazard ratio (HR) and number needed to be exposed for one additional person to be harmed (NNEH).
   Results: The adjusted HR for colon cancer in men before DM onset was 1.28 (95% CI 1.04-1.58, P = 0.0223) and the NNEH decreased with time, reaching 263 at DM onset. No such difference was observed in women. After DM onset, DM did not appear to alter colon cancer risk in either gender.
   Conclusions: Colon cancer risk is increased in diabetic men, but not women, before DM onset. DM did not alter colon cancer risk in men or women after clinical onset. In pre-diabetic men, colon cancer risk increased as time to DM onset decreased, suggesting that the effects of the pre-diabetes phase on colon cancer risk in men are cumulative.
C1 [Onitilo, Adedayo A.] Marshfield Clin Weston Ctr, Dept Hematol Oncol, Weston, WI USA.
   [Onitilo, Adedayo A.; Williams, Gail; Doi, Suhail A.] Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia.
   [Berg, Richard L.; Glurich, Ingrid; Stankowski, Rachel V.] Marshfield Clin Res Fdn, Marshfield, WI USA.
   [Engel, Jessica M.] Marshfield Clin Canc Care, Dept Hematol Oncol, Stevens Point, WI USA.
RP Onitilo, AA (reprint author), Marshfield Clin Weston Ctr, Dept Hematol Oncol, Weston, WI USA.
EM onitilo.adedayo@marshfieldclinic.org
RI Doi, Suhail/E-2770-2010
OI Williams, Gail/0000-0002-4822-5263; Doi, Suhail/0000-0002-2630-2125
FU Marshfield Clinic Research Foundation Disease Specific Funds
FX Financial support for this study was provided by the Marshfield Clinic
   Research Foundation Disease Specific Funds. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062
   Barratt AL, 2005, CAN MED ASSOC J, V172, P613, DOI 10.1503/cmaj.1041709
   Bertram MY, 2010, AUST NZ J PUBL HEAL, V34, P311, DOI 10.1111/j.1753-6405.2010.00532.x
   Brandstedt J, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-23
   Centers for Disease Control and Prevention, 2011, NAT DIAB FACT SHEET
   Chlebowski RT, 2004, NEW ENGL J MED, V350, P991, DOI 10.1056/NEJMoa032071
   Clendenen TV, 2009, CANCER EPIDEM BIOMAR, V18, P275, DOI 10.1158/1055-9965.EPI-08-0777
   Deng LY, 2012, DIGEST DIS SCI, V57, P1576, DOI 10.1007/s10620-012-2055-1
   Ferlitsch M, 2011, JAMA-J AM MED ASSOC, V306, P1352, DOI 10.1001/jama.2011.1362
   GIOVANNUCCI E, 1995, CANCER CAUSE CONTROL, V6, P164, DOI 10.1007/BF00052777
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Govannucci E, 2007, GASTROENTEROLOGY, V132, P2208, DOI 10.1053/j.gastro.2007.03.050
   Harriss DJ, 2009, COLORECTAL DIS, V11, P547, DOI 10.1111/j.1463-1318.2009.01766.x
   Hu FB, 1999, JNCI-J NATL CANCER I, V91, P542, DOI 10.1093/jnci/91.6.542
   Jiang Y, 2011, EUR J EPIDEMIOL, V26, P863, DOI 10.1007/s10654-011-9617-y
   Jinjuvadia R, 2013, J CLIN GASTROENTEROL, V47, P33, DOI 10.1097/MCG.0b013e3182688c15
   Kramer HU, 2012, EUR J CANCER, V48, P1269, DOI 10.1016/j.ejca.2011.07.010
   Kramer HU, 2012, EUR J EPIDEMIOL, V27, P341, DOI 10.1007/s10654-012-9686-6
   Larsson SC, 2005, J NATL CANCER I, V97, P1679, DOI 10.1093/jnci/dji375
   Lin JH, 2010, J NATL CANCER I, V102, P1746, DOI 10.1093/jnci/djq444
   Luo W, 2012, COLORECTAL DIS, V14, P1307, DOI 10.1111/j.1463-1318.2012.02875.x
   Ma J, 2004, JNCI-J NATL CANCER I, V96, P546, DOI 10.1093/jnci/djh082
   Nguyen SP, 2009, CLIN GASTROENTEROL H, V7, P676, DOI 10.1016/j.cgh.2009.01.008
   Ning Y, 2010, OBES REV, V11, P19, DOI 10.1111/j.1467-789X.2009.00613.x
   Niv Y, 2008, DIGEST DIS SCI, V53, P3049, DOI 10.1007/s10620-008-0286-y
   Onitilo AA, 2012, CANCER CAUSE CONTROL, V23, P991, DOI 10.1007/s10552-012-9971-4
   Ritenbaugh C, 2008, CANCER EPIDEM BIOMAR, V17, P2609, DOI 10.1158/1055-9965.EPI-08-0385
   Saydah SH, 2003, AM J EPIDEMIOL, V157, P1092, DOI 10.1093/aje/kwg100
   Siddiqui AA, 2008, DIGEST DIS SCI, V53, P2486, DOI 10.1007/s10620-008-0264-4
   Sun L, 2012, DIGEST DIS SCI, V57, P1586, DOI 10.1007/s10620-012-2059-x
   Tran TT, 2006, ENDOCRINOLOGY, V147, P1830, DOI 10.1210/en.2005-1012
   Vu HT, 2012, DDW 2012
   Wilke RA, 2007, CLIN MED RES, V5, P1, DOI 10.3121/cmr.2007.726
   Wilkinson JE, 2011, PREV CHRONIC DIS, V8
   Yang YX, 2004, GASTROENTEROLOGY, V127, P1044, DOI 10.1053/j.gastro.2004.07.011
   Yuhara H, 2011, AM J GASTROENTEROL, V106, P1911, DOI 10.1038/ajg.2011.301
NR 36
TC 9
Z9 10
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 2
PY 2013
VL 8
IS 8
AR e70426
DI 10.1371/journal.pone.0070426
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 219XU
UT WOS:000324545800041
PM 23936428
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Berrou, J
   Fougeray, S
   Venot, M
   Chardiny, V
   Gautier, JF
   Dulphy, N
   Toubert, A
   Peraldi, MN
AF Berrou, Jeannig
   Fougeray, Sophie
   Venot, Marion
   Chardiny, Victor
   Gautier, Jean-Francois
   Dulphy, Nicolas
   Toubert, Antoine
   Peraldi, Marie-Noelle
TI Natural Killer Cell Function, an Important Target for Infection and
   Tumor Protection, Is Impaired in Type 2 Diabetes
SO PLOS ONE
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; IN-VIVO; CYTOKINE PRODUCTION; OXIDATIVE
   STRESS; NK CELLS; RECEPTOR; NKG2D; EXPRESSION; HYPERGLYCEMIA; ACTIVATION
AB Patients with Type 2 diabetes (T2D) are highly susceptible to infection and have an increased incidence of some tumors, possibly due to immune system dysfunction. In the innate cellular immune system, Natural Killer (NK) lymphocytes are important effectors responsible for controlling infections and combating tumor development. We analyzed NK cell subsets in 51 patients with long-standing T2D. Compared with healthy blood donors, diabetic patients showed a profound decrease in both NKG2D-positive NK cells (44% vs. 55.5%, P<0.01) and NKp46-positive cells (26% vs. 50%, P<0.01). Decreased expression of these receptors was associated with functional defects, such as reduced NK degranulation capacity when challenged with the tumor target cell line K562 (10.3 vs. 15.8%, P<0.05). This defect could be restored in vitro by stimulating NK cells from T2D patients with IL-15 (P<0.05). NKG2D expression was found to be negatively correlated with HBA1c level (r = 20.50; P = 0.009), suggesting that sustained hyperglycemia could directly influence NK cell defects. We demonstrated that endoplasmic reticulum (ER) stress, an important mediator in diabetes-associated complications, was inducible in vitro in normal NK cells and that tunicamycin treatment resulted in a significant decrease in NKG2D expression (P<0.05). Furthermore, markers of the Unfolded Protein Response (UPR) BiP, PDI and sXBP1 mRNAs were significantly increased in NK cells from T2D patients (P<0.05, P<0.01, P<0.05, respectively), indicating that ER stress is activated in vivo through both PERK and IRE1 sensors. These results demonstate for the first time defects in NK cell-activating receptors NKG2D and NKp46 in T2D patients, and implicate the UPR pathway as a potential mechanism. These defects may contribute to susceptibility to infections and malignancies and could be targetted therapeutically.
C1 [Berrou, Jeannig; Venot, Marion; Chardiny, Victor; Dulphy, Nicolas; Toubert, Antoine; Peraldi, Marie-Noelle] INSERM, UMR 90, Paris, France.
   [Berrou, Jeannig; Dulphy, Nicolas; Toubert, Antoine] Hop St Louis, AP HP, Ctr Invest Biomed H O G, Paris, France.
   [Fougeray, Sophie] Ctr Univ St Peres, INSERM U775, Paris, France.
   [Fougeray, Sophie] Univ Paris 05, Paris, France.
   [Gautier, Jean-Francois] Hop St Louis, AP HP, Dept Endocrinol & Diabet, Paris, France.
   [Gautier, Jean-Francois; Dulphy, Nicolas; Toubert, Antoine; Peraldi, Marie-Noelle] Univ Paris 07, Paris, France.
   [Dulphy, Nicolas; Toubert, Antoine] Univ Paris Diderot, Inst Univ Hematol, Paris, France.
   [Peraldi, Marie-Noelle] Hop St Louis, AP HP, Nephrol & Transplantat Dept, Paris, France.
RP Peraldi, MN (reprint author), INSERM, UMR 90, Paris, France.
EM mnperaldi@gmail.com
RI Toubert, Antoine/Q-3404-2017; Fougeray, Sophie/M-2310-2015; Dulphy,
   Nicolas/J-5960-2017
OI Toubert, Antoine/0000-0002-7308-7317; Fougeray,
   Sophie/0000-0002-5745-3831; Dulphy, Nicolas/0000-0002-1243-6456
FU INSERM (French public research)
FX This work was supported by INSERM (French public research). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Akesson C, 2010, CLIN EXP IMMUNOL, V161, P48, DOI 10.1111/j.1365-2249.2010.04114.x
   Alter G, 2005, BLOOD, V106, P3366, DOI 10.1182/blood-2005-03-1100
   *AM DIAB ASS, 2009, DIABETES CARE, V32, P13
   Basha B, 2012, EXP DIABETES RES, V48, P1
   Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727
   Biassoni R, 2001, IMMUNOL REV, V181, P203, DOI 10.1034/j.1600-065X.2001.1810117.x
   Claus M, 2009, J IMMUNOL METHODS, V341, P154, DOI 10.1016/j.jim.2008.11.006
   Colucci F, 2003, NAT REV IMMUNOL, V3, P413, DOI 10.1038/nri1088
   Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9
   Eagle RA, 2007, NAT REV IMMUNOL, V7, P737, DOI 10.1038/nri2144
   Fisher L, 2006, EXPT HEMATOL, V34, P753
   Gazit R, 2006, NAT IMMUNOL, V7, P517, DOI 10.1038/ni1322
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Gur C, 2010, NAT IMMUNOL, V11, P121, DOI 10.1038/ni.1834
   Hand WL, 2007, DIABETES RES CLIN PR, V76, P44, DOI 10.1016/j.diabres.2006.07.015
   He B, 2006, CELL DEATH DIFFER, V13, P393, DOI 10.1038/sj.cdd.4401833
   Huntington ND, 2007, NAT REV IMMUNOL, V7, P703, DOI 10.1038/nri2154
   Huntington ND, 2009, J EXP MED, V206, P25, DOI 10.1084/jem.20082013
   Joshi N, 1999, NEW ENGL J MED, V341, P1906, DOI 10.1056/NEJM199912163412507
   Kuznetsov G, 1996, P NATL ACAD SCI USA, V93, P8584, DOI 10.1073/pnas.93.16.8584
   Lakshmikanth T, 2009, J CLIN INVEST, V119, P1251, DOI 10.1172/JCI36022
   Lin JH, 2008, ANNU REV PATHOL-MECH, V3, P399, DOI 10.1146/annurev.patho1.3.121806.151434
   Lynch LA, 2009, OBESITY, V17, P601, DOI 10.1038/oby.2008.565
   Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197
   Moretta A, 2002, NAT IMMUNOL, V3, P6, DOI 10.1038/ni0102-6
   Morgan CL, 2010, DIABETIC MED, V27, P673, DOI [10.1111/j.1464-5491.2010.02912.x, 10.1111/j.1464-5491.2009.02912.x]
   Nakayama Y, 2010, J BIOCHEM, V147, P471, DOI 10.1093/jb/mvp189
   Oppenheim DE, 2005, NAT IMMUNOL, V6, P928, DOI 10.1038/ni1239
   Peraldi MN, 2009, J IMMUNOL, V182, P1696, DOI 10.4049/jimmunol.182.3.1696
   Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199
   Rodacki M, 2007, DIABETES, V56, P177, DOI 10.2337/db06-0493
   Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134
   Stegenga ME, 2008, DIABETIC MED, V25, P157, DOI 10.1111/j.1464-5491.2007.02348.x
   Stegenga ME, 2008, BLOOD, V112, P82, DOI 10.1182/blood-2007-11-121723
   Stevens LA, 2010, NEPHROL DIAL TRANSPL, V25, P449, DOI 10.1093/ndt/gfp510
   Tang C, 2012, DIABETOLOGIA, V55, P1366, DOI 10.1007/s00125-012-2474-8
   Tieng V, 2002, P NATL ACAD SCI USA, V99, P2977, DOI 10.1073/pnas.032668099
   Veiga-Fernandes H, 2010, J EXP MED, V207, P269, DOI 10.1084/jem.20100105
   Vivier E, 2004, SCIENCE, V306, P1517, DOI 10.1126/science.1103478
   Xia MC, 2011, CIRCULATION, V124, P2933, DOI 10.1161/CIRCULATIONAHA.111.034850
   Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203
   Zhong YM, 2012, DIABETES, V61, P492, DOI 10.2337/db11-0315
   ZWIMER NW, 1999, HUM IMMUNOL, V60, P323
NR 43
TC 36
Z9 37
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 25
PY 2013
VL 8
IS 4
AR e62418
DI 10.1371/journal.pone.0062418
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 136DM
UT WOS:000318341400054
PM 23638076
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Zhang, F
   Xu, X
   Zhang, Y
   Zhou, B
   He, ZS
   Zhai, QW
AF Zhang, Fang
   Xu, Xiang
   Zhang, Yi
   Zhou, Ben
   He, Zhishui
   Zhai, Qiwei
TI Gene Expression Profile Analysis of Type 2 Diabetic Mouse Liver
SO PLOS ONE
LA English
DT Article
ID INSULIN-RESISTANCE; GLUCOSE-PRODUCTION; HEPATIC STEATOSIS; CONSENSUS
   REPORT; BLOOD-GLUCOSE; OBESITY; INFLAMMATION; METABOLISM; MELLITUS;
   CANCER
AB Liver plays a key role in glucose metabolism and homeostasis, and impaired hepatic glucose metabolism contributes to the development of type 2 diabetes. However, the precise gene expression profile of diabetic liver and its association with diabetes and related diseases are yet to be further elucidated. In this study, we detected the gene expression profile by high-throughput sequencing in 9-week-old normal and type 2 diabetic db/db mouse liver. Totally 12132 genes were detected, and 2627 genes were significantly changed in diabetic mouse liver. Biological process analysis showed that the upregulated genes in diabetic mouse liver were mainly enriched in metabolic processes. Surprisingly, the downregulated genes in diabetic mouse liver were mainly enriched in immune-related processes, although all the altered genes were still mainly enriched in metabolic processes. Similarly, KEGG pathway analysis showed that metabolic pathways were the major pathways altered in diabetic mouse liver, and downregulated genes were enriched in immune and cancer pathways. Analysis of the key enzyme genes in fatty acid and glucose metabolism showed that some key enzyme genes were significantly increased and none of the detected key enzyme genes were decreased. In addition, FunDo analysis showed that liver cancer and hepatitis were most likely to be associated with diabetes. Taken together, this study provides the digital gene expression profile of diabetic mouse liver, and demonstrates the main diabetes-associated hepatic biological processes, pathways, key enzyme genes in fatty acid and glucose metabolism and potential hepatic diseases.
C1 [Zhang, Fang; Xu, Xiang; Zhang, Yi; Zhou, Ben; He, Zhishui; Zhai, Qiwei] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Key Lab Nutr & Metab, Shanghai, Peoples R China.
RP Zhai, QW (reprint author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Key Lab Nutr & Metab, Shanghai, Peoples R China.
EM qwzhai@sibs.ac.cn
RI Zhou, Ben/G-1850-2017; Zhou, Ben/R-9844-2019
OI Zhou, Ben/0000-0001-7177-2882; 
FU National Natural Science Foundation of China [30825009, 30970619,
   31030022, 31200591, 81021002]; National Basic Research Program of China
   (973 Program) [2009CB918403]; Program of Shanghai Subject Chief
   Scientist [11XD1405800]; Knowledge Innovation Program of the Chinese
   Academy of Sciences [KSCX2-EW-R-09]; Postdoctor Research Program of
   Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
   [2011KIP511]; SA-SIBS Scholarship Program
FX This study was supported by grants from National Natural Science
   Foundation of China (30825009, 30970619, 31030022, 31200591 and
   81021002), National Basic Research Program of China (973 Program,
   2009CB918403), Program of Shanghai Subject Chief Scientist
   (11XD1405800), the Knowledge Innovation Program of the Chinese Academy
   of Sciences (KSCX2-EW-R-09), Postdoctor Research Program of Shanghai
   Institutes for Biological Sciences, Chinese Academy of Sciences
   (2011KIP511), and SA-SIBS Scholarship Program. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100
   Agius L, 2010, MINI-REV MED CHEM, V10, P1175, DOI 10.2174/1389557511009011175
   Audic S, 1997, GENOME RES, V7, P986, DOI 10.1101/gr.7.10.986
   Blencowe BJ, 2009, GENE DEV, V23, P1379, DOI 10.1101/gad.1788009
   Bouche C, 2004, ENDOCR REV, V25, P807, DOI 10.1210/er.2003-0026
   Bradbury MW, 2006, AM J PHYSIOL-GASTR L, V290, pG194, DOI 10.1152/ajpgi.00413.2005.
   Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995
   Coughlin SS, 2004, AM J EPIDEMIOL, V159, P1160, DOI 10.1093/aje/kwh161
   Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013
   DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318
   DeFronzo RA, 2004, MED CLIN N AM, V88, P787, DOI 10.1016/j.mcna.2004.04.013
   Demir M, 2008, EUR J GASTROEN HEPAT, V20, P668, DOI 10.1097/MEG.0b013e3282f55e1e
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Dhahbi Joseph M, 2003, Diabetes Technol Ther, V5, P411, DOI 10.1089/152091503765691910
   DUNAWAY GA, 1978, J BIOL CHEM, V253, P7460
   Fernandez-Real JM, 2008, TRENDS ENDOCRIN MET, V19, P10, DOI 10.1016/j.tem.2007.10.004
   FOLEY JE, 1992, DIABETES CARE, V15, P773, DOI 10.2337/diacare.15.6.773
   Giovannucci E, 2010, CA-CANCER J CLIN, V60, P207, DOI 10.3322/caac.20078
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   HESS B, 1971, ANNU REV BIOCHEM, V40, P237, DOI 10.1146/annurev.bi.40.070171.001321
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102
   Keller MP, 2008, GENOME RES, V18, P706, DOI 10.1101/gr.074914.107
   Kersten S, 2000, NATURE, V405, P421
   Kim S, 2004, GENE, V340, P99, DOI 10.1016/j.gene.2004.06.015
   Knolle PA, 2000, IMMUNOL REV, V174, P21, DOI 10.1034/j.1600-0528.2002.017408.x
   Koves TR, 2005, J BIOL CHEM, V280, P33588, DOI 10.1074/jbc.M507621200
   Lan H, 2003, DIABETES, V52, P688, DOI 10.2337/diabetes.52.3.688
   Lanthier N, 2010, AM J PHYSIOL-GASTR L, V298, pG107, DOI 10.1152/ajpgi.00391.2009
   Lefebvre P, 2006, J CLIN INVEST, V116, P571, DOI 10.1172/JCI27989
   Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201
   Liaskou E, 2012, MEDIAT INFLAMM, V2012, P21, DOI DOI 10.1155/2012/949157
   Marioni JC, 2008, GENOME RES, V18, P1509, DOI 10.1101/gr.079558.108
   Marzban L, 2002, ENDOCRINOLOGY, V143, P4636, DOI 10.1210/en.2002-220732
   Matschinsky FM, 2006, DIABETES, V55, P1
   Matsuzaka T, 2007, NAT MED, V13, P1193, DOI 10.1038/nm1662
   McCormack JG, 2001, CURR PHARM DESIGN, V7, P1451, DOI 10.2174/1381612013397393
   McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7
   Neyrinck AM, 2009, BIOCHEM BIOPH RES CO, V385, P351, DOI 10.1016/j.bbrc.2009.05.070
   Nordlie RC, 1999, ANNU REV NUTR, V19, P379, DOI 10.1146/annurev.nutr.19.1.379
   O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022
   Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846
   Osborne JD, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-S1-S6
   PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321
   Postic C, 2008, DIABETES METAB, V34, P643, DOI 10.1016/S1262-3636(08)74599-3
   Postic C, 2008, J CLIN INVEST, V118, P829, DOI 10.1172/JCI34275
   RABITZSCH G, 1995, CLIN CHEM, V41, P966
   Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4<263::AID-DMR233>3.0.CO;2-C
   RDC T, 2010, R LANG ENV STAT COMP
   Samuel VT, 2012, CELL, V148, P852, DOI 10.1016/j.cell.2012.02.017
   Sangiorgio L, 2000, DIABETES RES CLIN PR, V48, P147, DOI 10.1016/S0168-8227(99)00135-7
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069
   Soverini V, 2011, ACTA DIABETOL, V48, P337, DOI 10.1007/s00592-011-0293-x
   Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209
   Suh YH, 2005, J MOL ENDOCRINOL, V34, P299, DOI 10.1677/jme.1.01679
   t Hoen PAC, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn705
   van Lunteren E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007832
   van Poelje PD, 2007, CURR OPIN DRUG DISC, V10, P430
   Vigneri P, 2009, ENDOCR-RELAT CANCER, V16, P1103, DOI 10.1677/ERC-09-0087
   Voight BF, 2010, NAT GENET, V42, P579, DOI 10.1038/ng.609
   Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102
   Wu CD, 2005, CELL METAB, V2, P131, DOI 10.1016/j.cmet.2005.07.003
   Wu CD, 2001, J CLIN INVEST, V107, P91, DOI 10.1172/JCI11103
   Yach D, 2006, NAT MED, V12, P62, DOI 10.1038/nm0106-62
   Yang G, 2010, INT J IMPOT RES, V22, P310, DOI 10.1038/ijir.2010.21
   Zhang F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027553
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505
   Zhou HR, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-S1-S16
NR 69
TC 19
Z9 19
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 1
PY 2013
VL 8
IS 3
AR e57766
DI 10.1371/journal.pone.0057766
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 103EI
UT WOS:000315897100038
PM 23469233
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Soares, HP
   Ni, Y
   Kisfalvi, K
   Sinnett-Smith, J
   Rozengurt, E
AF Soares, Heloisa P.
   Ni, Yang
   Kisfalvi, Krisztina
   Sinnett-Smith, James
   Rozengurt, Enrique
TI Different Patterns of Akt and ERK Feedback Activation in Response to
   Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic
   Cancer Cells
SO PLOS ONE
LA English
DT Article
ID PROTEIN-COUPLED RECEPTOR; COMPETITIVE MAMMALIAN TARGET;
   INSULIN-RECEPTOR; TUMOR-SUPPRESSOR; GROWTH-FACTOR; PATHWAY ACTIVATION;
   SIGNALING SYSTEMS; DIABETIC-PATIENTS; KINASE; RISK
AB The mTOR pathway is aberrantly stimulated in many cancer cells, including pancreatic ductal adenocarcinoma (PDAC), and thus it is a potential target for therapy. However, the mTORC1/S6K axis also mediates negative feedback loops that attenuate signaling via insulin/IGF receptor and other tyrosine kinase receptors. Suppression of these feed-back loops unleashes over-activation of upstream pathways that potentially counterbalance the antiproliferative effects of mTOR inhibitors. Here, we demonstrate that treatment of PANC-1 or MiaPaCa-2 pancreatic cancer cells with either rapamycin or active-site mTOR inhibitors suppressed S6K and S6 phosphorylation induced by insulin and the GPCR agonist neurotensin. Rapamycin caused a striking increase in Akt phosphorylation at Ser(473) while the active-site inhibitors of mTOR (KU63794 and PP242) completely abrogated Akt phosphorylation at this site. Conversely, active-site inhibitors of mTOR cause a marked increase in ERK activation whereas rapamycin did not have any stimulatory effect on ERK activation. The results imply that first and second generation of mTOR inhibitors promote over-activation of different pro-oncogenic pathways in PDAC cells, suggesting that suppression of feed-back loops should be a major consideration in the use of these inhibitors for PDAC therapy. In contrast, metformin abolished mTORC1 activation without over-stimulating Akt phosphorylation on Ser(473) and prevented mitogen-stimulated ERK activation in PDAC cells. Metformin induced a more pronounced inhibition of proliferation than either KU63794 or rapamycin while, the active-site mTOR inhibitor was more effective than rapamycin. Thus, the effects of metformin on Akt and ERK activation are strikingly different from allosteric or active-site mTOR inhibitors in PDAC cells, though all these agents potently inhibited the mTORC1/S6K axis.
C1 [Soares, Heloisa P.; Ni, Yang; Kisfalvi, Krisztina; Sinnett-Smith, James; Rozengurt, Enrique] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, CURE Digest Dis Res Ctr,Div Digest Dis, Los Angeles, CA 90095 USA.
   [Soares, Heloisa P.; Ni, Yang; Kisfalvi, Krisztina; Sinnett-Smith, James; Rozengurt, Enrique] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.
   [Soares, Heloisa P.] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.
   [Ni, Yang] Shandong Univ, Prov Hosp, Dept Thorac Surg, Jinan, Shandong, Peoples R China.
RP Rozengurt, E (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, CURE Digest Dis Res Ctr,Div Digest Dis, Los Angeles, CA 90095 USA.
EM erozengurt@mednet.ucla.edu
FU National Institutes of Health [P30DK41301, P01CA163200, R01DK55003];
   Department of Veterans Affair Grant [1I01BX001473]; Ronald S. Hirshberg
   Chair of Pancreatic Cancer Research
FX This study was supported by National Institutes of Health Grants
   P30DK41301, P01CA163200 and R01DK55003, Department of Veterans Affair
   Grant 1I01BX001473 and funds from the endowed Ronald S. Hirshberg Chair
   of Pancreatic Cancer Research all to ER. (http://www.nih.gov/). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Arslan AA, 2010, ARCH INTERN MED, V170, P791, DOI 10.1001/archinternmed.2010.63
   Asano T, 2005, CANCER RES, V65, P9164, DOI 10.1158/0008-5472.CAN-05-0779
   Asano T, 2005, BIOCHEM BIOPH RES CO, V331, P295, DOI 10.1016/j.bbrc.2005.03.166
   Ben Sahra I, 2010, MOL CANCER THER, V9, P1092, DOI 10.1158/1535-7163.MCT-09-1186
   Bowker SL, 2006, DIABETES CARE, V29, P254, DOI 10.2337/diacare.29.02.06.dc05-1558
   Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247
   Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]
   Carriere A, 2011, J BIOL CHEM, V286, P567, DOI 10.1074/jbc.M110.159046
   Chong CR, 2009, ONCOLOGIST, V14, P1178, DOI 10.1634/theoncologist.2009-0286
   Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6
   DeCensi A, 2010, CANCER PREV RES, V3, P1451, DOI 10.1158/1940-6207.CAPR-10-0157
   Dong XQ, 2010, GASTROENTEROLOGY, V139, P464, DOI 10.1053/j.gastro.2010.04.042
   Easton JB, 2006, CANCER CELL, V9, P153, DOI 10.1016/j.ccr.2006.02.027
   Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007
   Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Feng ZH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001057
   Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003
   Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X
   Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Guha S, 2003, CANCER RES, V63, P2379
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hardie DG, 2007, ANNU REV PHARMACOL, V47, P185, DOI 10.1146/annurev.pharmtox.47.120505.105304
   Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069
   Hoang B, 2012, J BIOL CHEM, V287, P21796, DOI 10.1074/jbc.M111.304626
   Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498
   Inoki K, 2006, TRENDS CELL BIOL, V16, P206, DOI 10.1016/j.tcb.2006.02.002
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Jamieson S, 2011, BIOCHEM J, V438, P53, DOI 10.1042/BJ20110502
   Javle MM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-368
   Kisfalvi K, 2005, J CELL PHYSIOL, V202, P880, DOI 10.1002/jcp.20187
   Kisfalvi K, 2007, ENDOCRINOLOGY, V148, P3246, DOI 10.1210/en.2006-1711
   Kisfalvi K, 2009, CANCER RES, V69, P6539, DOI 10.1158/0008-5472.CAN-09-0418
   Kolb S, 2007, CANCER RES, V67, P4679, DOI 10.1158/0008-5472.CAN-06-3308
   Kornmann M, 1998, CANCER RES, V58, P4250
   Kwon J, 2009, CANCER RES, V69, P1350, DOI 10.1158/0008-5472.CAN-08-1328
   Landman GWD, 2010, DIABETES CARE, V33, P322, DOI 10.2337/dc09-1380
   Lane HA, 2009, CURR OPIN CELL BIOL, V21, P219, DOI 10.1016/j.ceb.2009.01.016
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lee MS, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-20
   Li DH, 2009, GASTROENTEROLOGY, V137, P482, DOI 10.1053/j.gastro.2009.04.013
   Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175
   Liu QS, 2012, J BIOL CHEM, V287, P9742, DOI 10.1074/jbc.M111.304485
   Liu QS, 2010, J MED CHEM, V53, P7146, DOI 10.1021/jm101144f
   LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003
   Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672
   Ning JY, 2010, MOL ENDOCRINOL, V24, P1218, DOI 10.1210/me.2009-0474
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Pham NA, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-43
   Rozengurt E, 2010, CLIN CANCER RES, V16, P2505, DOI 10.1158/1078-0432.CCR-09-2229
   Ryder NM, 2001, J CELL PHYSIOL, V186, P53, DOI 10.1002/1097-4652(200101)186:1<53::AID-JCP1004>3.0.CO;2-Q
   Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7
   Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007
   Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   Sinnett-Smith J, 2012, BIOCH BIOPH IN PRESS
   Stoeltzing O, 2003, AM J PATHOL, V163, P1001, DOI 10.1016/S0002-9440(10)63460-8
   Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006
   Tzatsos A, 2007, J BIOL CHEM, V282, P18069, DOI 10.1074/jbc.M610101200
   Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866
   Wolpin BM, 2009, J CLIN ONCOL, V27, P193, DOI 10.1200/JCO.2008.18.9514
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Ying HQ, 2011, CANCER DISCOV, V1, P158, DOI 10.1158/2159-8290.CD-11-0031
   Young SH, 2010, BIOCHEM BIOPH RES CO, V401, P154, DOI 10.1016/j.bbrc.2010.09.036
   Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299
   Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484
   Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 73
TC 78
Z9 80
U1 0
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 21
PY 2013
VL 8
IS 2
AR e57289
DI 10.1371/journal.pone.0057289
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093IT
UT WOS:000315186000095
PM 23437362
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Hsu, CN
   Chang, CH
   Lin, YS
   Lin, JW
   Caffrey, JL
AF Hsu, Chih-Neng
   Chang, Chia-Hsuin
   Lin, Yu-Sheng
   Lin, Jou-Wei
   Caffrey, James L.
TI Association of Serum C-Peptide Concentrations with Cancer Mortality Risk
   in Pre-Diabetes or Undiagnosed Diabetes
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-I; NUTRITION EXAMINATION SURVEY; IGF BINDING PROTEIN-3;
   3RD NATIONAL-HEALTH; METABOLIC SYNDROME; LIFE-STYLE; INSULIN; COHORT;
   DETERMINANTS; SUPPRESSION
AB Background: Known associations between diabetes and cancer could logically be attributed to hyperglycemia, hypersecretion of insulin, and/or insulin resistance. This study examined the relationship between initial glycemic biomarkers among men and women with impaired fasting glucose or undiagnosed diabetes and cancer mortality during follow up.
   Methods: The cohort included subjects aged 40 years and above from the Third National Health and Nutrition Examination Survey (NHANES III) with fasted serum glucose >100 mg/dl without the aid of pharmaceutical intervention (insulin or oral hypoglycemics). Cancer mortality was obtained from the NHANES III-linked follow-up database (up to December 31, 2006). A Cox regression model was applied to test for the associations between cancer mortality and fasting serum glucose, insulin, glycosylated hemoglobin (HbA1c), C-peptide, insulin like growth factor (IGF-1), IGF binding protein 3 (IGFBP3) and estimated insulin resistance.
   Results: A total of 158 and 100 cancer deaths were recorded respectively from 1,348 men and 1,161 women during the mean 134-month follow-up. After adjusting for the effect of age and smoking in women, all-cause cancer deaths (HR: 1.96 per pmol/ml, 95% CI: 1.02-3.77) and lung cancer deaths (HR: 2.65 per pmol/ml, 95% CI: 1.31-5.36) were specifically associated with serum C-peptide concentrations. Similar associations in men were not statistically significant. Serum glucose, HbA1c, IGF-1, IGFBP3 and HOMA were not independently related to long-term cancer mortality.
   Conclusion: C-peptide analyses suggest a modest association with both all-cause and lung cancer mortality in women but not in men. Further studies will be required to explore the mechanisms.
C1 [Hsu, Chih-Neng; Lin, Jou-Wei] Natl Taiwan Univ Hosp, Yun Lin Branch, Ctr Cardiovasc, Dou Liou City, Yun Lin County, Taiwan.
   [Chang, Chia-Hsuin; Lin, Jou-Wei] Natl Taiwan Univ, Coll Med, Dept Med, Taipei 10764, Taiwan.
   [Chang, Chia-Hsuin] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
   [Lin, Yu-Sheng] Univ N Texas, Hlth Sci Ctr, Dept Environm & Occupat Hlth, Ft Worth, TX USA.
   [Caffrey, James L.] Univ N Texas, Hlth Sci Ctr, Dept Integrat Physiol, Ft Worth, TX USA.
   [Caffrey, James L.] Univ N Texas, Hlth Sci Ctr, Cardiovasc Res Inst, Ft Worth, TX USA.
RP Lin, JW (reprint author), Natl Taiwan Univ Hosp, Yun Lin Branch, Ctr Cardiovasc, Dou Liou City, Yun Lin County, Taiwan.
EM jouweilin@yahoo.com
OI CHANG, CHIA-HSUIN/0000-0003-0024-6177
CR Allen NE, 2003, CANCER CAUSE CONTROL, V14, P65, DOI 10.1023/A:1022518321634
   Berrigan D, 2002, CARCINOGENESIS, V23, P817, DOI 10.1093/carcin/23.5.817
   Carpentier A, 2002, DIABETES, V51, P1867, DOI 10.2337/diabetes.51.6.1867
   CDC. National Center for Health Statistics (NCHS), 2010, 3 NAT HLTH NUTR EX S
   Centers for Disease Control and Prevention, NAT HLTH NUTR EX SUR
   Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS), 2009, NHANES3 LINK MORT FI
   Chan JM, 2002, J NATL CANCER I, V94, P1099
   CHANG C, 2011, FILM COMMENT, V47, P6, DOI DOI 10.1371/J0URNAL.P0NE.0021368]
   Chang CH, 2011, J CLIN ONCOL, V29, P3001, DOI 10.1200/JCO.2011.35.1908
   Chang KW, 2010, INT J CANCER, V127, P9, DOI 10.1002/ijc.25220
   Faupel-Badger JM, 2009, ANN EPIDEMIOL, V19, P841, DOI 10.1016/j.annepidem.2009.08.005
   Friis S, 2005, INT J CANCER, V114, P643, DOI 10.1002/ijc.20758
   Gallagher EJ, 2010, ENDOCR PRACT, V16, P864, DOI 10.4158/EP10098.RA
   Giovannucci E, 2007, AM J CLIN NUTR, V86, p836S, DOI 10.1093/ajcn/86.3.836S
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Goodwin PJ, 2002, J CLIN ONCOL, V20, P42, DOI 10.1200/JCO.20.1.42
   Hwang JJ, 2008, NUTR METAB CARDIOVAS, V18, P671, DOI 10.1016/j.numecd.2007.11.006
   Irwin ML, 2011, J CLIN ONCOL, V29, P47, DOI 10.1200/JCO.2010.28.4752
   Johnson JA, 2011, DIABETOLOGIA, V54, P25, DOI 10.1007/s00125-010-1933-3
   Lin JW, 2010, J CLIN ENDOCR METAB, V95, P4258, DOI 10.1210/jc.2010-0332
   Lin YS, 2010, CANCER EPIDEM BIOMAR, V19, P2950, DOI 10.1158/1055-9965.EPI-10-0617
   Pais R, 2009, WORLD J GASTROENTERO, V15, P5141, DOI 10.3748/wjg.15.5141
   Parekh N, 2010, ANN EPIDEMIOL, V20, P182, DOI 10.1016/j.annepidem.2009.11.008
   Parekh N, 2010, CANCER CAUSE CONTROL, V21, P631, DOI 10.1007/s10552-009-9492-y
   Ruiter R, 2012, DIABETES CARE, V35, P119, DOI 10.2337/dc11-0857
   Sarafidis Pantelis A, 2006, Curr Diab Rep, V6, P219, DOI 10.1007/s11892-006-0038-3
   Vogeser M, 2007, CLIN BIOCHEM, V40, P964, DOI 10.1016/j.clinbiochem.2007.05.009
   Wahren J, 2000, AM J PHYSIOL-ENDOC M, V278, pE759
   Wei W, 2001, AM J PUBLIC HEALTH, V91, P258, DOI 10.2105/AJPH.91.2.258
   Wild SH, 2011, DIABETOLOGIA, V54, P1589, DOI 10.1007/s00125-011-2169-6
   Wu TJ, 2004, ANN EPIDEMIOL, V14, P195, DOI 10.1016/S1047-2797(03)00119-4
   Yang XL, 2010, DIABETES, V59, P1254, DOI 10.2337/db09-1371
NR 32
TC 7
Z9 7
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 6
PY 2013
VL 8
IS 2
AR e55625
DI 10.1371/journal.pone.0055625
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 092WJ
UT WOS:000315153400126
PM 23405181
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Tseng, CH
AF Tseng, Chin-Hsiao
TI Thyroid Cancer Risk Is Not Increased in Diabetic Patients
SO PLOS ONE
LA English
DT Article
ID METABOLIC SYNDROME; POOLED ANALYSIS; UNITED-STATES; INSULIN; TAIWAN;
   POPULATION; EXPRESSION; COHORT; CELLS
AB Objective: This study evaluated thyroid cancer risk with regards to diabetes status and diabetes duration, and with the use of anti-diabetic drugs including sulfonylurea, metformin, insulin, acarbose, pioglitazone and rosiglitazone, by using a population-based reimbursement database in Taiwan.
   Methods: A random sample of 1,000,000 subjects covered by the National Health Insurance was recruited. After excluding patients with type 1 diabetes, 999730 subjects (495673 men and 504057 women) were recruited into the analyses. Logistic regression estimated the odds ratios (OR) and their 95% confidence intervals (Cl) for independent variables including age, sex, diabetes status/duration, anti-diabetic drugs, other medications, comorbidities, living regions, occupation and examinations that might potentially lead to the diagnosis of thyroid cancer in various models.
   Results: The diabetic patients had a significantly higher probability of receiving potential detection examinations (6.38% vs. 5.83%, P<0.0001). After multivariable-adjustment, the OR (95% Cl) for diabetes status was 0.816 (0.652-1.021); and for diabetes duration <1 year, 1-3 years, 3-5 years and >= 5 years vs. non-diabetes was 0.071 (0.010-0.507), 0.450 (0.250-0.813), 0.374 (0.203-0.689) and 1.159 (0.914-1.470), respectively. Among the anti-diabetic agents, only sulfonylurea was significantly associated with thyroid cancer, OR (95% Cl): 1.882 (1.202-2.947). The OR (95% Cl) for insulin, metformin, acarbose, pioglitazone and rosiglitazone was 1.701 (0.860-3.364), 0.696 (0.419-1.155), 0.581 (0.202-1.674), 0.522 (0.069-3.926) and 0.669 (0.230-1.948), respectively. Furthermore, patients with benign thyroid disease or other cancer, living in Kao-Ping/Eastern regions, or receiving potential detection examinations might have a significantly higher risk; and male sex, hypertension, dyslipidemia, chronic obstructive pulmonary disease, vascular complications or use of statin, aspirin or non-steroidal anti-inflammatory drugs might be associated with a significantly lower risk.
   Conclusions: There is a lack an overall association between diabetes and thyroid cancer, but patients with diabetes duration <5 years have a significantly lower risk. Sulfonylurea may increase the risk of thyroid cancer.
C1 [Tseng, Chin-Hsiao] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan.
   [Tseng, Chin-Hsiao] Natl Taiwan Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Taipei 100, Taiwan.
   [Tseng, Chin-Hsiao] Natl Hlth Res Inst, Div Environm Hlth & Occupat Med, Taipei, Taiwan.
RP Tseng, CH (reprint author), Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan.
EM ccktsh@ms6.hinet.net
OI TSENG, CHIN-HSIAO/0000-0001-9545-7123
CR Almquist M, 2011, CANCER CAUSE CONTROL, V22, P743, DOI 10.1007/s10552-011-9747-2
   Aschebrook-Kilfoy B, 2011, THYROID, V21, P957, DOI 10.1089/thy.2010.0396
   Bureau of Health Promotion, 2010, CANC REG ANN REP 200
   Cappelli C, 2012, OBES SURG, V22, P460, DOI 10.1007/s11695-011-0410-5
   Chen GG, 2008, CURR CANCER DRUG TAR, V8, P367, DOI 10.2174/156800908785133150
   Chiang CJ, 2010, JPN J CLIN ONCOL, V40, P897, DOI 10.1093/jjco/hyq057
   Chiou WK, 2011, ASIAN PAC J CANCER P, V12, P1577
   Cho NL, 2010, THYROID, V20, P615, DOI 10.1089/thy.2009.0415
   Chodick G, 2010, CANCER CAUSE CONTROL, V21, P879, DOI 10.1007/s10552-010-9515-8
   Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164
   Farasat T, 2011, PAK J ZOOL, V43, P379
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Guney E, 1999, TURKISH J ENDOCRINOL, V4, P173
   Hegedus L, 2008, CLIN ENDOCRINOL, V68, P2, DOI 10.1111/j.1365-2265.2007.02983.x
   HERSHMAN JM, 1968, ENDOCRINOLOGY, V83, P74, DOI 10.1210/endo-83-1-74
   HU RM, 1994, MOL CELL ENDOCRINOL, V103, P65
   Inzucchi SE, 2012, DIABETES CARE, V35, P1364, DOI 10.2337/dc12-0413
   Kadiyala R, 2010, INT J CLIN PRACT, V64, P1130, DOI 10.1111/j.1742-1241.2010.02376.x
   Kim HK, 2013, CLIN ENDOCRINOL, V78, P472, DOI 10.1111/cen.12027
   Kitahara CM, 2012, CANCER CAUSE CONTROL, V23, P1615, DOI 10.1007/s10552-012-0039-2
   Kitahara CM, 2012, CANCER CAUSE CONTROL, V23, P463, DOI 10.1007/s10552-012-9896-y
   McNally RJQ, 2012, EUR J EPIDEMIOL, V27, P615, DOI 10.1007/s10654-012-9710-x
   NIKKILA EA, 1960, ACTA ENDOCRINOL-COP, V33, P623
   Papini E, 2002, J CLIN ENDOCR METAB, V87, P1941, DOI 10.1210/jc.87.5.1941
   Roche LM, 2011, J ENVIRON PUBLIC HEA, DOI 10.1155/2011/850105
   Schultes B, 2002, METABOLISM, V51, P1370, DOI [10.1053/meta.2002.35193, 10.1053/meta.2002.351193]
   Shih SR, 2012, EXP DIABETES RES, DOI 10.1155/2012/578285
   Tarcin O, 2012, METAB SYNDR RELAT D, V10, P137, DOI 10.1089/met.2011.0098
   Tseng CH, 2012, EUR J ENDOCRINOL, V167, P409, DOI 10.1530/EJE-12-0369
   Wang CY, 2012, ENDOCR J, V59, P911, DOI 10.1507/endocrj.EJ12-0076
   Zhan YS, 2010, MED ONCOL, V27, P177, DOI 10.1007/s12032-009-9189-9
NR 31
TC 43
Z9 44
U1 1
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 27
PY 2012
VL 7
IS 12
AR e53096
DI 10.1371/journal.pone.0053096
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 061EA
UT WOS:000312829100117
PM 23300866
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Heni, M
   Hennenlotter, J
   Scharpf, M
   Lutz, SZ
   Schwentner, C
   Todenhofer, T
   Schilling, D
   Kuhs, U
   Gerber, V
   Machicao, F
   Staiger, H
   Haring, HU
   Stenzl, A
AF Heni, Martin
   Hennenlotter, Joerg
   Scharpf, Marcus
   Lutz, Stefan Z.
   Schwentner, Christian
   Todenhoefer, Tilman
   Schilling, David
   Kuehs, Ursula
   Gerber, Valentina
   Machicao, Fausto
   Staiger, Harald
   Haering, Hans-Ulrich
   Stenzl, Arnulf
TI Insulin Receptor Isoforms A and B as well as Insulin Receptor
   Substrates-1 and-2 Are Differentially Expressed in Prostate Cancer
SO PLOS ONE
LA English
DT Article
ID TYPE-2 DIABETES-MELLITUS; GROWTH-FACTOR RECEPTOR; TISSUE ADJACENT; IRS
   PROTEINS; RISK; METASTASIS; CONSENSUS; STRATEGY; PATHWAY; DISEASE
AB Aims/Hypothesis: In different cancers types, insulin receptor isoform composition or insulin receptor substrate (IRS) isoforms are different to healthy tissue. This may be a molecular link to increased cancer risk in diabetes and obesity. Since this is yet unclear for prostate cancer, we investigated IR isoform composition and IRS balance in prostate cancer compared to benign and tumor adjacent benign prostate tissue and brought this into relation to cell proliferation.
   Methods: We studied 23 benign prostate samples from radical cystectomy or benign prostatic hyperplasia surgery, 30 samples from benign tissue directly adjacent to prostate cancer foci and 35 cancer samples from different patients. RNA expression levels for insulin receptor isoforms A and B, IRS-1, IRS-2, and IGF-1 receptor were assessed by quantitative real-time RT-PCR. In addition, RNA-and protein expression of the cell cycle regulator p27(Kip1) was quantified by real-time RT-PCR and immunohistochemistry.
   Results: Insulin receptor isoform A to B ratio was significantly higher in cancer as well as in tumor adjacent benign prostate tissue compared to purely benign prostates (p<0.05). IRS-1 to IRS-2 ratios were lower in malignant than in benign prostatic tissue (p<0.05). These altered ratios both in cancer and adjacent tissue were significantly associated with reduced p27(Kip1) content (p<0.02). Interestingly, IGF-1 receptor levels were significantly lower in patients with type 2 diabetes (p = 0.0019).
   Conclusions/Interpretation: We found significant differences in the insulin signaling cascade between benign prostate tissue and prostate cancer. Histological benign tissue adjacent to cancer showed expression patterns similar to the malignancies. Our findings suggest a role of the insulin signaling pathway in prostate cancer and surrounding tissue and can hence be relevant for both novel diagnostic and therapeutic approaches in this malignancy.
C1 [Heni, Martin; Lutz, Stefan Z.; Machicao, Fausto; Staiger, Harald; Haering, Hans-Ulrich] Univ Tubingen, Dept Internal Med, Div Endocrinol Diabetol Angiol Nephrol & Clin Che, D-7400 Tubingen, Germany.
   [Hennenlotter, Joerg; Schwentner, Christian; Todenhoefer, Tilman; Schilling, David; Kuehs, Ursula; Gerber, Valentina; Stenzl, Arnulf] Univ Tubingen, Dept Urol, D-7400 Tubingen, Germany.
   [Scharpf, Marcus] Univ Tubingen, Inst Pathol, D-7400 Tubingen, Germany.
   [Machicao, Fausto; Staiger, Harald; Haering, Hans-Ulrich] Univ Tubingen, Inst Diabet Res & Metab Dis, Helmholtz Ctr Munich, German Ctr Diabet Res DZD, D-7400 Tubingen, Germany.
RP Haring, HU (reprint author), Univ Tubingen, Dept Internal Med, Div Endocrinol Diabetol Angiol Nephrol & Clin Che, D-7400 Tubingen, Germany.
EM hans-ulrich.haering@med.uni-tuebingen.de
RI Staiger, Harald/N-5871-2014
OI Heni, Martin/0000-0002-8462-3832; Staiger, Harald/0000-0002-9507-5333
FU German Federal Ministry of Education and Research (BMBF) [01GI0925]
FX The study was supported by a grant (01GI0925) from the German Federal
   Ministry of Education and Research (BMBF) to the German Center for
   Diabetes Research (DZD e.V.). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Belfiore A, 2009, ENDOCR REV, V30, P586, DOI 10.1210/er.2008-0047
   Chandran UR, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-45
   Cox ME, 2009, PROSTATE, V69, P33, DOI 10.1002/pros.20852
   Currie CJ, 2012, DIABETES CARE, V35, P299, DOI 10.2337/dc11-1313
   Gallagher EJ, 2010, TRENDS ENDOCRIN MET, V21, P610, DOI 10.1016/j.tem.2010.06.007
   Gibson SL, 2007, CELL CYCLE, V6, P631, DOI 10.4161/cc.6.6.3987
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Grossmann M, 2011, J CLIN ENDOCR METAB, V96, P2341, DOI 10.1210/jc.2011-0118
   Hellawell GO, 2002, CANCER RES, V62, P2942
   Heni M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021594
   Hribal ML, 2003, FASEB J, V17, P1340, DOI 10.1096/fj.02-0685fje
   Kasper JS, 2008, CANCER CAUSE CONTROL, V19, P703, DOI 10.1007/s10552-008-9133-x
   Ma ZF, 2006, MOL CELL BIOL, V26, P9338, DOI 10.1128/MCB.01032-06
   Macri E, 1998, CANCER METAST REV, V17, P337, DOI 10.1023/A:1006133620914
   Merseburger AS, 2006, ONCOL REP, V16, P79
   Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9
   Mussig K, 2011, DIABETIC MED, V28, P276, DOI 10.1111/j.1464-5491.2010.03132.x
   Renehan A, 2010, LANCET, V375, P2201, DOI 10.1016/S0140-6736(10)60706-4
   Sesti G, 2001, DIABETES-METAB RES, V17, P363, DOI 10.1002/dmrr.225
   Shaw LM, 2011, CELL CYCLE, V10, P1750, DOI 10.4161/cc.10.11.15824
   Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837
   Theodorescu D, 1997, J UROLOGY, V158, P131, DOI 10.1097/00005392-199707000-00040
   Waalkes S, 2010, ONCOL REP, V23, P1257, DOI 10.3892/or_00000758
   White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001
   White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619
   Wu C, 2011, PROSTATE CANCER P D, V14, P326, DOI 10.1038/pcan.2011.28
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
NR 27
TC 33
Z9 33
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 10
PY 2012
VL 7
IS 12
AR e50953
DI 10.1371/journal.pone.0050953
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 052ML
UT WOS:000312201900029
PM 23251408
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Jonasson, JM
   Cederholm, J
   Eliasson, B
   Zethelius, B
   Eeg-Olofsson, K
   Gudbjornsdottir, S
AF Jonasson, Junmei Miao
   Cederholm, Jan
   Eliasson, Bjorn
   Zethelius, Bjorn
   Eeg-Olofsson, Katarina
   Gudbjornsdottir, Soffia
TI HbA1C and Cancer Risk in Patients with Type 2 Diabetes - A Nationwide
   Population-Based Prospective Cohort Study in Sweden
SO PLOS ONE
LA English
DT Article
ID PROSTATE-SPECIFIC ANTIGEN; COLORECTAL-CANCER; GLYCOSYLATED HEMOGLOBIN;
   CONSENSUS REPORT; BREAST-CANCER; BLOOD-GLUCOSE; UNITED-STATES; MEN;
   WOMEN; MELLITUS
AB Background: Diabetes is associated with increased cancer risk. The underlying mechanisms remain unclear. Hyperglycemia might be one risk factor. HbA1c is an indicator of the blood glucose level over the latest 1 to 3 months. This study aimed to investigate association between HbA1c level and cancer risks in patients with type 2 diabetes based on real life situations.
   Methods: This is a cohort study on 25,476 patients with type 2 diabetes registered in the Swedish National Diabetes Register from 1997-1999 and followed until 2009. Follow-up for cancer was accomplished through register linkage. We calculated incidences of and hazard ratios (HR) for cancer in groups categorized by HbA1c <= 58 mmol/mol (7.5%) versus >58 mmol/mol, by quartiles of HbA1c, and by HbA1c continuously at Cox regression, with covariance adjustment for age, sex, diabetes duration, smoking and insulin treatment, or adjusting with a propensity score.
   Results: Comparing HbA1c >58 mmol/mol with <= 58 mmol/mol, adjusted HR for all cancer was 1.02 [95% CI 0.95-1.10] using baseline HbA1c, and 1.04 [95% CI 0.97-1.12] using updated mean HbA1c, and HRs were all non-significant for specific cancers of gastrointestinal, kidney and urinary organs, respiratory organs, female genital organs, breast or prostate. Similarly, no increased risks of all cancer or the specific types of cancer were found with higher quartiles of baseline or updated mean HbA1c, compared to the lowest quartile. HR for all cancer was 1.01 [0.98-1.04] per 1%-unit increase in HbA1c used as a continuous variable, with non-significant HRs also for the specific types of cancer per unit increase in HbA1c.
   Conclusions: In this study there were no associations between HbA1c and risks for all cancers or specific types of cancer in patients with type 2 diabetes.
C1 [Jonasson, Junmei Miao; Gudbjornsdottir, Soffia] Ctr Registers Reg Vastra Gotaland, Gothenburg, Sweden.
   [Jonasson, Junmei Miao] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Oncol, Gothenburg, Sweden.
   [Cederholm, Jan] Uppsala Univ, Dept Publ Hlth & Caring Sci Family Med & Clin Epi, Uppsala, Sweden.
   [Eliasson, Bjorn; Eeg-Olofsson, Katarina; Gudbjornsdottir, Soffia] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Med, Gothenburg, Sweden.
   [Zethelius, Bjorn] Uppsala Univ, Dept Publ Hlth & Caring Sci Geriatr, Uppsala, Sweden.
   [Zethelius, Bjorn] Med Prod Agcy, Uppsala, Sweden.
RP Jonasson, JM (reprint author), Ctr Registers Reg Vastra Gotaland, Gothenburg, Sweden.
EM junmei.miao.jonasson@gmail.com
RI Miao Jonasson, Junmei/B-3242-2014; Eliasson, Bjorn/H-5783-2016
OI Eliasson, Bjorn/0000-0003-2569-4160
FU VINNMER; VINNOVA; Lion's Cancer Fund in Western Sweden; Konrad and
   Helfrid Johansson Foundation; Swedish Society of Medicine; Swedish
   Diabetes Fund; AGFOND
FX This study was funded by VINNMER fellow, VINNOVA (JMJ), Lion's Cancer
   Fund in Western Sweden (JMJ), Konrad and Helfrid Johansson Foundation
   (JMJ), Swedish Society of Medicine (JMJ), Swedish Diabetes Fund (JMJ,
   SG), and AGFOND (JMJ). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Best JD, 2000, DRUGS, V59, P1101, DOI 10.2165/00003495-200059050-00006
   BUNN HF, 1978, SCIENCE, V200, P21, DOI 10.1126/science.635569
   D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
   Driver JA, 2010, AM J EPIDEMIOL, V172, P299, DOI 10.1093/aje/kwq127
   Fowke JH, 2008, PROSTATE CANCER P D, V11, P264, DOI 10.1038/sj.pcan.4501022
   Giovannucci E., 2007, Gastroenterology, V132, P2208, DOI 10.1053/j.gastro.2007.03.050
   Giovannucci E, 2010, CA-CANCER J CLIN, V60, P207, DOI 10.3322/caac.20078
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Hoelzel W, 2004, CLIN CHEM, V50, P166, DOI 10.1373/clinchem.2003.024802
   Ikeda F, 2009, GASTROENTEROLOGY, V136, P1234, DOI 10.1053/j.gastro.2008.12.045
   Jee SH, 2005, JAMA-J AM MED ASSOC, V293, P194, DOI 10.1001/jama.293.2.194
   Johnson JA, 2011, DIABETOLOGIA, V54, P25, DOI 10.1007/s00125-010-1933-3
   Jonasson JM, 2009, DIABETOLOGIA, V52, P1745, DOI 10.1007/s00125-009-1444-2
   Khaw KT, 2004, CANCER EPIDEM BIOMAR, V13, P915
   Lin J, 2006, CANCER RES, V66, P2869, DOI 10.1158/0008-5472.CAN-05-3922
   Lin J, 2005, CANCER EPIDEM BIOMAR, V14, P3010, DOI 10.1158/1055-9965.EPI-05-0533
   Lipscombe LL, 2006, BREAST CANCER RES TR, V98, P349, DOI 10.1007/s10549-006-9172-5
   Ljung R, 2011, ACTA ONCOLOGICA
   Muller H, 2009, CANCER EPIDEM BIOMAR, V18, P1350, DOI 10.1158/1055-9965.EPI-08-0794
   Ohwaki K, 2011, EUR J CANCER, V47, P262, DOI 10.1016/j.ejca.2010.09.023
   Pencina MJ, 2007, STAT MED, V26, P1343, DOI 10.1002/sim.2699
   Platz EA, 1999, CANCER CAUSE CONTROL, V10, P379, DOI 10.1023/A:1008953611657
   Rapp K, 2006, DIABETOLOGIA, V49, P945, DOI 10.1007/s00125-006-0207-6
   Renehan A, 2010, LANCET, V375, P2201, DOI 10.1016/S0140-6736(10)60706-4
   Rinaldi S, 2008, CANCER EPIDEM BIOMAR, V17, P3108, DOI 10.1158/1055-9965.EPI-08-0495
   Rothman K, 1998, MODERN EPIDEMIOLOGY
   Smith U, 2010, DIABETOLOGIA, V53, P1541, DOI 10.1007/s00125-010-1815-8
   Stattin P, 2007, DIABETES CARE, V30, P561, DOI 10.2337/dc06-0922
   Stefansdottir G, 2011, DIABETOLOGIA, V54, P1608, DOI 10.1007/s00125-011-2104-x
   Turner RC, 1998, LANCET, V352, P837
   van Staa TP, 2011, DIABETOLOGIA
   Yang XL, 2008, CAN MED ASSOC J, V179, P427, DOI 10.1503/cmaj.071474
   Yang XL, 2010, DIABETES, V59, P1254, DOI 10.2337/db09-1371
   Yang YX, 2010, CANCER EPIDEM BIOMAR, V19, P3027, DOI 10.1158/1055-9965.EPI-10-0486
   Zhou XH, 2010, DIABETOLOGIA, V53, P1867, DOI 10.1007/s00125-010-1796-7
NR 35
TC 22
Z9 22
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 14
PY 2012
VL 7
IS 6
AR e38784
DI 10.1371/journal.pone.0038784
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959WG
UT WOS:000305347800018
PM 22719946
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

PT J
AU Yang, WS
   Va, P
   Bray, F
   Gao, S
   Gao, J
   Li, HL
   Xiang, YB
AF Yang, Wan-Shui
   Va, Puthiery
   Bray, Freddie
   Gao, Shan
   Gao, Jing
   Li, Hong-Lan
   Xiang, Yong-Bing
TI The Role of Pre-Existing Diabetes Mellitus on Hepatocellular Carcinoma
   Occurrence and Prognosis: A Meta-Analysis of Prospective Cohort Studies
SO PLOS ONE
LA English
DT Article
ID CHRONIC HEPATITIS-C; POPULATION-BASED COHORT; CANCER-MORTALITY;
   UNITED-STATES; VIRAL-HEPATITIS; VIRUS-INFECTION; BREAST-CANCER;
   METABOLIC SYNDROME; PUBLICATION BIAS; LIVER-DISEASE
AB Background: The impact of pre-existing diabetes mellitus (DM) on hepatocellular carcinoma (HCC) occurrence and prognosis is complex and unclear. The aim of this meta-analysis is to evaluate the association between pre-existing diabetes mellitus and hepatocellular carcinoma occurrence and prognosis.
   Methods: We searched PubMed, Embase and the Cochrane Library from their inception to January, 2011 for prospective epidemiological studies assessing the effect of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence, mortality outcomes, cancer recurrence, and treatment-related complications. Study-specific risk estimates were combined by using fixed effect or random effect models.
   Results: The database search generated a total of 28 prospective studies that met the inclusion criteria. Among these studies, 14 reported the risk of HCC incidence and 6 studies reported risk of HCC specific mortality. Six studies provided a total of 8 results for all-cause mortality in HCC patients. Four studies documented HCC recurrence risks and 2 studies reported risks for hepatic decomposition occurrence in HCC patients. Meta-analysis indicated that pre-existing diabetes mellitus (DM) was significantly associated with increased risk of HCC incidence [meta-relative risk (RR) = 1.87, 95% confidence interval (CI): 1.15-2.27] and HCC-specific mortality (meta-RR = 1.88, 95% CI: 1.39-2.55) compared with their non-DM counterparts. HCC patients with pre-existing DM had a 38% increased (95% CI: 1.13-1.48) risk of death from all-causes and 91% increased (95% CI: 1.41-2.57) risk of hepatic decomposition occurrence compared to those without DM. In DM patients, the meta-RR for HCC recurrence-free survival was 1.93(95% CI: 1.12-3.33) compared with non-diabetic patients.
   Conclusion: The findings from the current meta-analysis suggest that DM may be both associated with elevated risks of both HCC incidence and mortality. Furthermore, HCC patients with pre-existing diabetes have a poorer prognosis relative to their non-diabetic counterparts.
C1 [Yang, Wan-Shui] Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai 200433, Peoples R China.
   [Yang, Wan-Shui; Gao, Shan; Gao, Jing; Li, Hong-Lan; Xiang, Yong-Bing] Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, State Key Lab Oncogene & Related Genes,Renji Hosp, Shanghai 200030, Peoples R China.
   [Yang, Wan-Shui; Gao, Shan; Gao, Jing; Li, Hong-Lan; Xiang, Yong-Bing] Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, Dept Epidemiol,Renji Hosp, Shanghai 200030, Peoples R China.
   [Va, Puthiery] Univ New England, Coll Osteopath Med, Biddeford, ME USA.
   [Bray, Freddie] Int Agcy Res Canc, Sect Canc Informat, F-69372 Lyon, France.
RP Yang, WS (reprint author), Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai 200433, Peoples R China.
EM ybxiang@shsci.org
FU State Key Project Specialized for Infectious Diseases of China
   [2008ZX10002-015]; Fogarty International Clinical Research Scholars;
   Fogarty International Center, National Institutes of Health
   [R24TW007988]
FX This study is supported by the fund of the State Key Project Specialized
   for Infectious Diseases of China (No. 2008ZX10002-015). W-SY and PV are
   also supported by the Fogarty International Clinical Research Scholars
   and Fellows Support Center at the Vanderbilt Institute for Global
   Health, funded by the Fogarty International Center, National Institutes
   of Health, through an R24 Training Grant (Grant number: R24TW007988).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753
   Barone BB, 2008, JAMA-J AM MED ASSOC, V300, P2754, DOI 10.1001/jama.2008.824
   Batty GD, 2004, CANCER CAUSE CONTROL, V15, P873, DOI 10.1007/s10552-004-1050-z
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chen Jian-guo, 2005, Zhonghua Yi Xue Za Zhi, V85, P3052
   Cheruvattath R, 2007, J CLIN GASTROENTEROL, V41, P403, DOI 10.1097/01.mcg.0000248018.08515.f9
   Chodick G, 2010, CANCER CAUSE CONTROL, V21, P879, DOI 10.1007/s10552-010-9515-8
   Clemmons DR, 2007, GROWTH HORM IGF RES, V17, P265, DOI 10.1016/j.ghir.2007.01.004
   Coughlin SS, 2004, AM J EPIDEMIOL, V159, P1160, DOI 10.1093/aje/kwh161
   Cowie CC, 2009, DIABETES CARE, V32, P287, DOI 10.2337/dc08-1296
   Cucchetti A, 2011, ANN SURG ONCOL, V18, P1630, DOI 10.1245/s10434-010-1463-8
   Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6
   Davila JA, 2005, GUT, V54, P533, DOI 10.1136/gut.2004.052167
   Davila JA, 2004, GASTROENTEROLOGY, V127, P1372, DOI 10.1053/j.gastro.2004.07.020
   Denley A, 2007, MOL CELL BIOL, V27, P3569, DOI 10.1128/MCB.01447-06
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Di Costanzo GG, 2008, EUR J GASTROEN HEPAT, V20, P674, DOI 10.1097/MEG.0b013e3282f762e1
   Donadon Valter, 2009, Expert Rev Gastroenterol Hepatol, V3, P465, DOI 10.1586/egh.09.41
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El-Serag HB, 2004, GASTROENTEROLOGY, V126, P460, DOI 10.1053/j.gastro.2003.10.065
   El-Serag HB, 2001, AM J GASTROENTEROL, V96, P2462, DOI 10.1111/j.1572-0241.2001.04054.x
   Feng YH, 2011, MED ONCOL, V28, P1080, DOI 10.1007/s12032-010-9650-9
   Ferlay J., 2010, IARC CANC BASE
   Fujino Y, 2001, DIABETES METAB RES, V17, P374, DOI 10.1002/dmrr.214
   FULLER JH, 1983, DIABETOLOGIA, V24, P336
   Giovannucci E, 2001, J NUTR, V131, p3109S, DOI 10.1093/jn/131.11.3109S
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666
   Hassan MM, 2002, J CLIN GASTROENTEROL, V35, P266, DOI 10.1097/01.MCG.0000024617.97388.72
   Hassan MM, 2002, HEPATOLOGY, V36, P1206, DOI 10.1053/jhep.2002.36780
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hoerger TJ, 2008, DIABETES CARE, V31, P81, DOI 10.2337/dc07-1.572
   Hung CH, 2011, INT J CANCER, V128, P2344, DOI 10.1002/ijc.25585
   Huo TI, 2010, LIVER INT, V30, P198, DOI 10.1111/j.1478-3231.2009.02143.x
   Huo TI, 2004, AM J GASTROENTEROL, V99, P1479, DOI 10.1111/j.1572-0241.2004.30024.x
   Huo TI, 2003, EUR J GASTROEN HEPAT, V15, P1203, DOI 10.1097/01.meg.0000085498.01212.6a
   Huo TI, 2003, AM J GASTROENTEROL, V98, P2293, DOI 10.1016/S0002-9270(03)00694-4
   Ikeda Y, 1998, HEPATOLOGY, V27, P1567, DOI 10.1002/hep.510270615
   Inoue M, 2006, ARCH INTERN MED, V166, P1871, DOI 10.1001/archinte.166.17.1871
   Ioannou GN, 2007, CLIN GASTROENTEROL H, V5, P938, DOI 10.1016/j.cgh.2007.02.039
   Jee SH, 2005, JAMA-J AM MED ASSOC, V293, P194, DOI 10.1001/jama.293.2.194
   Jin F, 1999, INT J CANCER, V83, P435, DOI 10.1002/(SICI)1097-0215(19991112)83:4<435::AID-IJC1>3.0.CO;2-J
   Jonsson JR, 2005, J HEPATOL, V43, P929, DOI 10.1016/j.jhep.2005.05.030
   Kawamura Y, 2008, J GASTROEN HEPATOL, V23, P1739, DOI 10.1111/j.1440-1746.2008.05436.x
   Khan Mmh, 2006, Asian Pac J Cancer Prev, V7, P253
   Komura T, 2007, AM J GASTROENTEROL, V102, P1939, DOI 10.1111/j.1572-0241.2007.01354.x
   Lai MS, 2006, HEPATOLOGY, V43, P1295, DOI 10.1002/hep.21208
   Lam EKK, 2011, ANN ONCOL, V22, P730, DOI 10.1093/annonc/mdq405
   Landman GWD, 2010, DIABETES CARE, V33, P322, DOI 10.2337/dc09-1380
   Lau WY, 2008, HEPATOB PANCREAT DIS, V7, P237
   LaVecchia C, 1997, INT J CANCER, V73, P204, DOI 10.1002/(SICI)1097-0215(19971009)73:2<204::AID-IJC7>3.3.CO;2-A
   Lee CL, 2003, CANCER EPIDEM BIOMAR, V12, P57
   Lipscombe LL, 2006, BREAST CANCER RES TR, V98, P349, DOI 10.1007/s10549-006-9172-5
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Mardilovich K, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-14
   Martin LM, 2000, AM J PREV MED, V18, P215, DOI 10.1016/S0749-3797(99)00158-0
   Meyerkardt JA, 2003, J CLIN ONCOL, V21, P433, DOI 10.1200/JCO.2003.07.125
   Monami M, 2008, EXP CLIN ENDOCR DIAB, V116, P184, DOI 10.1055/s-2007-992157
   Morss AS, 2007, J BIOL CHEM, V282, P14635, DOI 10.1074/jbc.M608565200
   Oba S, 2008, J EPIDEMIOL, V18, P197, DOI 10.2188/jea.JE2008004
   Ogunleye AA, 2009, BRIT J CANCER, V101, P1199, DOI 10.1038/sj.bjc.6605240
   Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052
   Park SM, 2006, J CLIN ONCOL, V24, P5017, DOI 10.1200/JCO.2006.07.0243
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   PAYNE JE, 1995, AUST NZ J SURG, V65, P398, DOI 10.1111/j.1445-2197.1995.tb01767.x
   Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536
   Poon RTP, 2002, AM J GASTROENTEROL, V97, P1480, DOI 10.1016/S0002-9270(02)04148-5
   Radhakrishnan Y, 2008, J BIOL CHEM, V283, P16320, DOI 10.1074/jbc.M801687200
   Renehan AG, 2006, TRENDS ENDOCRIN MET, V17, P328, DOI 10.1016/j.tem.2006.08.006
   Richardson LC, 2005, NAT CLIN PRACT ONCOL, V2, P48, DOI 10.1038/ncponc0062
   Roden M, 2006, NAT CLIN PRACT ENDOC, V2, P335, DOI 10.1038/ncpendmet0190
   Rose DP, 2007, ENDOCR REV, V28, P763, DOI 10.1210/er.2006-0019
   Rousseau MC, 2006, INT J CANCER, V118, P2105, DOI 10.1002/ijc.21600
   Sanyal AJ, 2010, ONCOLOGIST, V15, P14, DOI 10.1634/theoncologist.2010-S4-14
   Sanz C, 2010, DIABETES METAB, V36, P346, DOI 10.1016/j.diabet.2010.06.001
   Shi M, 2004, WORLD J SURG, V28, P376, DOI 10.1007/s00268-003-7308-x
   Snyder CF, 2010, PROSTATE CANCER P D, V13, P58, DOI 10.1038/pcan.2009.39
   Takiya L, 2002, AM J MANAG CARE, V8, P1009
   Tazawa J, 2002, DIGEST DIS SCI, V47, P710, DOI 10.1023/A:1014715327729
   Torisu Y, 2007, HEPATOL RES, V37, P517, DOI 10.1111/j.1872-034X.2007.00077.x
   van de Poll-Franse LV, 2007, INT J CANCER, V120, P1986, DOI 10.1002/ijc.22532
   Veldt BJ, 2008, HEPATOLOGY, V47, P1856, DOI 10.1002/hep.22251
   Wang CS, 2009, CANCER EPIDEM BIOMAR, V18, P2054, DOI 10.1158/1055-9965.EPI-08-1131
   Weiser MA, 2004, CANCER, V100, P1179, DOI 10.1002/cncr.20071
   Whitehead JP, 2006, DIABETES OBES METAB, V8, P264, DOI 10.1111/j.1463-1326.2005.00510.x
   Wong IHN, 2001, CANCER LETT, V167, P183, DOI 10.1016/S0304-3835(01)00455-4
   Wu SC, 2000, PUBLIC HEALTH, V114, P137, DOI 10.1016/S0033-3506(00)00323-1
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   YU MC, 1991, JNCI-J NATL CANCER I, V83, P1820, DOI 10.1093/jnci/83.24.1820
   Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229
   Zhang H, 2007, CANCER RES, V67, P391, DOI 10.1158/0008-5472.CAN-06-1712
   Zhu AX, 2010, ONCOLOGIST, V15, P1, DOI 10.1634/theoncologist.2010-S4-01
NR 93
TC 54
Z9 57
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 21
PY 2011
VL 6
IS 12
AR e27326
DI 10.1371/journal.pone.0027326
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 876NF
UT WOS:000299113600002
PM 22205924
OA DOAJ Gold, Green Published
DA 2019-06-25
ER

EF